33 - Neonatal hemochromatosis  pp. 308-312


By James C. Barton et al.

Image View Previous Chapter Next Chapter



Neonatal hemochromatosis (NH) is a heterogeneous group of disorders characterized by severe fetal or neonatal liver injury including cirrhosis, and hepatic and extrahepatic iron overload that occurs in a distribution similar to that of HFE hemochromatosis. Extensive liver injury and dysfunction are the dominant clinical features. Fetal loss or early neonatal death is usual, although some children survive. Despite its rarity, NH is one of the most commonly recognized causes of liver failure in neonates, has a high recurrence rate in sibships, and is a frequent indication for liver transplantation in the first 3 months of life. There is mounting evidence that many cases are caused by maternal alloimmunity against a fetal liver determinant. Treating at-risk mothers during pregnancy with intravenous IgG markedly decreases the risk and severity of NH in their subsequent offspring. Other NH cases are due to other acquired conditions of the mother, to intrauterine infection, or to rare heritable disorders of the fetus.

History

In 1956, Kiaer and Olesen described a Danish kinship in which six of nine sibs died in utero or as neonates of a disorder consistent with NH. In 1960, Fienberg reported two pairs of male siblings with “perinatal idiopathic hemochromatosis” and “giant cell hepatitis,” and suggested that this condition was caused by an “inborn error of metabolism.” In 1961, Laurendeau and colleagues described “idiopathic neonatal hemochromatosis” in two sisters.

Reference Title: References

Reference Type: reference-list

Virchow R . Die pathologischen Pigmente. Arch Pathol Anat 1847; 1: 379–486.
Perls M . Nachweis von Eisenoxyd in gewissen Pigmenten. Virchow Arch Pathol Anat 1867; 39: 42–8.
Scheuer PJ , Williams R , Muir AR . Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol 1962; 84: 53–64.
Trousseau A . Glycosurie, diabète sucré. Paris, J.-B. Baillière. 1865; 663–98.
Troisier M . Diabète sucré. Bull Soc Anat Paris 1871; 16: 231–5.
von Recklinghausen FD . Über hämochromatose. Tagebl Versamml Natur Ärtze Heidelberg 1889; 62: 324–5.
Bezançon F , de Gennes L , Delarue J , Oumensky V . Cirrhose pigmentaire avec infantilisme et insuffisance cardiaque et aplasie endocriniennes multiples. Bull Mém Soc Med Hôp Paris 1932; 48: 967–74.
de Gennes L , Delarue J , de Vericourt R. Sur un nouveau cas de cirrhose pigmentaire avec infantilisme et myocarde. Le syndrome endocrine-hepato-cardiaque. Bull Mem Soc Méd Hôp Paris 1935; 51: 1228.
de Vericourt R. Le syndrome endocrino-hepato-myocardique (sur un aspect des cirrhoses pigmentaires) . Paris, 1935.
Strachan AS. Haemosiderosis and haemochromatosis in South African natives with a comment on the eiology of haemochromatosis. MD Thesis. University of Glasgow, 1929.
Gordeuk VR , McLaren CE , MacPhail AP , Deichsel G , Bothwell TH . Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996; 87: 3470–6.
Bacon BR. Joseph H. Sheldon and hereditary hemochromatosis: historical highlights. J Lab Clin Med 1989; 113: 761–2.
Sheldon JH . Haemochromatosis. London, Oxford University Press, 1935.
MacDonald RA . Hemochromatosis and Hemosiderosis. Springfield, Charles C. Thomas, 1964.
Bothwell TH , Seftel H , Jacobs P , Torrance JD , Baumslag M. Iron overload in Bantu subjects. Studies on the availability of iron in Bantu beer. Am J Clin Nutr 1964; 14: 47–51.
Edwards CQ , Carroll M , Bray P , Cartwright GE. Hereditary hemochromatosis. Diagnosis in siblings and children. N Engl J Med 1977; 297: 7–13.
Cartwright GE , Edwards CQ , Kravitz K , et al. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 1979; 301: 175–9.
Bassett ML , Halliday JW , Powell LW . Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24–9.
Brittenham GM , Farrell DE , Harris JW , et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307: 1671–5.
Runge VM , Clanton JA , Smith FW , et al. Nuclear magnetic resonance of iron and copper disease states. Am J Roentgenol 1983; 141: 943–8.
Brown KE , Bacon BR . Hepatic iron metabolism in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 157–62.
Adams PC , Barton JC . Haemochromatosis. Lancet 2007; 370: 1855–60.
Schumacher HRJ . Hemochromatosis and arthritis. Arth Rheum 1964; 7: 50.
Chevrant-Breton J . Cutaneous manifestations of hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 290–6.
Britton RS . Mechanisms of iron toxicity. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 229–38.
Deugnier Y , Loréal O . Iron as a carcinogen. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 239–49.
Deugnier YM , Charalambous P , le Quilleuc D , et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18: 1363–9.
Deugnier YM , Guyader D , Crantock L , et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228–34.
Brock JH . Role of iron in infections and immunity. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 371–80.
Bullen JJ . Bacterial infections in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 381–6.
de Sousa M , Porto G , Arosa FA , et al. T-lymphocyte expression and function in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 396–410.
Barton JC , Bertoli LF , Acton RT . Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y. Blood Cells Mol Dis 2003; 31: 102–11.
Barton JC , Wiener HW , Acton RT , Go RC . Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. BMC Blood Disord 2005; 5: 5.
Davis WD Jr , Arrowsmith WR . The effect of repeated phlebotomies in hemochromatosis; report of three cases. J Lab Clin Med 1952; 39: 526–32.
Niederau C , Fischer R , Sonnenberg A , Stremmel W , Trampisch HJ , Strohmeyer G . Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256–62.
Niederau C , Fischer R , Purschel A , Stremmel W , Haussinger D , Strohmeyer G . Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107–19.
Sephton-Smith R . Iron excretion in thalassemia major after administration of chelating agents. Br Med J 1962; 2: 1577.
Brittenham GM , Griffith PM , Nienhuis AW , et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567–73.
Kontoghiorghes GJ , Aldouri MA , Sheppard L , Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; 1: 1294–5.
Galanello R , Piga A , Alberti D , Rouan MC , Bigler H , Sechaud R . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565–72.
Simon M , Pawlotsky Y , Bourel M , Fauchet R , Genetet B . Hémochromatose idiopathique: maladie associée a l'antigéne tissulaire HLA 3? Nouv Presse Méd 1975; 19: 1432.
Edwards CQ , Griffen LM , Goldgar D , Drummond C , Skolnick MH , Kushner JP . Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–62.
Feder JN , Gnirke A , Thomas W , et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.
Andrews NC . Forging a field: the golden age of iron biology. Blood 2008; 112: 219–30.
Phatak PD , Sham RL , Raubertas RF , et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998; 129: 954–61.
Beutler E , Felitti V , Gelbart T , Ho N . The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329–37.
Beutler E , Felitti VJ . The C282Y mutation does not shorten life span. Arch Intern Med 2002; 162: 1196–7.
Asberg A , Hveem K , Thorstensen K , et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001; 36: 1108–15.
Olynyk JK , Cullen DJ , Aquilia S , Rossi E , Summerville L , Powell LW . A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718–24.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769–78.
Whitlock EP , Garlitz BA , Harris EL , Beil TL , Smith PR . Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145: 209–23.
Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145: 204–8.
Barton JC , Rothenberg BE , Bertoli LF , Acton RT . Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999; 1: 89–93.
Acton RT , Barton JC , Passmore LV , et al. Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2008.
Barton JC , Acton RT . Population screening for hemochromatosis: has the time finally come? Curr Gastroenterol Rep 2000; 2: 18–26.
Bacon BR , Olynyk JK , Brunt EM , Britton RS , Wolff RK . HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953–62.
Waalen J , Felitti VJ , Gelbart T , Beutler E . Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111: 3373–6.
Shaheen NJ , Lawrence LB , Bacon BR , et al. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. Am J Gastroenterol 2003; 98: 1175–80.
Hicken BL , Calhoun DA , Barton JC , Tucker DC . Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test 2004; 8: 90–7.
Power TE , Adams PC , Barton JC , et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test 2007; 11: 55–64.
Hall MA , Barton JC , Adams PC , et al. Genetic screening for iron overload: No evidence of discrimination at 1 year. J Fam Pract 2007; 56: 829–34.
Barton JC , Grindon AJ , Barton NH , Bertoli LF . Hemochromatosis probands as blood donors. Transfusion 1999; 39: 578–85.
Brittenham GM , Klein HG , Kushner JP , Ajioka RS . Preserving the national blood supply. Hematology Am Soc Hematol Educ Program 2001; 422–32.
Power TE , Adams PC . Hemochromatosis patients as voluntary blood donors. Can J Gastroenterol 2004; 18: 393–6.
Camaschella C , Roetto A , Cali A , et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14–15.
Merryweather-Clarke AT , Cadet E , Bomford A , et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241–7.
Roetto A , Papanikolaou G , Politou M , et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21–2.
Papanikolaou G , Samuels ME , Ludwig EH , et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77–82.
Sham RL , Phatak PD , West C , Lee P , Andrews C , Beutler E . Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005; 34: 157–61.
Cooley TB . A severe type of hereditary anemia with elliptocytosis: interesting sequence of splenectomy. Am J Med Sci 1945; 209: 561–8.
Cotter PD , Rucknagel DL , Bishop DF . X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood 1994; 84: 3915–24.
Heilmeyer L , Keller W , Vivell O , et al. [Congenital atransferrinemia in a 7-year-old girl.] Dtsch Med Wochenschr 1961; 86: 1745–51.
Beutler E , Gelbart T , Lee P , Trevino R , Fernandez MA , Fairbanks VF . Molecular characterization of a case of atransferrinemia. Blood 2000; 96: 4071–4.
Miyajima H , Nishimura Y , Mizoguchi K , Sakamoto M , Shimizu T , Honda N . Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761–7.
Harris ZL , Takahashi Y , Miyajima H , Serizawa M , MacGillivray RT , Gitlin JD . Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995; 92: 2539–43.
Yoshida K , Furihata K , Takeda S , et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 267–72.
Beaumont C , Leneuve P , Devaux I , et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet 1995; 11: 444–6.
Girelli D , Corrocher R , Bisceglia L , et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the “Verona mutation”). Blood 1995; 86: 4050–3.
Girelli D , Olivieri O , De Franceschi L , Corrocher R , Bergamaschi G , Cazzola M . A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol 1995; 90: 931–4.
Pietrangelo A , Montosi G , Totaro A , et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725–32.
Montosi G , Donovan A , Totaro A , et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619–23.
Kato J. [Mutation of H-ferritin gene in a family associated with hereditary iron overload: a new iron overload-related gene?] Rinsho Ketsueki 2001; 42: 403–7.
Priwitzerova M , Pospisilova D , Prchal JT , et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood 2004; 103: 3991–2.
Mims MP , Guan Y , Pospisilova D , et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005; 105: 1337–42.
Camaschella C , Campanella A , De Falco L , et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110: 1353–8.
Gordeuk V , Mukiibi J , Hasstedt SJ , et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95–100.

Reference Title: References

Reference Type: reference-list

Finch CA , Deubelbeiss K , Cook JD , et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49: 17–53.
Conrad ME , Barton JC . Factors affecting iron balance. Am J Hematol 1981; 10: 199–225.
Chung J , Wessling-Resnick M . Molecular mechanisms and regulation of iron transport. Crit Rev Clin Lab Sci 2003; 40: 151–82.
Bothwell TH , Charlton RW , Cook JD , Finch CA. Iron loss. Iron Metabolism in Man. Oxford, Blackwell Scientific Publications. 1979; 245–55.
Harrison PM , Fischbach FA , Hoy TG , Haggis GH . Ferric oxyhydroxide core of ferritin. Nature 1967; 216: 1188–90.
Theil EC . Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 1987; 56: 289–315.
Levi S , Yewdall SJ , Harrison PM , et al. Evidence of H-and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. Biochem J 1992; 288 (Pt 2): 591–6.
Harrison PM , Arosio P . The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161–203.
Wixom RL , Prutkin L , Munro HN . Hemosiderin: nature, formation, and significance. Int Rev Exp Pathol 1980; 22: 193–225.
de Domenico I , Vaughn MB , Li L , et al. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J 2006; 25: 5396–404.
Levy JE , Jin O , Fujiwara Y , Kuo F , Andrews NC . Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 1999; 21: 396–9.
Ned RM , Swat W , Andrews NC . Transferrin receptor 1 is differentially required in lymphocyte development. Blood 2003; 102: 3711–18.
Ohgami RS , Campagna DR , Greer EL , et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 2005; 37: 1264–9.
Fleming MD , Trenor CC, III , Su MA , et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16: 383–6.
Gunshin H , Mackenzie B , Berger UV , et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482–8.
Gunshin H , Fujiwara Y , Custodio AO , Direnzo C , Robine S , Andrews NC . Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005; 115: 1258–66.
Shindo M , Torimoto Y , Saito H , et al. Functional role of DMT1 in transferrin-independent iron uptake by human hepatocyte and hepatocellular carcinoma cell, HLF. Hepatol Res 2006; 35: 152–62.
Davies PS , Zhang AS , Anderson EL , et al. Evidence for the interaction of the hereditary haemochromatosis protein, HFE, with the transferrin receptor in endocytic compartments. Biochem J 2003; 373: 145–53.
Aziz N , Munro HN . Iron regulates ferritin mRNA translation through a segment of its 5' untranslated region. Proc Natl Acad Sci USA 1987; 84: 8478–82.
Hentze MW , Rouault TA , Caughman SW , Dancis A , Harford JB , Klausner RD . A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci USA 1987; 84: 6730–4.
Casey JL , Koeller DM , Ramin VC , Klausner RD , Harford JB . Iron regulation of transferrin receptor mRNA levels requires iron-responsive elements and a rapid turnover determinant in the 3' untranslated region of the mRNA. EMBO J 1989; 8: 3693–9.
Abboud S , Haile DJ . A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19 906–12.
McKie AT , Marciani P , Rolfs A , et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299–309.
Hubert N , Hentze MW . Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci USA 2002; 99: 12 345–50.
Lymboussaki A , Pignatti E , Montosi G , Garuti C , Haile DJ , Pietrangelo A . The role of the iron-responsive element in the control of ferroportin 1/IREG1/MTP1 gene expression. J Hepatol 2003; 39: 710–15.
Leipuviene R , Theil EC . The family of iron-responsive RNA structures regulated by changes in cellular iron and oxygen. Cell Mol Life Sci 2007; 64: 2945–55.
Casey JL , Hentze MW , Koeller DM , et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science 1988; 240: 924–8.
Hentze MW , Caughman SW , Rouault TA , et al. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science 1987; 238: 1570–3.
Caughman SW , Hentze MW , Rouault TA , Harford JB , Klausner RD. The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor. J Biol Chem 1988; 263: 19,048–52.
Leibold EA , Munro HN . Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy- and light-subunit mRNAs. Proc Natl Acad Sci USA 1988; 85: 2171–5.
Rouault TA , Hentze MW , Caughman SW , Harford JB , Klausner RD . Binding of a cytosolic protein to the iron-responsive element of human ferritin messenger RNA. Science 1988; 241: 1207–10.
Chen Y , Qian ZM , Du J , et al. Iron loading inhibits ferroportin 1 expression in PC12 cells. Neurochem Int 2005; 47: 507–13.
Hentze MW , Argos P. Homology between IRE-BP, a regulatory RNA-binding protein, aconitase, and isopropylmalate isomerase. Nucleic Acids Res 1991; 19: 1739–40.
Kaptain S , Downey WE , Tang C , et al. A regulated RNA-binding protein also possesses aconitase activity. Proc Natl Acad Sci USA 1991; 88: 10 109–13.
Eisenstein RS . Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000; 20: 627–62.
Walden WE , Selezneva AI , Dupuy J , et al. Structure of dual function iron regulatory protein 1 complexed with ferritin IRE-RNA. Science 2006; 314: 1903–8.
Haile DJ , Hentze MW , Rouault TA , Harford JB , Klausner RD . Regulation of interaction of the iron-responsive element-binding protein with iron-responsive RNA elements. Mol Cell Biol 1989; 9: 5055–61.
Meyron-Holtz EG , Ghosh MC , Iwai K , et al. Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J 2004; 23: 386–95.
Muckenthaler M , Gray NK , Hentze MW . IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex eIF4F. Mol Cell 1998; 2: 383–8.
Ganz T . Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006; 29–35.
Krause A , Neitz S , Magert HJ , et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147–50.
Park CH , Valore EV , Waring AJ , Ganz T . Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–10.
Pigeon C , Ilyin G , Courselaud B , et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811–19.
Scamuffa N , Basak A , Lalou C , et al. Regulation of prohepcidin processing and activity by the subtilisin-like pro-protein convertases Furin, PC5, PACE4, and PC7. Gut 2008; 57: 1573–82.
Andrews NC . Forging a field: the golden age of iron biology. Blood 2008; 112: 219–30.
Gehrke SG , Kulaksiz H , Herrmann T , et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102: 371–6.
Papanikolaou G , Samuels ME , Ludwig EH , et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77–82.
Nemeth E , Roetto A , Garozzo G , Ganz T , Camaschella C . Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105: 1803–6.
Piperno A , Girelli D , Nemeth E , et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 2007; 110: 4096–100.
Wrighting DM , Andrews NC . Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204–9.
Truksa J , Lee P , Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 2009; 113: 688–95.
Casanovas G , Mleczko-Sanecka K , Altamura S , Hentze MW , Muckenthaler MU . Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med 2009; 87: 471–80.
Merryweather-Clarke AT , Cadet E , Bomford A , et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241–7.
Jacolot S , Le Gac G , Scotet V , Quere I , Mura C , Ferec C . HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103: 2835–40.
Porto G , Roetto A , Daraio F , et al. A Portuguese patient homozygous for the -25G>A mutation of the HAMP promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron. Blood 2005; 106: 2922–3.
Nicolas G , Bennoun M , Devaux I , et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780–5.
Lesbordes-Brion JC , Viatte L , Bennoun M , et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 2006; 108: 1402–5.
Nicolas G , Bennoun M , Porteu A , et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596–601.
Roy CN , Mak HH , Akpan I , Losyev G , Zurakowski D , Andrews NC . Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007; 109: 4038–44.
Nicolas G , Chauvet C , Viatte L , et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037–44.
Weinstein DA , Roy CN , Fleming MD , Loda MF , Wolfsdorf JI , Andrews NC . Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100: 3776–81.
Adamsky K , Weizer O , Amariglio N , et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004; 124: 123–4.
Ashrafian H . Hepcidin: the missing link between hemochromatosis and infections. Infect Immun 2003; 71: 6693–700.
Ganz T . Hepcidin–a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol 2006; 306: 183–98.
Paradkar PN , De Domenico I , Durchfort N , Zohn I , Kaplan J , Ward DM . Iron depletion limits intracellular bacterial growth in macrophages. Blood 2008; 112: 866–74.
Babitt JL , Huang FW , Xia Y , Sidis Y , Andrews NC , Lin HY . Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117: 1933–9.
Babitt JL , Huang FW , Wrighting DM , et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531–9.
Wang RH , Li C , Xu X , et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399–409.
Anderson GJ , Frazer DM . Iron metabolism meets signal transduction. Nat Genet 2006; 38: 503–4.
Kautz L , Meynard D , Monnier A , et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008; 112: 1503–9.
McReynolds LJ , Gupta S , Figueroa ME , Mullins MC , Evans T . Smad1 and Smad5 differentially regulate embryonic hematopoiesis. Blood 2007; 110: 3881–90.
Truksa J , Lee P , Peng H , Flanagan J , Beutler E . The distal location of the iron-responsive region of the hepcidin promoter. Blood 2007; 110: 3436–7.
Verga Falzacappa MV , Vujic SM , Kessler R , Stolte J , Hentze MW , Muckenthaler MU . STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109: 353–8.
Peyssonnaux C , Zinkernagel AS , Schuepbach RA , et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926–32.
de Domenico I , Nemeth E , Nelson JM , et al. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab 2008; 8: 146–56.
de Domenico I , Ward DM , Musci G , Kaplan J . Evidence for the multimeric structure of ferroportin. Blood 2007; 109: 2205–9.
Schimanski LM , Drakesmith H , Talbott C , et al. Ferroportin: lack of evidence for multimers. Blood Cells Mol Dis 2008; 40: 360–9.
Nemeth E , Tuttle MS , Powelson J , et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090–3.
de Domenico I , Ward DM , Langelier C , et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007; 18: 2569–78.
Parmley RT , Barton JC , Conrad ME , Austin RL . Ultrastructural cytochemistry of iron absorption. Am J Pathol 1978; 93: 707–27.
McKie AT , Barrow D , Latunde-Dada GO , et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001; 291: 1755–9.
Ohgami RS , Campagna DR , McDonald A , Fleming MD . The Steap proteins are metalloreductases. Blood 2006; 108: 1388–94.
Canonne-Hergaux F , Gruenheid S , Ponka P , Gros P . Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 1999; 93: 4406–17.
Lam-Yuk-Tseung S , Touret N , Grinstein S , Gros P . Carboxyl-terminus determinants of the iron transporter DMT1/SLC11A2 isoform II (-IRE/1B) mediate internalization from the plasma membrane into recycling endosomes. Biochemistry 2005; 44: 12 149–59.
Andrews NC . The iron transporter DMT1. Int J Biochem Cell Biol 1999; 31: 991–4.
Frazer DM , Wilkins SJ , Becker EM , et al. A rapid decrease in the expression of DMT1 and Dcytb but not Ireg1 or hephaestin explains the mucosal block phenomenon of iron absorption. Gut 2003; 52: 340–6.
Priwitzerova M , Pospisilova D , Prchal JT , et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood 2004; 103: 3991–2.
Conrad ME , Umbreit JN , Moore EG . Rat duodenal iron-binding protein mobilferrin is a homologue of calreticulin. Gastroenterology 1993; 104: 1700–4.
Conrad ME , Umbreit JN , Peterson RD , Moore EG , Harper KP . Function of integrin in duodenal mucosal uptake of iron. Blood 1993; 81: 517–21.
Grasbeck R , Kouvonen I , Lundberg M , Tenhunen R . An intestinal receptor for heme. Scand J Haematol 1979; 23: 5–9.
Parmley RT , Barton JC , Conrad ME , Austin RL , Holland RM . Ultrastructural cytochemistry and radioautography of hemoglobin–iron absorption. Exp Mol Pathol 1981; 34: 131–44.
Grasbeck R , Majuri R , Kouvonen I , Tenhunen R . Spectral and other studies on the intestinal haem receptor of the pig. Biochim Biophys Acta 1982; 700: 137–42.
Uc A , Stokes JB , Britigan BE . Heme transport exhibits polarity in Caco-2 cells: evidence for an active and membrane protein-mediated process. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1150–7.
Shayeghi M , Latunde-Dada GO , Oakhill JS , et al. Identification of an intestinal heme transporter. Cell 2005; 122: 789–801.
Qiu A , Jansen M , Sakaris A , et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127: 917–28.
Donovan A , Brownlie A , Zhou Y , et al. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776–81.
Zoller H , Theurl I , Koch R , Kaser A , Weiss G . Mechanisms of iron mediated regulation of the duodenal iron transporters divalent metal transporter 1 and ferroportin 1. Blood Cells Mol Dis 2002; 29: 488–97.
Graham RM , Chua AC , Herbison CE , Olynyk JK , Trinder D . Liver iron transport. World J Gastroenterol 2007; 13: 4725–36.
Osaki S , Johnson DA , Frieden E . The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241: 2746–51.
Roeser HP , Lee GR , Nacht S , Cartwright GE . The role of ceruloplasmin in iron metabolism. J Clin Invest 1970; 49: 2408–17.
Vulpe CD , Kuo YM , Murphy TL , et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21: 195–99.
Anderson GJ , Frazer DM , Wilkins SJ , et al. Relationship between intestinal iron-transporter expression, hepatic hepcidin levels and the control of iron absorption. Biochem Soc Trans 2002; 30: 724–6.
de Domenico I , Ward DM , di Patti MC , et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007; 26: 2823–31.
Parmley RT , Barton JC , Conrad ME . Ultrastructural localization of transferrin, transferrin receptor, and iron-binding sites on human placental and duodenal microvilli. Br J Haematol 1985; 60: 81–9.
Feder JN , Penny DM , Irrinki A , et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472–7.
Lebron JA , Bennett MJ , Vaughn DE , et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111–23.
Shaw GC , Cope JJ , Li L , et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006; 440: 96–100.
Quigley JG , Yang Z , Worthington MT , et al. Identification of a human heme exporter that is essential for erythropoiesis. Cell 2004; 118: 757–66.
Keel SB , Doty RT , Yang Z , et al. A heme export protein is required for red blood cell differentiation and iron homeostasis. Science 2008; 319: 825–8.
Ponka P , Sheftel AD . It's hepcidin again, but is it the only master? Blood 2006; 108: 3631–2.
Yoon D , Pastore YD , Divoky V , et al. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 2006; 281: 25 703–11.
Jaakkola P , Mole DR , Tian YM , et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468–72.
Takeda K , Aguila HL , Parikh NS , et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008; 111: 3229–35.
Yamashita T , Ohneda O , Sakiyama A , Iwata F , Ohneda K , Fujii-Kuriyama Y . The microenvironment for erythropoiesis is regulated by HIF-2alpha through VCAM-1 in endothelial cells. Blood 2008; 112: 1482–92.
Chong ZZ , Kang JQ , Maiese K . Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22: 503–14.
Vokurka M , Krijt J , Sulc K , Necas E . Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55: 667–74.
Pak M , Lopez MA , Gabayan V , Ganz T , Rivera S . Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730–5.
Tanno T , Bhanu NV , Oneal PA , et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–101.
Mast AE , Foster TM , Pinder HL , et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48: 2197–204.
Brown KE , Bacon BR . Hepatic iron metabolism in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 157–62.
Hershko C , Cook JD , Finch DA. Storage iron kinetics, 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med 1973; 81: 876–86.
Morgan EH , Smith GD , Peters TJ . Uptake and subcellular processing of 59Fe-125I-labeled transferrin by rat liver. Biochem J 1986; 237: 163–73.
Young SP , Roberts S , Bomford A . Intracellular processing of transferrin and iron by isolated rat hepatocytes. Biochem J 1985; 232: 819–23.
Donovan A , Lima CA , Pinkus JL , et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1: 191–200.
Bastin J , Drakesmith H , Rees M , Sargent I , Townsend A . Localization of proteins of iron metabolism in the human placenta and liver. Br J Haematol 2006; 134: 532–43.
Canonne-Hergaux F , Donovan A , Delaby C , Wang HJ , Gros P . Comparative studies of duodenal and macrophage ferroportin proteins. Am J Physiol Gastrointest Liver Physiol 2006; 290: G156–63.
Lu JP , Hayashi K , Awai M . Transferrin receptor expression in normal, iron-deficient and iron-overloaded rats. Acta Pathol Jpn 1989; 39: 759–64.
Trinder D , Morgan EH , Baker E . The effects of an antibody to the rat transferrin receptor and of rat serum albumin on the uptake of diferric transferrin by rat hepatocytes. Biochim Biophys Acta 1988; 943: 440–6.
Sciot R , Paterson AC , Van den Oord JJ , Desmet VJ . Lack of hepatic transferrin receptor expression in hemochromatosis. Hepatology 1987; 7: 831–7.
Lombard M , Bomford A , Hynes M , et al. Regulation of the hepatic transferrin receptor in hereditary hemochromatosis. Hepatology 1989; 9: 1–5.
Morgan EH , Baker E . Iron uptake and metabolism by hepatocytes. Fed Proc 1986; 45: 2810–16.
Trinder D , Zak O , Aisen P . Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology 1996; 23: 1512–20.
Thorstensen K , Romslo I . Albumin prevents non-specific transferrin-binding and iron uptake by isolated hepatocytes. Biochim Biophys Acta 1984; 804: 393–7.
Cole ES , Glass J . Transferrin-binding and iron uptake in mouse hepatocytes. Biochim Biophys Acta 1983; 762: 102–10.
Kawabata H , Yang R , Hirama T , et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826–32.
Chua AC , Delima RD , Morgan EH , et al. Iron uptake from plasma transferrin by a transferrin receptor 2 mutant mouse model of haemochromatosis, J Hepatol 2010; 52: 425–31.
Merle U , Theilig F , Fein E , et al. Localization of the iron regulatory proteins hemojuvelin and transferrin receptor 2 to the basolateral membrane domain of hepatocytes. Histochem Cell Biol 2007; 127: 221–6.
Goswami T , Andrews NC . Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006; 281: 28 494–8.
Fleming RE , Migas MC , Holden CC , et al. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci USA 2000; 97: 2214–19.
Deaglio S , Capobianco A , Cali A , et al. Structural, functional, and tissue distribution analysis of human transferrin receptor 2 by murine monoclonal antibodies and a polyclonal antiserum. Blood 2002; 100: 3782–9.
Lee AW , Oates PS , Trinder D . Effects of cell proliferation on the uptake of transferrin-bound iron by human hepatoma cells. Hepatology 2003; 38: 967–77.
Robb A , Wessling-Resnick M . Regulation of transferrin receptor 2 protein levels by transferrin. Blood 2004; 104: 4294–9.
Johnson MB , Enns CA . Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004; 104: 4287–93.
Camaschella C . Why do humans need two types of transferrin receptor? Lessons from a rare genetic disorder. Haematologica 2005; 90: 296.
Sarkar B . State of iron(3) in normal human serum: low molecular weight and protein ligands besides transferrin. Can J Biochem 1970; 48: 1339–50.
Batey RG , Lai Chung FP , Shamir S , Sherlock S . A non-transferrin-bound serum iron in idiopathic hemochromatosis. Dig Dis Sci 1980; 25: 340–6.
Stojkovski S , Goumakos W , Sarkar B . Iron(III)-binding polypeptide in human cord and adult serum: isolation, purification and partial characterization. Biochim Biophys Acta 1992; 1137: 155–61.
Chua AC , Olynyk JK , Leedman PJ , Trinder D . Non-transferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood 2004; 104: 1519–25.
Trinder D , Morgan E . Inhibition of uptake of transferrin-bound iron by human hepatoma cells by non-transferrin-bound iron. Hepatology 1997; 26: 691–8.
Graham RM , Morgan EH , Baker E . Ferric citrate uptake by cultured rat hepatocytes is inhibited in the presence of transferrin. Eur J Biochem 1998; 253: 139–45.
Scheiber-Mojdehkar B , Zimmermann I , Dresow B , Goldenberg H . Differential response of non-transferrin-bound iron uptake in rat liver cells on long-term and short-term treatment with iron. J Hepatol 1999; 31: 61–70.
Trinder D , Oates PS , Thomas C , Sadleir J , Morgan EH . Localization of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. Gut 2000; 46: 270–6.
Worwood M , Dawkins S , Wagstaff M , Jacobs A . The purification and properties of ferritin from human serum. Biochem J 1976; 157: 97–103.
Mack U , Powell LW , Halliday JW . Detection and isolation of a hepatic membrane receptor for ferritin. J Biol Chem 1983; 258: 4672–5.
Osterloh K , Aisen P . Pathways in the binding and uptake of ferritin by hepatocytes. Biochim Biophys Acta 1989; 1011: 40–5.
Kristiansen M , Graversen JH , Jacobsen C , et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198–201.
Hvidberg V , Maniecki MB , Jacobsen C , Hojrup P , Moller HJ , Moestrup SK . Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005; 106: 2572–9.
Oshiro S , Nakajima H . Intrahepatocellular site of the catabolism of heme and globin moiety of hemoglobin-haptoglobin after intravenous administration to rats. J Biol Chem 1988; 263: 16032–8.
Hinton RH , Dobrota M , Mullock BM . Haptoglobin-mediated transfer of haemoglobin from serum into bile. FEBS Lett 1980; 112: 247–50.
Meilinger M , Haumer M , Szakmary KA , et al. Removal of lactoferrin from plasma is mediated by binding to low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor and transport to endosomes. FEBS Lett 1995; 360: 70–4.
Ziere GJ , van Dijk MC , Bijsterbosch MK , van Berkel TJ. Lactoferrin uptake by the rat liver. Characterization of the recognition site and effect of selective modification of arginine residues. J Biol Chem 1992; 267: 11 229–35.
Bennatt DJ , Ling YY , McAbee DD . Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner. Biochemistry 1997; 36: 8367–76.
Niederkofler V , Salie R , Arber S . Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005; 115: 2180–6.
Huang FW , Pinkus JL , Pinkus GS , Fleming MD , Andrews NC . A mouse model of juvenile hemochromatosis. J Clin Invest 2005; 115: 2187–91.
Feder JN , Tsuchihashi Z , Irrinki A , et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997; 272: 14,025–8.
Ganz T . Iron homeostasis: fitting the puzzle pieces together. Cell Metab 2008; 7: 288–90.
Terpstra V , van Berkel TJ . Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice. Blood 2000; 95: 2157–63.
Dennis C . Haemoglobin scavenger. Nature 2001; 409: 141.
Schaer DJ , Schaer CA , Buehler PW , et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 2006; 107: 373–80.
Knutson MD , Vafa MR , Haile DJ , Wessling-Resnick M . Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood 2003; 102: 4191–7.
Zhang AS , Xiong S , Tsukamoto H , Enns CA . Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood 2004; 103: 1509–14.
Maines MD , Gibbs PE. Thirty some years of heme oxygenase: from a “molecular wrecking ball” to a “mesmerizing” trigger of cellular events. Biochem Biophys Res Commun 2005; 338: 568–77.
Delaby C , Pilard N , Puy H , Canonne-Hergaux F . Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by heme followed by iron-dependent protein expression. Biochem J 2008; 411: 123–31.
Delaby C , Pilard N , Goncalves AS , Beaumont C , Canonne-Hergaux F . Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 2005; 106: 3979–84.
Knutson MD , Oukka M , Koss LM , Aydemir F , Wessling-Resnick M . Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 over expression and down-regulated by hepcidin. Proc Natl Acad Sci USA 2005; 102: 1324–8.
Kondo H , Saito K , Grasso JP , Aisen P . Iron metabolism in the erythrophagocytosing Kupffer cell. Hepatology 1988; 8: 32–8.
Galli A , Bergamaschi G , Recalde H , et al. Ferroportin gene silencing induces iron retention and enhances ferritin synthesis in human macrophages. Br J Haematol 2004; 127: 598–603.
Valenti L , Guido M , Dongiovanni P , Cremonesi L , Fracanzani AL , Fargion S . Ferroportin 1 in the recurrence of hepatic iron overload after liver transplantation. Dig Liver Dis 2009; 41: e17–20.
Jouanolle AM , Douabin-Gicquel V , Halimi C , et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol 2003; 39: 286–9.
Wallace DF , Clark RM , Harley HA , Subramaniam VN . Autosomal dominant iron overload due to a novel mutation of ferroportin 1 associated with parenchymal iron loading and cirrhosis. J Hepatol 2004; 40: 710–13.
Drakesmith H , Schimanski LM , Ormerod E , et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106: 1092–7.
de Domenico I , Ward DM , Musci G , Kaplan J . Iron overload due to mutations in ferroportin. Haematologica 2006; 91: 92–5.
Birgens HS , Kristensen LO , Borregaard N , Karle H , Hansen NE . Lactoferrin-mediated transfer of iron to intracellular ferritin in human monocytes. Eur J Haematol 1988; 41: 52–7.
Butler TW , Heck LW , Berkow R , Barton JC . Radioimmunometric quantification of surface lactoferrin in blood mononuclear cells. Am J Med Sci 1994; 307: 102–7.
Andreesen R , Sephton RG , Gadd S , Atkins RC , De Abrew S . Human macrophage maturation in vitro: expression of functional transferrin-binding sites of high affinity. Blut 1988; 57: 77–83.
van Berkel TJ , Dekker CJ , Kruijt JK , van Eijk HG . The interaction in vivo of transferrin and asialotransferrin with liver cells. Biochem J 1987; 243: 715–22.
Bastin JM , Jones M , O'Callaghan CA , Schimanski L , Mason DY , Townsend AR . Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Br J Haematol 1998; 103: 931–41.

Reference Title: References

Reference Type: reference-list

Britton RS . Mechanisms of iron toxicity. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 229–38.
Pietrangelo A . Mechanism of iron toxicity. Adv Exp Med Biol 2002; 509: 19–43.
Britton RS , Leicester KL , Bacon BR . Iron toxicity and chelation therapy. Int J Hematol 2002; 76: 219–28.
Papanikolaou G , Pantopoulos K . Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 119–211.
Ramm GA , Ruddell RG. Hepatotoxicity of iron overload: Mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005; 25: 433–49.
Bacon BR. Hemochromatosis: Diagnosis and management. Gastroenterology 2001; 120: 718–25.
Powell LW . Hereditary hemochromatosis and iron overload diseases. J Gastroenterol Hepatol 2002; 17 (Suppl 1): 191.
Bottomley SS . Secondary iron overload disorders. Semin Hematol 1998; 35: 77–86.
Halliwell B , Gutteridge JMC . Free Radicals in Biology and Medicine. 3rd edition. Oxford, Oxford University Press, 1999.
Young IS , Trouton TG , Torney JJ , McMaster D , Callender ME , Trimble ER . Antioxidant status and lipid peroxidation in hereditary haemochromatosis. Free Radic Biol Med 1994; 16: 393–7.
Niemela O , Parkkila S , Britton RS , Brunt E , Janney C , Bacon BR . Hepatic lipid peroxidation in hereditary hemochromatosis and alcoholic liver injury. J Lab Clin Med 1999; 133: 451–60.
Houglum K , Ramm GA , Crawford DHG , Witztum JL , Powell LW , Chojkier M . Excess iron induces hepatic oxidative stress and transforming growth factor β1 in genetic hemochromatosis. Hepatology 1997; 26: 605–10.
Kom GD , Schwedhelm E , Nielsen P , Boger RH. Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: A case-control study. Free Radic Biol Med 2006; 40: 1194–200.
Livrea MA , Tesoriere L , Pintaudi AM , et al. Oxidative stress and antioxidant status in β-thalassemia major: Iron overload and depletion of lipid-soluble antioxidants. Blood 1996; 88: 3608–14.
Iancu TC , Shiloh H. Morphological observations in iron overload: An update. Adv Exp Med Biol 1994; 356: 255–65.
Selden C , Owen M , Hopkins JMP , Peters TJ . Studies on the concentration and intracellular localization of iron proteins in liver biopsy specimens from patients with iron overload with special reference to their role in lysosomal disruption. Br J Haematol 1980; 44: 593–603.
Peters TJ , O'Connell MJ , Ward RJ . Role of free-radical mediated lipid peroxidation in the pathogenesis of hepatic damage by lysosomal disruption. In: Poli G , Cheeseman KH , Dianzani MU , Slater TF , eds. Free Radicals in Liver Injury. Oxford, IRL Press. 1985; 107–15.
O'Connell M , Halliwell B , Moorhouse CP , Aruoma OI , Baum H , Peters TJ. Formation of hydroxyl radicals in the presence of ferritin and haemosiderin. Is haemosiderin formation a biological protective mechanism? Biochem J 1986; 234: 727–31.
Myers BM , Prendergast FG , Holman R , Kuntz SM , LaRusso NF . Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest 1991; 88: 1207–15.
Bacon BR , Park CH , Brittenham GM , O'Neill R , Tavill AS . Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1985; 5: 789–97.
Bacon BR , O'Neill R , Britton RS . Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 1993; 105: 1134–40.
Bacon BR , Healey JF , Brittenham GM , et al. Hepatic microsomal function in rats with chronic dietary iron overload. Gastroenterology 1986; 90: 18443.
Britton RS , O'Neill R , Bacon BR . Chronic dietary iron overload in rats results in impaired calcium sequestration by hepatic mitochondria and microsomes. Gastroenterology 1991; 101: 806–11.
Hershko C , Link G , Konijn AM . Cardioprotective effect of iron chelators. Adv Exp Med Biol 2002; 509: 77–89.
Miranda CJ , Makui H , Soares RJ , et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 2003; 102: 2574–80.
Kowdley KV . Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127: S79–86.
Okada S. Iron-induced tissue damage and cancer: The role of reactive oxygen species-free radicals. Pathol Int 1996; 46: 311–32.
Park J-W , Floyd RA. Lipid peroxidation products mediate the formation of 8-hydroxydeoxyguanosine in DNA. Free Radic Biol Med 1992; 12: 2450.
Zhang D , Okada S , Yu Y , Zheng P , Yamaguchi R , Kasai H. Vitamin E inhibits apoptosis, DNA modification, and cancer incidence induced by iron-mediated peroxidation in Wistar rat kidney. Cancer Res 1997; 57: 2410–14.
Carmichael PL , Hewer A , Osborne MR , Strain AJ , Phillips DH . Detection of bulky DNA lesions in the liver of patients with Wilson's disease and primary haemochromatosis. Mutation Res 1995; 326: 235–43.
Nair J , Carmichael PL , Fernando RC , Phillips DH , Strain AJ , Bartsch H . Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Cancer Epidemiol Biomarkers Prev 1998; 7: 435–40.
Hussain SP , Raja K , Amstad PA , et al. Increased p53 mutation load in nontumorous human liver of Wilson's disease and hemochromatosis: Oxyradical overload diseases. Proc Natl Acad Sci USA 2000; 97: 12770.

Reference Title: References

Reference Type: reference-list

Benyamin B , McRae AF , Zhu G , et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet 2009; 84: 60.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769–78.
Barton JC , Acton RT , Dawkins FW , et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test 2005; 9: 231–41.
Harris EL , McLaren CE , Reboussin DM , et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med 2007; 167: 722–6.
Edwards CQ , Griffen LM , Kaplan J , Kushner JP. Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes. J Intern Med 1989; 226: 373–9.
Torti FM , Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505–16.
Witte DL , Crosby WH , Edwards CQ , Fairbanks VF , Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200.
Adams PC , Bhayana V. Unsaturated iron-binding capacity: a screening test for C282Y hemochromatosis? Clin Chem 2000; 46: 1870–1.
Adams PC , Kertesz AE , McLaren CE , Barr R , Bamford A , Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5211 voluntary blood donors. Hepatology 2000; 31: 1160–64.
Witte DL. Mild liver enzyme abnormalities: eliminating hemochromatosis as cause. Clin Chem 1997; 43: 1535–38.
Adams PC , Reboussin DM , Press RD , et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120: 999. e1–7.
Beutler E , Felitti VJ , Koziol JA , Ho NJ , Gelbart T. Penetrance of 845G>A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211–18.
Westerhausen M , Meuret G. Transferrin-immune complex disease. Acta Haematol 1977; 57: 96–101.
Harrison PM , Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161–203.
Worwood M. Serum ferritin. CRC Crit Rev Clin Lab Sci 1979; 10: 171–204.
Worwood M. Serum ferritin. Clin Sci (Lond) 1986; 70: 215–20.
Worwood M. Ferritin. Blood Rev 1990; 4: 259–69.
Worwood M. The diagnostic value of serum ferritin determinations for assessing iron status. Haematologia (Budap) 1987; 20: 229–35.
Herbert V , Jayatilleke E , Shaw S , et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 1997; 15: 291–6.
Morrison ED , Brandhagen DJ , Phatak PD , et al. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627–33.
Beaumont C , Simon M , Fauchet R , et al. Serum ferritin as a possible marker of the hemochromatosis allele. N Engl J Med 1979; 301: 169–74.
Waalen J , Felitti VJ , Gelbart T , Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111: 3373–6.
Barton JC. Ferritin >1000: grand for hemochromatosis screening? Blood 2008; 111: 3309.
Cox DW. Factors influencing serum ceruloplasmin levels in normal individuals. J Lab Clin Med 1966; 68: 893–904.
Tutor-Crespo MJ , Hermida J , Tutor JC. Assessment of copper status in epileptic patients treated with anticonvulsant drugs by measuring the specific oxidase activity of ceruloplasmin. Epilepsy Res 2003; 56: 1473.
de Domenico I , Word DM , di Patti MC et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing EPI-ceruloplasmin. EMBOJ 2007; 26; 2823–31.
Wilson SAK. Progressive lenticular degeneration. A familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295–309.
Davies LP , Macintyre G , Cox DW. New mutations in the Wilson disease gene, ATP7B: implications for molecular testing. Genet Test 2008; 12: 139–45.
Davies L , Kenney S , Cox DW . Wilson Disease Mutation Database. University of Alberta. 01/23/2010.
Mak CM , Lam CW. Diagnosis of Wilson's disease: a comprehensive review. Crit Rev Clin Lab Sci 2008; 45: 263–90.
Scheinberg I , Sternlieb AI. Wilson's disease. Major Probl Intern Med 1984; 23: 1–24.
Olivarez L , Caggana M , Pass KA , Ferguson P , Brewer GJ. Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach. Ann Hum Genet 2001; 65: 459–63.
Owada M , Suzuki K , Fukushi M , Yamauchi K , Kitagawa T. Mass screening for Wilson's disease by measuring urinary holoceruloplasmin. J Pediatr 2002; 140: 614–16.
Ohura T , Abukawa D , Shiraishi H , et al. Pilot study of screening for Wilson's disease using dried blood spots obtained from children seen at outpatient clinics. J Inherit Metab Dis 1999; 22: 74–80.
Yamaguchi Y , Aoki T , Arashima S , et al. Mass screening for Wilson's disease: results and recommendations. Pediatr Int 1999; 41: 405–8.
Kim GH , Yang JY , Park JY , Lee JJ , Kim JH , Yoo HW. Estimation of Wilson's disease incidence and carrier frequency in the Korean population by screening ATP7B major mutations in newborn filter papers using the SYBR green intercalator method based on the amplification refractory mutation system. Genet Test 2008; 12: 395–9.
Walshe JM , Cox DW. Effect of treatment of Wilson's disease on natural history of haemochromatosis. Lancet 1998; 352: 112–13.
Hafkemeyer P , Schupp M , Storch M , Gerok W , Haussinger D. Excessive iron storage in a patient with Wilson's disease. Clin Investig 1994; 72: 134–6.
Shiono Y , Wakusawa S , Hayashi H , et al. Iron accumulation in the liver of male patients with Wilson's disease. Am J Gastroenterol 2001; 96: 31471.
Hayashi H , Yano M , Fujita Y , Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease. Med Mol Morphol 2006; 39: 121–6.
Fasano A , Bentivoglio AR , Colosimo C. Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis. J Neurol 2007; 254: 113–14.
Abuzetun JY , Hazin R , Suker M , Porter J. A rare case of hemochromatosis and Wilson's disease coexisting in the same patient. J Natl Med Assoc 2008; 100: 112–14.
Sheldon JH. Haemochromatosis. London, Oxford University Press, 1935.
Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001; 120: 718–25.
Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321–8.
Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis 2002; 13: 80–8.
Tavill AS , Adams PC. A diagnostic approach to hemochromatosis. Can J Gastroenterol 2006; 20: 535–40.
Wheeler CJ , Kowdley KV. Hereditary hemochromatosis: a review of the genetics, mechanism, diagnosis, and treatment of iron overload. Compr Ther 2006; 32: 10–16.
Deugnier Y , Brissot P , Loreal O . Iron and the liver: update 2008. J Hepatol 2008; 48 Suppl 1: S113–123.
Emond MJ , Bronner MP , Carlson TH , Lin M , Labbe RF , Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999; 45: 340–6.
Shah S , Mayberry JF , Wicks AC , Rees Y , Playford RJ. Liver biopsy under ultrasound control: implications for training in the Calman era. Gut 1999; 45: 628–29.
Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis 2005; 25: 392–401.
Alla V , Bonkovsky HL. Iron in non-hemochromatotic liver disorders. Semin Liver Dis 2005; 25: 461–72.
Guyader D , Gandon Y. Computed tomography and magnetic resonance imaging in the diagnosis of hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 219–25.
Brittenham GM , Badman DG. Non-invasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15–19.
Gossuin Y , Roch A , Muller RN , Gillis P. Relaxation induced by ferritin and ferritin-like magnetic particles: the role of proton exchange. Magn Reson Med 2000; 43: 237–43.
Brasch RC , Wesbey GE , Gooding CA , Koerper MA. Magnetic resonance imaging of transfusional hemosiderosis complicating thalassemia major. Radiology 1984; 150: 767–71.
Stark DD , Moseley ME , Bacon BR , et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985; 154: 137–42.
Ernst O , Sergent G , Bonvarlet P , Canva-Delcambre V , Paris JC , L'Hermine C. Hepatic iron overload: diagnosis and quantification with MR imaging. Am J Roentgenol 1997; 168: 1205–8.
Gandon Y , Guyader D , Heautot JF , et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994; 193: 533–38.
Angelucci E , Giovagnoni A , Valeri G , et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood 1997; 90: 4736–42.
Olynyk JK , St Pierre TG , Britton RS , Brunt EM , Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005; 100: 837–41.
Pietrangelo A , Corradini E , Ferrara F , et al. Magnetic resonance imaging to identify classic and non-classic forms of ferroportin disease. Blood Cells Mol Dis 2006; 37: 192–6.
Ptaszek LM , Price ET , Hu MY , Yang PC. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. J Cardiovasc Magn Reson 2005; 7: 689–92.
Schocke MF , Zoller H , Vogel W , et al. Cardiac phosphorus-31 two-dimensional chemical shift imaging in patients with hereditary hemochromatosis. Magn Reson Imaging 2004; 22: 515–21.
He T , Gatehouse PD , Kirk P , et al. Black-blood T2* technique for myocardial iron measurement in thalassemia. J Magn Reson Imaging 2007; 25: 1205–9.
Wood JC , Tyszka JM , Carson S , Nelson MD , Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103: 1934–6.
Mavrogeni SI , Markussis V , Kaklamanis L , et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 2005; 75: 241–7.
Sparacia G , Iaia A , Banco A , D'Angelo P , Lagalla R. Transfusional hemochromatosis: quantitative relation of MR imaging pituitary signal intensity reduction to hypogonadotropic hypogonadism. Radiology 2000; 215: 818–23.
Karimi M , Jamalian N , Rasekhi A , Kashef S. Magnetic resonance imaging (MRI) findings of joints in young beta-thalassemia major patients: fluid surrounding the scaphoid bone: a novel finding, as the possible effect of secondary hemochromatosis. J Pediatr Hematol Oncol 2007; 29: 393–8.
Zhang J , Krinsky GA. Iron-containing nodules of cirrhosis. NMR Biomed 2004; 17: 459–64.
Rocchi E. [Magnetic resonance and hepatic siderosis]. Recenti Prog Med 1994; 85: 4471.
Barton JC , Lee PL. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G>A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis 2006; 36: 342–6.
Borgna-Pignatti C , Vergine G , Lombardo T , et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124: 114–17.
Mancuso A , Sciarrino E , Renda MC , Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006; 30: 119–24.
Deugnier YM , Guyader D , Crantock L , et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228–34.
Hiatt T , Trotter JF , Kam I. Hepatocellular carcinoma in a non-cirrhotic patient with hereditary hemochromatosis. Am J Med Sci 2007; 334: 228–30.
Mancuso A , Rigano P , Renda D , et al. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. Am J Hematol 2005; 78: 158–9.
Guyader D , Gandon Y , Sapey T , et al. Magnetic resonance iron-free nodules in genetic hemochromatosis. Am J Gastroenterol 1999; 94: 1083–6.
Bonkovsky HL , Rubin RB , Cable EE , Davidoff A , Rijcken TH , Stark DD. Hepatic iron concentration: non-invasive estimation by means of MR imaging techniques. Radiology 1999; 212: 227–34.
St Pierre TG , Clark PR , Chua-anusorn W , et al. Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855–61.
St Pierre TG , Clark PR , Chua-anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed 2004; 17: 4468.
Clark PR , Chua-anusorn W , St Pierre TG. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI. Magn Reson Med 2003; 49: 572.
Westwood MA , Anderson LJ , Firmin DN , et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging 2003; 18: 616–20.
Hankins JS , McCarville MB , Loeffler RB , et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009; 113: 4853.
Brittenham GM , Farrell DE , Harris JW , et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307: 1671.
Nielsen P , Fischer R , Engelhardt R , Tondury P , Gabbe EE , Janka GE. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 1995; 91: 827–33.
Brittenham GM , Sheth S , Allen CJ , Farrell DE. Non-invasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38: 376.
Wood JC. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol 2007; 82: 1132.
Phatak PD , Barton JC. Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients. Hematology 2003; 8: 429–32.
Olatunbosun D , Corbett WE , Ludwig J , Valberg LS. Alteration of cobalt absorption in portal cirrhosis and idiopathic hemochromatosis. J Lab Clin Med 1970; 75: 754–62.
Sorbie J , Olatunbosun D , Corbett WE , Valberg LS. Cobalt excretion test for the assessment of body iron stores. Can Med Assoc J 1971; 104: 777–82.
Valberg LS , Ludwig J , Olatunbosun D. Alteration in cobalt absorption in patients with disorders of iron metabolism. Gastroenterology 1969; 56: 2411.
Miller A , Zimelman A , Brauer MJ. A family study of a patient with idiopathic hemochromatosis. Am J Hematol 1977; 2: 41–6.
Barton JC. The absorption and metabolism of non-ferrous metals in hemochromatosis. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 131–3.
Smith TA. Human serum transferrin cobalt complex: stability and cellular uptake of cobalt. Bioorg Med Chem 2005; 13: 4576–9.
Simon M , Le Mignon L , Fauchet R , et al. A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population; and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association. Am J Hum Genet 1987; 41: 89–105.
Simon M , Yaouanq J , Fauchet R , Le Gall JY , Brissot P , Bourel M. Genetics of hemochromatosis: HLA association and mode of inheritance. Ann N Y Acad Sci 1988; 526: 11–22.
Simon M , Bourel M , Fauchet R , Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976; 17: 332–4.
Simon M , Alexandre JL , Bourel M , Le Marec B , Scordia C. Heredity of idiopathic haemochromatosis: a study of 106 families. Clin Genet 1977; 11: 327–41.
Yaouanq J. Human leukocyte antigen (HLA) association and typing in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 63–74.
Porto G , de Sousa M. Variation of hemochromatosis prevalence and genotype in national groups. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 51–62.
Barton JC , Acton RT. HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFE C282Y homozygosity in central Alabama. BMC Med Genet 2002; 3: 9.
Jazwinska EC. The ancestral haplotype in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 91–8.
Feder JN , Gnirke A , Thomas W , et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.
Distante S , Robson KJ , Graham-Campbell J , Arnaiz-Villena A , Brissot P , Worwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004; 115: 269–79.
Ajioka RS , Jorde LB , Gruen JR , et al. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am J Hum Genet 1997; 60: 1439–47.
Milman N , Pedersen P. Evidence that the Cys282Tyr mutation of the HFE gene originated from a population in southern Scandinavia and spread with the Vikings. Clin Genet 2003; 64: 36–47.
Crawford DHG , Powell LW , Leggett BA , et al. Evidence that the ancestral haplotype in Australian hemochromatosis patients may be associated with a common mutation in the gene. Am J Hum Genet 1995; 57: 362–7.
Barton JC , Harmon L , Rivers C , Acton RT. Hemochromatosis: association of severity of iron overload with genetic markers. Blood Cells Mol Dis 1996; 22: 195–204.
Piperno A , Arosio C , Fargion S , et al. The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology 1996; 24: 43–6.
Barton JC , Shih WW , Sawada-Hirai R , et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997; 23: 135–45.
Barton JC , Wiener HW , Acton RT , Go RC. HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol Dis 2005; 34: 38–47.
Barton JC , Wiener HW , Acton RT , Go RC. Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. BMC Blood Disord 2005; 5: 5.
Krayenbuehl PA , Maly FE , Hersberger M , et al. Tumor necrosis factor-alpha -308G>A allelic variant modulates iron accumulation in patients with hereditary hemochromatosis. Clin Chem 2006; 52: 1552–8.
Fargion S , Valenti L , Dongiovanni P , et al. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001; 97: 3707–12.
Acton RT , Snively BM , Barton JC , et al. A genome-wide linkage scan for iron phenotype quantitative trait loci: the HEIRS Family Study. Clin Genet 2007; 71: 518–29.
Meynard D , Kautz L , Darnaud V , Canonne-Hergaux F , Coppin H , Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41: 478–81.
Andriopoulos B, Jr. , Corradini E , Xia Y , et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482–7.
Cappuccio J , Phatak PD. Cost-effectiveness of screening for hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 525–34.
Biasiotto G , Belloli S , Ruggeri G , et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003; 49: 1981–8.
Dupradeau FY , Pissard S , Coulhon MP , et al. An unusual case of hemochromatosis due to a new compound heterozygosity in HFE (p.[Gly43Asp;His63Asp]+[Cys282Tyr]): structural implications with respect to binding with transferrin receptor 1. Hum Mutat 2008; 29: 206.
Mendes AI , Ferro A , Martins R , et al. Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes. Ann Hematol 2009; 88: 229–34.
de Villiers JN , Hillermann R , Loubser L , Kotze MJ. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum Mol Genet 1999; 8: 1517–22.
Henz S , Reichen J, Liechti-Gallati S. HLA-H gene mutations and haemochromatosis: the likely association of H63D with mild phenotype and the detection of S65C, a novel variant in exon 2 [abstract]. J Hepatol 1997; 26: 57A.
Beutler E , Griffin MJ , Gelbart T , West C. A previously undescribed nonsense mutation of the HFE gene. Clin Genet 2002; 61: 40–2.
Barton JC , Sawada-Hirai R , Rothenberg BE , Acton RT. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis 1999; 25: 1475.
Barton JC , West C , Lee PL , Beutler E. A previously undescribed frameshift deletion mutation of HFE (c.del277; G93fs) associated with hemochromatosis and iron overload in a C282Y heterozygote. Clin Genet 2004; 66: 214–16.
Cukjati M , Koren S , Curin S , V , Vidan-Jeras B , Rupreht R. A novel homozygous frameshift deletion c.471del of HFE associated with hemochromatosis. Clin Genet 2007; 71: 350–3.
Pointon JJ , Lok CY , Shearman JD , et al. A novel HFE mutation (c.del478) results in nonsense-mediated decay of the mutant transcript in a hemochromatosis patient. Blood Cells Mol Dis 2009; 43: 194–8.
Oberkanins C , Moritz A , de Villiers JN , Kotze MJ , Kury F. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 2000; 4: 121–4.
Piperno A , Arosio C , Fossati L , et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology 2000; 119: 441.
Bradbury R , Fagan E , Payne SJ. Two novel polymorphisms (E277K and V212V) in the haemochromatosis gene HFE . Hum Mutat 2000; 15: 120.
A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997; 41: 841–4.
Rosmorduc O , Poupon R , Nion I , et al. Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology 2000; 119: 1075–86.
Le Gac G , Dupradeau FY , Mura C , et al. Phenotypic expression of the C282Y/Q283P compound heterozygosity in HFE and molecular modeling of the Q283P mutation effect. Blood Cells Mol Dis 2003; 30: 231–7.
Beutler E , West C. New diallelic markers in the HLA region of chromosome 6. Blood Cells Mol Dis 1997; 23: 219–29.
Wallace DF , Dooley JS , Walker AP. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 1999; 116: 1409–12.
Steiner M , Ocran K , Genschel J , et al. A homozygous HFE gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin. Gastroenterology 2002; 122: 789–95.
Le Gac G , Gourlaouen I , Ronsin C , et al. Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype. Blood 2008; 112: 5238–40.
Pelucchi S , Mariani R , Bertola F , Arosio C , Piperno A. Homozygous deletion of HFE: the Sardinian hemochromatosis? Blood 2009; 113: 3886.
Cohen AR , Galanello R , Pennell DJ , Cunningham MJ , Vichinsky E . Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 14–34.
Barton JC , Rothenberg BE , Bertoli LF , Acton RT. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999; 1: 89–93.

Reference Title: References

Reference Type: reference-list

Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001; 120: 718–25.
Brissot P. Clinical spectrum of hepatic disease in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 250.
Britton RS. Mechanisms of iron toxicity. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 229–38.
Papanikolaou G , Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199–211.
Powell LW. Hereditary hemochromatosis and iron overload diseases. J Gastroenterol Hepatol 2002; 17 Suppl: S191.
Ramm GA , Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005; 25: 433–49.
Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321–8.
Bottomley SS. Secondary iron overload disorders. Semin Hematol 1998; 35: 77–86.
Harrison SA , Bacon BR. Hereditary hemochromatosis: update for 2003. J Hepatol 2003; 38 Suppl 1: S14–S23.
Alla V , Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005; 25: 4612.
Phillips JD , Bergonia HA , Reilly CA , Franklin MR , Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 2007; 104: 5079–84.
Lambrecht RW , Thapar M , Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis 2007; 27: 99–108.
Adams PC , Kertesz AE , Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991; 90: 445–9.
Bacon BR , Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92: 784–9.
Adams P , Brissot P , Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 48504.
Bulaj ZJ , Ajioka RS , Phillips JD , et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529–35.
Powell LW , Dixon JL , Ramm GA , et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166: 294–301.
Asberg A , Hveem K , Kannelonning K , Irgens WO. Penetrance of the C28Y/C282Y genotype of the HFE gene. Scand J Gastroenterol 2007; 42: 1073.
Allen KJ , Gurrin LC , Constantine CC , et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221–30.
Fletcher LM , Dixon JL , Purdie DM , Powell LW , Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122: 281–9.
Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis 2005; 25: 392–401.
Deugnier Y , Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 2007; 13: 4755–60.
Grove J , Daly AK , Burt AD , et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998; 43: 262–6.
Lauret E , Rodriguez M , Gonzalez S , et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 1016–21.
Harrison-Findik DD , Schafer D , Klein E , et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 2006; 281: 22974–82.
Van Thiel DH , Friedlander L , Fagiuoli S , Wright HI , Irish W , Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410–15.
Olynyk JK , Reddy KR , Di Bisceglie AM , et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104–9.
Piperno A , Sampietro M , D'Alba R , et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 2484.
Fargion S , Fracanzani AL , Sampietro M , et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997; 9: 49703.
Fong TL , Han SH , Tsai NC , et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998; 28: 3694.
Fontana RJ , Israel J , LeClair P , et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000; 31: 730–6.
Di Bisceglie AM , Bonkovsky HL , Chopra S , et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135–8.
Yano M , Hayashi H , Wakusawa S , et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002; 97: 133.
Rulyak SJ , Eng SC , Patel K , McHutchison JG , Gordon SC , Kowdley KV. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005; 100: 332.
Beinker NK , Voigt MD , Arendse M , Smit J , Stander IA , Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996; 25: 633–8.
Smith BC , Gorve J , Guzail MA , et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695–9.
Martinelli AL , Franco RF , Villanova MG , et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000; 102: 152–6.
Negro F , Samii K , Rubbia-Brandt L , et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000; 60: 21.
George DK , Goldwurm S , MacDonald GA , et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311–18.
Bonkovsky HL , Jawaid Q , Tortorelli K , et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421–9.
Chitturi S , Weltman M , Farrell GC , et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142–9.
Valenti L , Dongiovanni P , Fracanzani AL , et al. Increased susceptibility to non-alcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172–8.
Nishina S , Hino K , Korenaga M , et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226–38.
Niederau C , Fischer R , Sonnenberg A , Stremmel W , Trampisch HJ , Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256–62.
Deugnier YM , Loreal O. Iron as a carcinogen. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 239–49.
Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127: S79–S86.
Harrison SA , Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 2005; 89: 391–409.
Ellervik C , Birgens H , Tybjaerg-Hansen A , Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46: 1071–80.
Lowes KN , Brennan BA , Yeoh GC , Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154: 537–41.
Deugnier YM , Charalambous P , Le Quilleuc D , et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18: 1363–9.
Deugnier YM , Guyader D , Crantock L , et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228–34.
Bezançon F , de Gennes I , Delarue J , Oumensky V. Cirrhose pigmentaire avec infantilisme et insuffisance cardiaque et aplasie endocriniennes multiples. Bull Mém Soc Méd Hôp Paris 1932; 48: 967.
de Vericourt R. Le syndrome endocrino-hepato-myocardiaque (sur un aspect des cirrhoses pigmentaires). Paris. 1935.
Sheldon JH. Haemochromatosis. London, Oxford University Press, 1935.
Muhlestein JB. Cardiac abnormalities in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 297–311.
Willis G , Scott DG , Jennings BA , Smith K , Bukhari M , Wimperis JZ. HFE mutations in an inflammatory arthritis population. Rheumatology (Oxford) 2002; 41: 176–9.
Stevens SM , Edwards CQ. Identifying and managing hemochromatosis arthropathy. J Musculoskel Med 2009; 26: 15–24.
Schumacher HR , Straka PC , Krikker MA , Dudley AT. The arthropathy of hemochromatosis. Recent studies. Ann NY Acad Sci 1988; 526: 224–33.
McClain DA , Abraham D , Rogers J , et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006; 49: 1661–9.
Wilson JG. Iron and glucose homeostasis: new lessons from hereditary haemochromatosis. Diabetologia 2006; 49: 1459–61.
Cooksey RC , Jouihan HA , Ajioka RS , et al. Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 2004; 145: 5305–12.
Fernández-Real JM , López-Bermejo A , Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 2005; 51: 1201.
Finch SC , Finch CA. Idiopathic hemochromatosis, an iron storage disease. Medicine 1966; 34: 381–430.
Dymock IW , Cassar J , Pyke DA , Oakley WG , Williams R. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972; 52: 203–10.
Saddi R , Feingold J. Idiopathic haemochromatosis and diabetes mellitus. Clin Genet 1974; 5: 242.
Niederau C , Fischer R , Purschel A , Stremmel W , Haussinger D , Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107–19.
Yaouanq JM. Diabetes and haemochromatosis: current concepts, management, and prevention. Diabete Metab 1995; 21: 319–29.
Adams PC , Valberg LS. Evolving expression of hereditary hemochromatosis. Semin Liver Dis 1996; 16: 474.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.
Beutler E , Felitti VJ , Koziol JA , Ho NJ , Gelbart T. Penetrance of 845G–> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211–18.
Braun J , Donner H , Plock K , Rau H , Usadel KH , Badenhoop K. Hereditary haemochromatosis mutations (HFE) in patients with type 2 diabetes mellitus. Diabetologia 1998; 41: 983–4.
Davis TM , Beilby J , Davis WA , et al. Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2008; 31: 1795–801.
Dubois-Laforgue D , Larger E , Timsit J. [Is diabetes mellitus a sufficient condition to suspect hemochromatosis?] Diabetes Metab 2000; 26: 318–21.
Fernández-Real JM , Vendrell J , Baiget M , Gimferrer E , Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 1999; 22: 525–6.
Frayling T , Ellard S , Grove J , Walker M , Hattersley AT. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet 1998; 351: 1933–4.
Habeos IG , Psyrogiannis A , Kyriazopoulou V , Psilopanagiotou A , Papavassiliou AG , Vagenakis AG. The role of hemochromatosis C282Y and H63D mutations in the development of type 2 diabetes mellitus in Greece. Hormones (Athens) 2003; 2: 55–60.
Hahn JU , Steiner M , Bochnig S , Schmidt H , Schuff-Werner P , Kerner W. Evaluation of a diagnostic algorithm for hereditary hemochromatosis in 3500 patients with diabetes. Diabetes Care 2006; 29: 464–6.
Halsall DJ , McFarlane I , Luan J , Cox TM , Wareham NJ. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case-control study. Hum Mol Genet 2003; 12: 1361.
Singh BM , Grunewald RA , Press M , Muller BR , Wise PH. Prevalence of haemochromatosis among patients with diabetes mellitus. Diabet Med 1992; 9: 730–1.
Turnbull AJ , Mitchison HC , Peaston RT , et al. The prevalence of hereditary haemochromatosis in a diabetic population. Q J Med 1997; 90: 271.
Vantyghem MC , Fajardy I , Dhondt F , et al. Phenotype and HFE genotype in a population with abnormal iron markers recruited from an Endocrinology Department. Eur J Endocrinol 2006; 154: 835–41.
Conte D , Manachino D , Colli A , et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998; 128: 370–3.
Ellervik C , Mandrup-Poulsen T , Nordestgaard BG , et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 1405–9.
Kwan T , Leber B , Ahuja S , Carter R , Gerstein HC. Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med 1998; 21: 251.
Moczulski DK , Grzeszczak W , Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 2001; 24: 1187–91.
Phelps G , Chapman I , Hall P , Braund W , Mackinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet 1989; 2: 233–4.
Strohmeyer G , Niederau C. Diabetes mellitus and hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 2694.
Bomford A , Williams R. Long-term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976; 45: 611–23.
Niederau C , Strohmeyer G. Survival in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 359–68.
Duranteau L , Chanson P , Blumberg-Tick J , et al. Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. Acta Endocrinol (Copenh) 1993; 128: 351–4.
McDermott JH , Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 2005; 90: 2451.
Bezwoda WR , Bothwell TH , Van Der Walt LA , Kronheim S , Pimstone BL. An investigation into gonadal dysfunction in patients with idiopathic haemochromatosis. Clin Endocrinol (Oxf) 1977; 6: 377–85.
Charbonnel B , Chupin M , Le Grand A , Guillon J. Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) 1981; 98: 178–83.
Kelly TM , Edwards CQ , Meikle AW , Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101: 629–32.
Lufkin EG , Baldus WP , Bergstralh EJ , Kao PC. Influence of phlebotomy treatment on abnormal hypothalamic-pituitary function in genetic hemochromatosis. Mayo Clin Proc 1987; 62: 473–9.
MacDonald RA , Mallory GK. Hemochromatosis and hemosiderosis. Arch Intern Med 1960; 105: 68600.
Piperno A , Rivolta MR , D'Alba R , et al. Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction. J Endocrinol Invest 1992; 15: 423–28.
Walsh CH , Wright AD , Williams JW , Holder G. A study of pituitary function in patients with idiopathic hemochromatosis. J Clin Endocrinol Metab 1976; 43: 8662.
Walton C , Kelly WF , Laing I , Bu'lock DE. Endocrine abnormalities in idiopathic haemochromatosis. Q J Med 1983; 52: 99–110.
Edwards CQ , Kelly TM , Ellwein G , Kushner JP. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 1983; 143: 1890–3.
Tamagno G , De Carlo E , Murialdo G , Scandellari C. A possible link between genetic hemochromatosis and autoimmune thyroiditis. Minerva Med 2007; 98: 7692.
Hempenius LM , van Dam PS , Marx JJ , Koppeschaar HP. Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis. J Endocrinol Invest 1999; 22: 3696.
Murphy MS , Walsh CH. Thyroid function in haemochromatosis. Ir J Med Sci 2004; 173: 27–9.
Paris I , Hermans M , Buysschaert M. [Endocrine complications of genetic hemochromatosis.] Acta Clin Belg 1999; 54: 334–45.
Walsh CH. Non-diabetic endocrinopathy in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 278–89.
Barton JC , Leiendecker-Foster C , Reboussin DM , Adams PC , Acton RT , Eckfeldt JH. Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS Study. Thyroid 2008; 18: 831–8.
Asberg A , Hveem K , Kruger O , Bjerve KS. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol 2002; 37: 719–24.
Cawley EP , Hsu YT , Wood BT , Weary PE. Hemochromatosis and the skin. Arch Dermatol 1969; 100: 1–6.
Edwards CQ , Cartwright GE , Skolnick MH , Amos DB. Homozygosity for hemochromatosis: clinical manifestations. Ann Intern Med 1980; 93: 519–25.
Troisier M. Diabète sucré. Bull Soc Anat Paris 1871; 16: 231–35.
Chevrant-Breton J , Simon M , Bourel M , Ferrand B. Cutaneous manifestations of idiopathic hermochromatosis. Study of 100 cases. Arch Dermatol 1977; 113: 161.
Chevrant-Breton J. Cutaneous manifestations of hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment, Cambridge, Cambridge University Press. 2000; 290–6.
Milman N. Hereditary haemochromatosis in Denmark 1950–1985. Clinical, biochemical and histological features in 179 patients and 13 preclinical cases. Dan Med Bull 1991; 38: 385–93.
Bacon BR , Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92: 784–9.
Barton JC , Barton NH , Alford TJ. Diagnosis of hemochromatosis probands in a community hospital. Am J Med 1997; 103: 49803.
De Gobbi M , Roetto A , Piperno A , et al. Natural history of juvenile haemochromatosis. Br J Haematol 2002; 117: 973–9.
Davies G , Dymock I , Harry J , Williams R. Deposition of melanin and iron in ocular structures in haemochromatosis. Br J Ophthalmol 1972; 56: 338–42.
Mills PR , Skerrow CJ , MacKie RM. Melanin pigmentation of the skin in primary biliary cirrhosis. J Cutan Pathol 1981; 8: 404–10.
Smith AG , Shuster S , Bomford A , Williams R. Plasma immunoreactive beta-melanocyte-stimulating hormone in chronic liver disease and fulminant hepatic failure. J Invest Dermatol 1978; 70: 326–27.
Byrnes V , Ryan E , O'Keane C , Crowe J. Immunohistochemistry of the Hfe protein in patients with hereditary hemochromatosis, iron deficiency anemia, and normal controls. Blood Cells Mol Dis 2000; 26: 2–8.
Parkkila S , Parkkila AK , Waheed A , et al. Cell surface expression of HFE protein in epithelial cells, macrophages, and monocytes. Haematologica 2000; 85: 340.
Mukerji SK , Pimstone NR. In vitro studies of the mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron under anaerobic conditions. Arch Biochem Biophys 1986; 244: 619–29.
Young LC. Porphyria cutanea tarda associated with Cys282Tyr mutation in HFE gene in hereditary hemochromatosis: a case report and review of the literature. Cutis 2007; 80: 415–18.
Syn WK , Ahmed MM. Genetic haemochromatosis presenting as porphyria cutanea tarda. Int J Clin Pract Suppl 2005; 480.
Mehrany K , Drage LA , Brandhagen DJ , Pittelkow MR. Association of porphyria cutanea tarda with hereditary hemochromatosis. J Am Acad Dermatol 2004; 51: 205–11.
Lambrecht RW , Bonkovsky HL. Hemochromatosis and porphyria. Semin Gastrointest Dis 2002; 13: 109–19.
Bulaj ZJ , Phillips JD , Ajioka RS , et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95: 15651.
Witte DL , Crosby WH , Edwards CQ , Fairbanks VF , Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200.
Adams PC , Deugnier Y , Moirand R , Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 162–6.
Waalen J , Felitti V , Gelbart T , Ho NJ , Beutler E. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc 2002; 77: 522–30.
Stovner LJ , Hagen K , Waage A , Bjerve KS. Hereditary haemochromatosis in two cousins with cluster headache. Cephalalgia 2002; 22: 317–19.
Barton JC , Wooten VD , Acton RT. Hemochromatosis and iron therapy of restless legs syndrome. Sleep Med 2001; 2: 2491.
Shaughnessy P , Lee J , O'Keeffe ST. Restless legs syndrome in patients with hereditary hemochromatosis. Neurology 2005; 64: 2158.
Earley CJ. Hemochromatosis and iron therapy of restless legs syndrome. Sleep Med 2001; 2: 181–3.
Haba-Rubio J , Staner L , Petiau C , Erb G , Schunck T , Macher JP. Restless legs syndrome and low brain iron levels in patients with haemochromatosis. J Neurol Neurosurg Psychiatry 2005; 76: 1009–10.
Barton JC , Bertoli LF , Acton RT. Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y. Blood Cells Mol Dis 2003; 31: 102–11.
Barton JC , Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol 2009; 43: 890–3.
Edwards CQ , Carroll M , Bray P , Cartwright GE. Hereditary hemochromatosis. Diagnosis in siblings and children. N Engl J Med 1977; 297: 7–13.
Island ML , Jouanolle AM , Mosser A , et al. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica 2009; 94: 720–4.
Barton JC , LaFreniere SA , Leiendecker-Foster C , et al. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. Am J Hematol 2009; 84: 710–14.
Asberg A , Hveem K , Thorstensen K , et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001; 36: 1108–15.
Milder MS , Cook JD , Stray S , Finch CA. Idiopathic hemochromatosis, an interim report. Medicine (Baltimore) 1980; 59: 34–49.
Edwards CQ , Dadone MM , Skolnick MH , Kushner JP. Hereditary haemochromatosis. Clin Haematol 1982; 11: 411–35.
Fargion S , Mandelli C , Piperno A , et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992; 15: 655–9.
Moirand R , Adams PC , Bicheler V , Brissot P , Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997; 127: 105–10.
Edwards CQ , Griffen LM , Bulaj ZS , Ajioka RS , Kushner JP. Estimate of the frequency of morbid complications of hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 312–17.
Edwards CQ. Hemochromatosis. In: Greer JP , Foerster J , Rodgers GM , et al., eds. Wintrobe's Clinical Hematology 12th edn. Philadelphia, Lippincott Williams and Wilkins. 2009; 857–80.
Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003; 101: 33470.
Ajioka RS , Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 2003; 101: 3351–3.
McCune A , Worwood M. Penetrance in hereditary hemochromatosis. Blood 2003; 102: 2696.
Wojcik JP , Speechley MR , Kertesz AE , Chakrabarti S , Adams PC. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002; 16: 297–302.

Reference Title: References

Reference Type: reference-list

Moirand R , Mortaji AM , Loreal O , Paillard F , Brissot P , Deugnier Y . A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349: 95.
Fernandez-Real JM , Ricart-Engel W , Arroyo E , et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62–8.
Mendler MH , Turlin B , Moirand R , et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155–63.
Fargion S , Mattioli M , Fracanzani AL , et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for non-alcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 24485.
Wrede CE , Buettner R , Bollheimer LC , Scholmerich J , Palitzsch KD , Hellerbrand C . Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333–40.
Bozzini C , Girelli D , Olivieri O , et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061–3.
Dongiovanni P , Valenti L , Ludovica FA , Gatti S , Cairo G , Fargion S . Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008; 172: 738–47.
Grundy SM . A constellation of complications: the metabolic syndrome. Clin Cornerstone 2005; 7: 36–45.
Reaven GM . The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391–406.
Grundy SM . Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629–36.
Batsis JA , Nieto-Martinez RE , Lopez-Jimenez F . Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007; 82: 509–24.
Valenti L , Dongiovanni P , Fracanzani AL , et al. Increased susceptibility to non-alcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172–8.
Harrison SA , Neuschwander-Tetri BA . Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Clin Liver Dis 2004; 8: 8619, ix.
Marchesini G , Brizi M , Morselli-Labate AM , et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450.
Marchesini G , Brizi M , Bianchi G , et al. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 18440.
Neuschwander-Tetri BA . Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007; 23: 193–8.
Aigner E , Theurl I , Theurl M , et al. Pathways underlying iron accumulation in human non-alcoholic fatty liver disease. Am J Clin Nutr 2008; 87: 1374–83.
Facchini FS , Hua NW , Stoohs RA . Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 931–9.
Valenti L , Fracanzani AL , Dongiovanni P , et al. Iron depletion by phlebotomy improves insulin resistance in patients with non-alcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251–8.
Fernandez-Real JM , Lopez-Bermejo A , Ricart W . Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 23484.
Swaminathan S , Fonseca VA , Alam MG , Shah SV . The role of iron in diabetes and its complications. Diabetes Care 2007; 30: 1926–33.
Turlin B , Mendler MH , Moirand R , Guyader D , Guillygomarc'h A , Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001; 116: 2630.
Non-alcoholic steatohepatitis clinical research network . Hepatology 2003; 37: 244.

Reference Title: References

Reference Type: reference-list

Blake PA , Merson MH , Weaver RE , Hollis DG , Heublein PC . Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 1979; 300: 1.
Bonner JR , Coker AS , Berryman CR , Pollock HM . Spectrum of Vibrio infections in a Gulf Coast community. Ann Intern Med 1983; 99: 464–9.
McManus R , Gordon RS . Highly invasive new bacterium isolated from US East Coast waters. JAMA 1984; 251: 323.
Muench KH . Hemochromatosis and infection: alcohol and iron, oysters and sepsis. Am J Med 1989; 87: 40N–3N.
Bullen JJ , Spalding PB , Ward CG , Gutteridge JM . Hemochromatosis, iron, and septicemia caused by Vibrio vulnificus . Arch Intern Med 1991; 151: 1606–9.
Bullen JJ . Bacterial infections in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge, Cambridge University Press. 2000; 381–6.
Gerhard GS , Levin KA , Price GJ , Wojnar MM , Chorney MJ , Belchis DA . Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation. Arch Pathol Lab Med 2001; 125: 1107–9.
Barton JC , Coghlan ME , Reymann MT , Ozbirn TW , Acton RT . Vibrio vulnificus infection in a hemodialysis patient receiving intravenous iron therapy. Clin Infect Dis 2003; 37: e63–e67.
Barton JC , Ratard RC . Vibrio vulnificus bacteremia associated with chronic lymphocytic leukemia, hypogammaglobulinemia, and hepatic cirrhosis: relation to host and exposure factors in 252 V. vulnificus infections reported in Louisiana. Am J Med Sci 2006; 332: 216–20.
Byrnes JM . Necrotizing fasciitis: a common problem in Darwin. Int J Low Extrem Wounds 2006; 5: 2716.
Khan FA , Fisher MA , Khakoo RA . Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis 2007; 11: 482.
Ralph A , Currie BJ . Vibrio vulnificus and V. parahaemolyticus necrotising fasciitis in fishermen visiting an estuarine tropical northern Australian location. J Infect 2007; 54: e111–14.
Kim DM , Cho HS , Kang JI , Kim HS , Park CY . Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction. J Infect 2008; 57: 489–92.
Barton JC , Acton RT . Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol 2009; 43: 890–3.
Robins-Browne RM , Rabson AR , Koornhof HJ . Generalized infection with Yersinia enterocolitica and the role of iron. Contrib Microbiol Immunol 1979; 5: 277–82.
Abbott M , Galloway A , Cunningham JL . Haemochromatosis presenting with a double Yersinia infection. J Infect 1986; 13: 143.
Conway SP , Dudley N , Sheridan P , Ross H . Haemochromatosis and aldosterone deficiency presenting with Yersinia pseudotuberculosis septicaemia. Postgrad Med J 1989; 65: 174–6.
Olesen LL , Ejlertsen T , Paulsen SM , Knudsen PR . Liver abscesses due to Yersinia enterocolitica in patients with haemochromatosis. J Intern Med 1989; 225: 351–4.
Munoz MT , Garcia PJ , Collazos GJ , de Miguel PJ . [Yersinia enterocolitica bacteremia and hemochromatosis.] Rev Clin Esp 1991; 189: 92.
Vadillo M , Corbella X , Pac V , Fernandez-Viladrich P , Pujol R . Multiple liver abscesses due to Yersinia enterocolitica discloses primary hemochromatosis: three cases reports and review. Clin Infect Dis 1994; 18: 938–41.
Collazos J , Guerra E , Fernandez A , Mayo J , Martinez E . Miliary liver abscesses and skin infection due to Yersinia enterocolitica in a patient with unsuspected hemochromatosis. Clin Infect Dis 1995; 21: 223–4.
Abdelli N , Thiefin G , Chevalier P , Zeitoun P . [Spontaneously regressive liver abscess caused by Yersinia enterocolitica revealing genetic hemochromatosis: a second case.] Gastroenterol Clin Biol 1996; 20: 212–13.
Piroth L , Meyer P , Bielefeld P , Besancenot JF . [Yersinia bacteremia and iron overload.] Rev Med Interne 1997; 18: 932–8.
Bergmann TK , Vinding K , Hey H . Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis. Scand J Gastroenterol 2001; 36: 891.
Hopfner M , Nitsche R , Rohr A , Harms D , Schubert S , UR Folsch . Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis. Scand J Gastroenterol 2001; 36: 220–4.
Mennecier D , Lapprand M , Hernandez E , et al. [Liver abscesses due to Yersinia pseudotuberculosis discloses a genetic hemochromatosis.] Gastroenterol Clin Biol 2001; 25: 1113–15.
Benbrika S , Boukari L , Stirnemann J , et al. [A case of yersiniasis with multiple liver abscesses.] Rev Med Interne 2005; 26: 151–2.
Crosbie J , Varma J , Mansfield J . Yersinia enterocolitica infection in a patient with hemochromatosis masquerading as proximal colon cancer with liver metastases: report of a case. Dis Colon Rectum 2005; 48: 390–2.
Sinkovics JG , Cormia F , Plager C . Hemochromatosis and Listeria infection. Arch Intern Med 1980; 140: 284.
van Asbeck BS , Verbrugh HA , van Oost BA , Marx JJ , Imhof HW , Verhoef J . Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J (Clin Res Ed) 1982; 284: 542–4.
Mossey RT , Sondheimer J . Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 1985; 79: 397–400.
Henrion J , de Neve A , Heller F . [Bacterial septicemia: an unrecognized complication of hemochromatosis. Study of 3 cases and review of the literature.] Acta Clin Belg 1986; 41: 10–17.
Calubiran OV , Horiuchi J , Klein NC , Cunha BA . Listeria monocytogenes meningitis in a human immunodeficiency virus-positive patient undergoing hemodialysis. Heart Lung 1990; 19: 21–3.
Hoen B , Kessler M . [Infectious risks in patients with renal failure on hemodialysis. Importance of iron overload and deferoxamine.] Presse Med 1991; 20: 681–2.
Manso C , Rivas I , Peraire J , Vidal F , Richart C . Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Scand J Infect Dis 1997; 29: 308–9.
Seeger W , Hugo F , Heine C , Handrick W . [Listeriosis in a patient with hemodialysis and iron overload.] Med Klin (Munich) 2007; 102: 483.
Brennan RO , Crain BJ , Proctor AM , Durack DT . Cunninghamella: a newly recognized cause of rhinocerebral mucormycosis. Am J Clin Pathol 1983; 80: 98–102.
Van Johnson E , Kline LB , Julian BA , Garcia JH . Bilateral cavernous sinus thrombosis due to mucormycosis. Arch Ophthalmol 1988; 106: 1089–92.
McNab AA , McKelvie P . Iron overload is a risk factor for zygomycosis. Arch Ophthalmol 1997; 115: 919–21.
MacSween RNM . Acute abdominal crises, circulatory collapse and sudden death in haemochromatosis. Q J Med 1966; 35: 589–98.
Christopher GW . Escherichia coli bacteremia, meningitis, and hemochromatosis. Arch Intern Med 1985; 145: 1908.
Corke PJ , McLean AS , Stewart D , Adams S . Overwhelming Gram-negative septic shock in haemochromatosis. Anaesth Intensive Care 1995; 23: 346–9.
Christopher GW . Escherichia coli bacteremia, meningitis, and hemochromatosis. Arch Intern Med 1985; 145: 1908.
Corke PJ , McLean AS , Stewart D , Adams S . Overwhelming Gram-negative septic shock in haemochromatosis. Anaesth Intensive Care 1995; 23: 346–9.
Klontz KC , Lieb S , Schreiber M , Janowski HT , Baldy LM , Gunn RA . Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981–1987. Ann Intern Med 1988; 109: 318–23.
Kumamoto KS , Vukich DJ . Clinical infections of Vibrio vulnificus: a case report and review of the literature. J Emerg Med 1998; 16: 61–6.
Bufano G , Ceruti T , Ferrari L , Pecchini F . Listeriosis in a patient with long-term hemodialysis but without iron overload. Nephron 1995; 69: 356.
Mead PS , Slutsker L , Dietz V , et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5: 607–25.
Johnson RW , Arnett FC . A fatal case of Vibrio vulnificus presenting as septic arthritis. Arch Intern Med 2001; 161: 2616–18.
Tsai YH , Hsu RW , Huang KC , et al. Systemic Vibrio infection presenting as necrotizing fasciitis and sepsis. A series of 13 cases. J Bone Joint Surg Am 2004; 86-A: 249702.
Dechet AM , Yu PA , Koram N , Painter J . Non-foodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997–2006. Clin Infect Dis 2008; 46: 970–6.
Hlady WG , Klontz KC . The epidemiology of Vibrio infections in Florida, 1981–1993. J Infect Dis 1996; 173: 1176–83.
Hlady WG , Mullen RC , Hopkin RS . Vibrio vulnificus from raw oysters. Leading cause of reported deaths from foodborne illness in Florida. J Fla Med Assoc 1993; 80: 536–8.
Shih YT , Peng CT , Tsai CH , Tsai FJ . [Beta-thalassemia major complicated with Vibrio vulnificus septicemia: report of one case.] Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1994; 35: 84–9.
Chang JJ , Sheen IS , Peng SM , Chen PC , Wu CS , Leu HS . Vibrio vulnificus infection–report of 8 cases and review of cases in Taiwan. Changgeng Yi Xue Za Zhi 1994; 17: 339–46.
Kuo CH , Dai ZK , Wu JR , Hsieh TJ , Hung CH , Hsu JH . Septic arthritis as the initial manifestation of fatal Vibrio vulnificus septicemia in a patient with thalassemia and iron overload. Pediatr Blood Cancer 2009; 53: 1156–8.
Wang SC , Lin KH , Chern JP , et al. Severe bacterial infection in transfusion-dependent patients with thalassemia major. Clin Infect Dis 2003; 37: 984–8.
Katz BZ . Vibrio vulnificus meningitis in a boy with thalassemia after eating raw oysters. Pediatrics 1988; 82: 784–6.
Ashrafian H . Hepcidin: the missing link between hemochromatosis and infections. Infect Immun 2003; 71: 669300.
Gholami P , Lew SQ , Klontz KC . Raw shellfish consumption among renal disease patients. A risk factor for severe Vibrio vulnificus infection. Am J Prev Med 1998; 15: 243.
Stabellini N , Camerani A , Lambertini D , et al. Fatal sepsis from Vibrio vulnificus in a hemodialyzed patient. Nephron 1998; 78: 221–4.
Wang SM , Liu CC , Chiou YY , Yang HB , Chen CT . Vibrio vulnificus infection complicated by acute respiratory distress syndrome in a child with nephrotic syndrome. Pediatr Pulmonol 2000; 29: 400–3.
Ruiz CC , Agraharkar M . Unusual marine pathogens causing cellulitis and bacteremia in hemodialysis patients: report of two cases and review of the literature. Hemodial Int 2003; 7: 356–9.
Wright AC , Simpson LM , Oliver JD . Role of iron in the pathogenesis of Vibrio vulnificus infections. Infect Immun 1981; 34: 503.
Hor LI , Chang TT , Wang ST . Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis 1999; 179: 275–8.
Hor LI , Chang YK , Chang CC , Lei HY , Ou JT . Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol 2000; 44: 871–8.
Neupane GP , Kim DM . Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion 2009; 49: 1762–9.
Barton JC , Bertoli LF , Rothenberg BE . Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med 2000; 135: 96–104.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.
Beckman EN , Leonard GL , Castillo LE , Genre CF , Pankey GA . Histopathology of marine vibrio wound infections. Am J Clin Pathol 1981; 76: 7652.
Shinoda S . [Pathogenic factors of vibrios with special emphasis on Vibrio vulnificus.] Yakugaku Zasshi 2005; 125: 531–47.
Litwin CM , Byrne BL . Cloning and characterization of an outer membrane protein of Vibrio vulnificus required for heme utilization: regulation of expression and determination of the gene sequence. Infect Immun 1998; 66: 3134–41.
Kim CM , Park RY , Park JH , et al. Vibrio vulnificus vulnibactin, but not metalloprotease VvpE, is essentially required for iron-uptake from human holotransferrin. Biol Pharm Bull 2006; 29: 911–18.
Colodner R , Chazan B , Kopelowitz J , Keness Y , Raz R . Unusual portal of entry of Vibrio vulnificus: evidence of its prolonged survival on the skin. Clin Infect Dis 2002; 34: 714–15.
Witte DL , Crosby WH , Edwards CQ , Fairbanks VF , Mitros FA . Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200.
Barton JC , McDonnell SM , Adams PC , et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9.
Gilbert DN , Moellering RC , Eliopoulos GM , Sande MA , eds. The Sanford Guide to Antimicrobial Therapy, 38th edn. Sperryville, Antimicrobial Therapy Inc. 2008.
Stoddard JJ , Wechsler DS , Nataro JP , Casella JF . Yersinia enterocolitica infection in a patient with sickle cell disease after exposure to chitterlings. Am J Pediatr Hematol Oncol 1994; 16: 153.
Lafleur L , Hammerberg O , Delage G , Pai CH . Yersinia enterocolitica infection in children: 4 years experience in the Montreal urban community. Contrib Microbiol Immunol 1979; 5: 298–303.
Adamkiewicz TV , Berkovitch M , Krishnan C , Polsinelli C , Kermack D , Olivieri NF . Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis 1998; 27: 1362–6.
Ewald JH , Heesemann J , Rudiger H , Autenrieth IB . Interaction of polymorphonuclear leukocytes with Yersinia enterocolitica: role of the Yersinia virulence plasmid and modulation by the iron-chelator desferrioxamine B. J Infect Dis 1994; 170: 1400.
Lesic B , Foulon J , Carniel E . Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica . Antimicrob Agents Chemother 2002; 46: 1741.
Capron JP , Capron-Chivrac D , Tossou H , Delamarre J , Eb F . Spontaneous Yersinia enterocolitica peritonitis in idiopathic hemochromatosis. Gastroenterology 1984; 87: 1372.
Green NS . Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment. Pediatr Hematol Oncol 1992; 9: 2474.
Cherchi GB , Pacifico L , Cossellu S , et al. Prospective study of Yersinia enterocolitica infection in thalassemic patients. Pediatr Infect Dis J 1995; 14: 579–84.
Hansen MG , Pearl G , Levy M . Intussusception due to Yersinia enterocolitica enterocolitis in a patient with beta-thalassemia. Arch Pathol Lab Med 2001; 125: 1486–8.
Pallister C , Rotstein OD . Yersinia enterocolitica as a cause of intra-abdominal abscess: the role of iron. Can J Surg 2001; 44: 135–6.
Greco L , Marino F , Gentile A , Catalano G , Angilletta D . Yersinia enterocolitica ileocolitis in beta-thalassemic patients. Colorectal Dis 2006; 8: 525.
Bullen JJ , Spalding PB , Ward CG , Gutteridge JM . Hemochromatosis, iron and septicemia caused by Vibrio vulnificus . Arch Intern Med 1991; 151: 1606–9.
Hewstone AS , Davidson GP . Yersinia enterocolitica septicaemia with arthritis in a thalassaemic child. Med J Aust 1972; 1: 1035–8.
Thirumoorthi MC , Dajani AS . Yersinia enterocolitica osteomyelitis in a child. Am J Dis Child 1978; 132: 578–80.
De Virgiliis S , Dessi S , Melis R , Cao A . Fatal Yersinia enterocolitica meningitis in thalassemia major. Boll Ist Sieroter Milan 1984; 63: 171–2.
Gordts B , Rummens E , deMeirleir L , Butzler JP . Yersinia pseudotuberculosis septicaemia in thalassaemia major. Lancet 1984; 1: 41–2.
Pierron H , Gillet R , Perrimond H , Broudeur JC , Soudry G . [Yersinia infection and hemoglobin disorder. Apropos of 4 cases.] Pediatrie 1990; 45: 379–82.
Blei F , Puder DR . Yersinia enterocolitica bacteremia in a chronically transfused patient with sickle cell anemia. Case report and review of the literature. Am J Pediatr Hematol Oncol 1993; 15: 430–4.
Kruger N , Kraus C , Tillmann W , Schroter W . [Frequent occurrence of Yersinia infection in hemosiderosis.] Monatsschr Kinderheilkd 1985; 133: 876–8.
Stuart SJ , Greenwood KT , Luke RK . Iron-suppressible production of hydroxamate by Escherichia coli isolates. Infect Immun 1982; 36: 870.
Neilands JB . Parallels in the mode of regulation of iron assimilation in all living species. In: Ponka P , Schulman HM , Woodworth RC , eds. Iron Transport and Storage. Boca Raton, CRC Press, Inc. 1990; 424.
Ouyang Z , Isaacson R . Identification and characterization of a novel ABC iron transport system, fit, in Escherichia coli . Infect Immun 2006; 74: 69496.
Bullen JJ . Iron-binding proteins and other factors in milk responsible for resistance to Escherichia coli . Ciba Found Symp 1976; 149–69.
Rogers HJ . Ferric iron and the antibacterial effects of horse 7S antibodies to Escherichia coli O111. Immunology 1976; 30: 425–33.
Baltimore RS , Shedd DG , Pearson HA . Effect of iron saturation on the bacteriostasis of human serum: in vivo does not correlate with in vitro saturation. J Pediatr 1982; 101: 519–23.
Rivier D , Page N , Isliker H . Synergism between iron chelators and complement for bactericidal activity. Ann Immunol (Paris) 1983; 134C: 25–30.
Chart H , Buck M , Stevenson P , Griffiths E . Iron regulated outer membrane proteins of Escherichia coli: variations in expression due to the chelator used to restrict the availability of iron. J Gen Microbiol 1986; 132: 1373–8.
Rainard P . Bacteriostasis of Escherichia coli by bovine lactoferrin, transferrin, and immunoglobulins (IgG1, IgG2, IgM) acting alone or in combination. Vet Microbiol 1986; 11: 103–15.
Brock JH , Liceaga J , Kontoghiorghes GJ . The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol 1988; 1: 55–60.
Peng CT , Tsai CH , Wang JH , Chiu CF , Chow KC . Bacterial infection in patients with transfusion-dependent beta-thalassemia in central Taiwan. Acta Paediatr Taiwan 2000; 41: 318–21.
Wanachiwanawin W . Infections in E-beta-thalassemia. J Pediatr Hematol Oncol 2000; 22: 581.
Alebouyeh M , Moussavi F . Occurrence of overwhelming Gram-negative infections in splenectomised patients with thalassaemia major. Eur J Pediatr 2003; 162: 637–8.
Becroft DM , Dix MR , Farmer K . Intramuscular iron-dextran and susceptibility of neonates to bacterial infections. In vitro studies. Arch Dis Child 1977; 52: 778–81.
Zala G . [Acute abdomen with irreversible shock, a rare but typical complication of hemochromatosis.] Schweiz Med Wochenschr 1985; 115: 1461.
Jain AP , Chandra LS , Gupta S , Gupta OP , Jajoo UN , Kalantri SP . Spontaneous bacterial peritonitis in liver cirrhosis with ascites. J Assoc Physicians India 1999; 47: 619–21.
Dinis-Ribeiro M , Cortez-Pinto H , Marinho R , et al. Spontaneous bacterial peritonitis in patients with hepatic cirrhosis: evaluation of a treatment protocol at specialized units. Rev Esp Enferm Dig 2002; 94: 473–81.
Thanopoulou AC , Koskinas JS , Hadziyannis SJ . Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. Eur J Intern Med 2002; 13: 194–8.
Caruntu FA , Benea L . Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointestin Liver Dis 2006; 15: 51–6.
van Erpecum KJ . Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis. Scand J Gastroenterol Suppl 2006; 79–84.
Ribeiro TC , Chebli JM , Kondo M , Gaburri PD , Chebli LA , Feldner AC . Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication? Ther Clin Risk Manag 2008; 4: 919–25.
Bert F , Panhard X , Johnson J , et al. Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis. Clin Microbiol Infect 2008; 14: 1034–40.
Cereto F , Herranz X , Moreno E , et al. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2008; 20: 924–9.
Desforges G . Abdominal pain in hemochromatosis. N Engl J Med 1949; 241: 485.
Jones NL . Irreversible shock in haemochromatosis. Lancet 1962; 1: 5692.
Garvie WH , Caridis DT . Idiopathic hemochromatosis presenting as “acute abdomen”: a report of two cases. Can J Surg 1970; 13: 262–6.
Cuenca-Moron B , Solis-Herruzo JA , Moreno D , Guijarro C , Gentil AA , Castellano G . Spontaneous bacterial peritonitis due to Yersinia enterocolitica in secondary alcoholic hemochromatosis. J Clin Gastroenterol 1989; 11: 675–8.
Rex JH , Ginsberg AM , Fries LF , Pass HI , Kwon-Chung KJ. Cunninghamella bertholletiae infection associated with deferoxamine therapy. Rev Infect Dis 1988; 10: 1187–94.
Gaziev D , Baronciani D , Galimberti M , et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant 1996; 17: 409–14.
Beutler E , Gelbart T . Helicobacter pylori infection and HFE hemochromatosis. Blood Cells Mol Dis 2006; 37: 188–91.
de Montalembert M , Girot R . Infections in thalassemic patients (hepatitis and bone marrow transplantation-related infections excluded). Prog Clin Biol Res 1989; 309: 231–8.
Wanachiwanawin W . Infections in E-beta-thalassemia. J Pediatr Hematol Oncol 2000; 22: 581.
Rahav G , Volach V , Shapiro M , Rund D , Rachmilewitz EA , Goldfarb A . Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol 2006; 133: 6674.
De Virgiliis S , Fiorelli G , Fargion S , et al. Chronic liver disease in transfusion-dependent thalassaemia: hepatitis B virus marker studies. J Clin Pathol 1980; 33: 9493.
Fargion S , Piperno A , Cappellini MD , et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322–6.
Sampietro M , Corbetta N , Cerino M , et al. Prevalence and clinical significance of hepatitis G virus infection in adult beta-thalassaemia major patients. Br J Haematol 1997; 97: 904.
Edwards CQ , Griffen LM , Kushner JP . Coincidental hemochromatosis and viral hepatitis. Am J Med Sci 1991; 301: 50–4.
Piperno A , Fargion S , D'Alba R , et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 1992; 16: 364–8.
Strachan AS . Haemosiderosis and haemochromatosis in South African natives with a comment on the etiology of haemochromatosis. MD Thesis. University of Glasgow, 1929.
Kasvosve I , Gangaidzo IT , Gomo ZA , Gordeuk VR . African iron overload. Acta Clin Belg 2000; 55: 88–93.
Boelaert JR , Vandecasteele SJ , Appelberg R , Gordeuk VR . The effect of the host's iron status on tuberculosis. J Infect Dis 2007; 195: 17453.
Gordeuk VR , Delanghe JR , Langlois MR , Boelaert JR . Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001; 20: 111–15.
Barton JC , Bertoli LF . Histochemistry of iron and iron proteins. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 200–218.
de Vet BJ , ten Hoopen CH . Lactoferrin in human neutrophilic polymorphonuclear leukocytes in relation to iron metabolism. Acta Med Scand 1978; 203: 197–203.
Chung S , Hayward C , Brock DJ , Van Heyningen V . A monoclonal antibody-based immunoassay for human lactoferrin. J Immunol Methods 1985; 84: 135–41.
Moguilevsky N , Masson PL , Courtoy PJ . Lactoferrin uptake and iron processing into macrophages: a study in familial haemochromatosis. Br J Haematol 1987; 66: 129–36.
Butler TW , Heck LW , Huster WJ , Grossi CE , Barton JC . Assessment of total immunoreactive lactoferrin in hematopoietic cells using flow cytometry. J Immunol Methods 1988; 108: 1590.
Barton JC , Huster WJ , Parmley RT . Iron-binding reactivity in mature neutrophils: relative cell content quantification by cytochemical scoring. J Histochem Cytochem 1988; 36: 6498.
van Asbeck BS , Marx JJ , Struyvenberg A , Verhoef J . Functional defects in phagocytic cells from patients with iron overload. J Infect 1984; 8: 232–40.
Butler TW , Heck LW , Berkow R , Barton JC . Radioimmunometric quantification of surface lactoferrin in blood mononuclear cells. Am J Med Sci 1994; 307: 102.
Moura E , Verheul AF , Marx JJ . A functional defect in hereditary haemochromatosis monocytes and monocyte-derived macrophages. Eur J Clin Invest 1998; 28: 1643.
Moura E , Verheul AF , Marx JJ . Evaluation of the role of Fc gamma and complement receptors in the decreased phagocytosis of hereditary haemochromatosis patients. Scand J Immunol 1997; 46: 399–405.
Amadori A , Zamarchi R , De Silvestro G , et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med 1995; 1: 1279–83.
Hall MA , Ahmadi KR , Norman P , et al. Genetic influence on peripheral blood T lymphocyte levels. Genes Immun 2000; 1: 423.
Barton JC , Wiener HW , Acton RT , Go RC . Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. BMC Blood Disord 2005; 5: 5.
Cruz E , Vieira J , Almeida S , et al. A study of 82 extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload. BMC Med Genet 2006; 7: 16.
Arosa FA , Oliveira L , Porto G , et al. Anomalies of the CD8+ T cell pool in haemochromatosis: HLA-A3-linked expansions of CD8+. Clin Exp Immunol 1997; 107: 5484.
Reimao R , Porto G , de Sousa M . Stability of CD4/CD8 ratios in man: new correlation between CD4/CD8 profiles and iron overload in idiopathic haemochromatosis patients. C R Acad Sci III 1991; 313: 481.
Porto G , Reimao R , Goncalves C , Vicente C , Justica B , de Sousa M . Haemochromatosis as a window into the study of the immunological system: a novel correlation between CD8+ lymphocytes and iron overload. Eur J Haematol 1994; 52: 283–90.
Nemeth E , Valore EV , Territo M , Schiller G , Lichtenstein A , Ganz T . Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461–3.
Feder JN , Gnirke A , Thomas W , et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.
Parkkila S , Parkkila AK , Waheed A , et al. Cell surface expression of HFE protein in epithelial cells, macrophages, and monocytes. Haematologica 2000; 85: 340.
Chitambar CR , Wereley JP . Expression of the hemochromatosis (HFE) gene modulates the cellular uptake of 67Ga. J Nucl Med 2003; 44: 943–6.
Feeney GP , Carter K , Masters GS , Jackson HA , Cavil I , Worwood M . Changes in erythropoiesis in hereditary hemochromatosis are not mediated by HFE expression in nucleated red cells. Haematologica 2005; 90: 180.
Miranda CJ , Makui H , Andrews NC , Santos MM . Contributions of beta2-microglobulin-dependent molecules and lymphocytes to iron regulation: insights from HfeRag1(-/-) and beta2mRag1(-/-) double knockout mice. Blood 2004; 103: 2847–9.
Pratiwi R , Fletcher LM , Pyper WR , et al. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. J Hepatol 1999; 31: 39–46.
Acton RT , Snively BM , Barton JC , et al. A genome-wide linkage scan for iron phenotype quantitative trait loci: the HEIRS Family Study. Clin Genet 2007; 71: 518–29.
Barton JC , Bertoli LF , Acton RT . Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y. Blood Cells Mol Dis 2003; 31: 102–11.
Joske RA , Traub M . Haemochromatosis, active chronic hepatitis, and familial IgA deficiency. Digestion 1975; 12: 32–8.
Jolivet-Gougeon A , Ingels A , Danic B , et al. No increased seroprevalence of anti-Yersinia antibodies in patients with type 1 (C282Y/C282Y) hemochromatosis. Scand J Gastroenterol 2007; 42: 1388–9.
Barton JC , Acton RT . HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFE C282Y homozygosity in central Alabama. BMC Med Genet 2002; 3: 9.
Barton JC , Bertoli LF , Acton RT . HLA-A and -B alleles and haplotypes in 240 index patients with common variable immunodeficiency and selective IgG subclass deficiency in central Alabama. BMC Med Genet 2003; 4: 3.
Spickett GP , Farrant J , North ME , Zhang JG , Morgan L , Webster AD . Common variable immunodeficiency: how many diseases? Immunology Today 1997; 18: 325–8.
Alper CA , Marcus-Bagley D , Awdeh Z , et al. Prospective analysis suggests susceptibility genes for deficiencies of IgA and several other immunoglobulins on the [HLA-B8, SC01, DR3] conserved extended haplotype. Tissue Antigens 2000; 56: 207–16.
Vorechovsky I , Cullen M , Carrington M , Hammarstrom L , Webster AD . Fine mapping of is in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol 2000; 164: 4408–16.
Kralovicova J , Hammarstrom L , Plebani A , Webster AD , Vorechovsky I . Fine-scale mapping at IGAD1 and genome-wide genetic linkage analysis implicate HLA-DQ/DR as a major susceptibility locus in selective IgA deficiency and common variable immunodeficiency. J Immunol 2003; 170: 27655.
Volanakis JE , Zhu ZB , Schaffer FM , et al. Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency. J Clin Invest 1992; 89: 1914–22.
De la Concha EG , Fernandez-Arquero M , Gual L , et al. MHC susceptibility genes to IgA deficiency are located in different regions on different HLA haplotypes. J Immunol 2002; 169: 4637–43.
Castigli E , Wilson SA , Garibyan L , et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829–34.
Salzer U , Chapel HM , Webster AD , et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37: 820–8.
Mullighan CG , Marshall SE , Welsh KI . Mannose-binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency. Scand J Immunol 2000; 51: 111–22.

Reference Title: References

Reference Type: reference-list

Simon M , Bourel M , Fauchet R , Genetet B . Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976; 17: 332–4.
Feder JN , Gnirke A , Thomas W , et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.
Zhou XY , Tomatsu S , Fleming RE , et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 1998; 95: 2492.
Levy JE , Montross LK , Cohen DE , Fleming MD , Andrews NC . The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999; 94: 9–11.
Feder JN , Tsuchihashi Z , Irrinki A , et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997; 272: 14025–8.
Waheed A , Parkkila S , Zhou XY , et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997; 94: 12384–9.
Santos M , Schilham MW , Rademakers LH , Marx JJ , de Sousa M , Clevers H . Defective iron homeostasis in beta2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996; 184: 1975–85.
Fleming RE , Britton RS , Waheed A , Sly WS , Bacon BR . Pathogenesis of hereditary hemochromatosis. Clin Liver Dis 2004; 8: 7553, vii.
Beckman LE , Saha N , Spitsyn V , Van Landeghem G , Beckman L . Ethnic differences in the HFE codon 282 (Cys/Tyr) polymorphism. Hum Hered 1997; 47: 263.
Rochette J , Pointon JJ , Fisher CA , et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999; 64: 1056–62.
Beutler E , Felitti VJ , Koziol JA , Ho NJ , Gelbart T . Penetrance of 845G–> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211–18.
Jacolot S , Le Gac G , Scotet V , Quere I , Mura C , Ferec C . HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103: 2835–40.
Steinberg KK , Cogswell ME , Chang JC , et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001; 285: 2216–22.
Gochee PA , Powell LW , Cullen DJ , Du SD , Rossi E , Olynyk JK . A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002; 122: 6461.
Barton JC , Shih WW , Sawada-Hirai R , et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997; 23: 135–45.
Pointon JJ , Wallace D , Merryweather-Clarke AT , Robson KJ . Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 2000; 4: 151–61.
Beutler E , Griffin MJ , Gelbart T , West C . A previously undescribed nonsense mutation of the HFE gene. Clin Genet 2002; 61: 40–2.
Barton JC , West C , Lee PL , Beutler E . A previously undescribed frameshift deletion mutation of HFE (c.del277; G93fs) associated with hemochromatosis and iron overload in a C282Y heterozygote. Clin Genet 2004; 66: 214–16.
Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. 01–23–2010.
Fleming RE , Britton RS. Iron Imports. VI. HFE and regulation of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol 2006; 290: G590–4.
Goswami T , Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006; 281: 28 494–8.
Schmidt PJ , Toran PT , Giannetti AM , Bjorkman PJ , Andrews NC . The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008; 7: 205–14.
Bridle KR , Frazer DM , Wilkins SJ , et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 6693.
Vujic Spasic M , Kiss J , Herrmann T , et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab 2008; 7: 173–8.
Stuart KA , Anderson GJ , Frazer DM , et al. Duodenal expression of iron transport molecules in untreated haemochromatosis subjects. Gut 2003; 52: 953–9.
Bezwoda WR , Disler PB , Lynch SR , et al. Patterns of food iron absorption in iron-deficient white and Indian subjects and in venesected haemochromatotic patients. Br J Haematol 1976; 33: 425–36.
Lynch SR , Skikne BS , Cook JD . Food iron absorption in idiopathic hemochromatosis. Blood 1989; 74: 2187–93.
Parmley RT , Barton JC , Conrad ME . Ultrastructural localization of transferrin, transferrin receptor, and iron-binding sites on human placental and duodenal microvilli. Br J Haematol 1985; 60: 81–9.
Whittaker P , Skikne BS , Covell AM , et al. Duodenal iron proteins in idiopathic hemochromatosis. J Clin Invest 1989; 83: 261.
Feder JN , Penny DM , Irrinki A , et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472.
Lebron JA , Bennett MJ , Vaughn DE , et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111–23.
Kelleher T , Ryan E , Barrett S , et al. Increased DMT1 but not IREG1 or HFE mRNA following iron depletion therapy in hereditary haemochromatosis. Gut 2004; 53: 1174–9.
Turnbull A , Giblett ER . The binding and transport of iron by transferrin variants. J Lab Clin Med 1961; 57: 450–9.
Bothwell TH , Jacobs P , Torrance JD . Studies on the behavior of transferrin in idiopathic haemochromatosis. S Afr J Med Sci 1962; 27: 35–9.
Wheby MS , Balcerzak SP , Anderson P , Crosby WH . Clearance of iron from hemochromatotic and normal transferin in vivo. Blood 1964; 24: 765–9.
Batey RG , Lai Chung FP , Shamir S , Sherlock S . A non-transferrin-bound serum iron in idiopathic hemochromatosis. Dig Dis Sci 1980; 25: 340–6.
Cairo G , Conte D , Bianchi L , Fraquelli M , Recalcati S . Reduced serum ceruloplasmin levels in hereditary haemochromatosis. Br J Haematol 2001; 114: 226–9.
Laine F , Ropert M , Lan CL , et al. Serum ceruloplasmin and ferroxidase activity are decreased in HFE C282Y homozygote male iron overloaded patients. J Hepatol 2002; 36: 60.
Sciot R , Paterson AC , Van den Oord JJ , Desmet VJ . Lack of hepatic transferrin receptor expression in hemochromatosis. Hepatology 1987; 7: 831.
Lombard M , Bomford A , Hynes M , et al. Regulation of the hepatic transferrin receptor in hereditary hemochromatosis. Hepatology 1989; 9: 1.
Kawabata H , Yang R , Hirama T , et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826–32.
Chua ACG , Delima RD , Morgan EH , et al. Iron uptake from plasma transferrin by a transferrin receptor 2 mutant mouse model of haemachromatosis, J Hepatol (in press).
Merle U , Theilig F , Fein E , et al. Localization of the iron-regulatory proteins hemojuvelin and transferrin receptor 2 to the basolateral membrane domain of hepatocytes. Histochem Cell Biol 2007; 127: 221–6.
Davies PS , Zhang AS , Anderson EL , et al. Evidence for the interaction of the hereditary haemochromatosis protein, HFE, with the transferrin receptor in endocytic compartments. Biochem J 2003; 373: 1453.
Mackenzie B , Ujwal ML , Chang MH , Romero MF , Hediger MA . Divalent metal-ion transporter DMT1 mediates both H+ coupled Fe2+ transport and uncoupled fluxes. Pflugers Arch 2006; 451: 5448.
Rahier J , Loozen S , Goebbels RM , Abrahem M . The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987; 30: 5–12.
Lu JP , Hayashi K . Selective iron deposition in pancreatic islet B cells of transfusional iron overloaded autopsy cases. Pathol Int 1994; 44: 194–9.
Sheldon JH . Haemochromatosis. London, Oxford University Press, 1935.
Peillon F , Racadot J. [Histopathological modification in the hypophysis in 6 cases of hemochromatosis.] Ann Endocrinol (Paris) 1969; 30: 800.
Bergeron C , Kovacs K. Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am J Pathol 1978; 93: 295–309.
Atkin SL , Burnett HE , Green VL , White MC , Lombard M . Expression of the transferrin receptor in human anterior pituitary adenomas is confined to gonadotrophinomas. Clin Endocrinol (Oxf) 1996; 44: 4671.
Tampanaru-Sarmesiu A , Stefaneanu L , Thapar K , Kontogeorgos G , Sumi T , Kovacs K . Transferrin and transferrin receptor in human hypophysis and pituitary adenomas. Am J Pathol 1998; 152: 413–22.
McDermott JH , Walsh CH . Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 2005; 90: 2451.
Barton JC , Bertoli LF , Rothenberg BE . Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med 2000; 135: 96–104.
Beutler E , Felitti V , Gelbart T , Ho N . The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329–37.
McLaren CE , Barton JC , Gordeuk VR , et al. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study. Am J Hematol 2007; 82: 898–905.
Feeney GP , Carter K , Masters GS , Jackson HA , Cavil I , Worwood M . Changes in erythropoiesis in hereditary hemochromatosis are not mediated by HFE expression in nucleated red cells. Haematologica 2005; 90: 180.
Lin JP , O'Donnell CJ , Jin L , Fox C , Yang Q , Cupples LA . Evidence for linkage of red blood cell size and count: genome-wide scans in the Framingham Heart Study. Am J Hematol 2007; 82: 605–10.
Kozewski BJ . The occurrence of megaloblastic erythropoiesis in patients with hemochromatosis. Blood 1952; 7: 1182–95.
Quigley JG , Yang Z , Worthington MT , et al. Identification of a human heme exporter that is essential for erythropoiesis. Cell 2004; 118: 757–66.
Keel SB , Doty RT , Yang Z , et al. A heme export protein is required for red blood cell differentiation and iron homeostasis. Science 2008; 319: 825–8.
Gehrke SG , Kulaksiz H , Herrmann T , et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102: 371–6.
Piperno A , Girelli D , Nemeth E , et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 2007; 110: 4096–100.
Ganz T . Iron homeostasis: fitting the puzzle pieces together. Cell Metab 2008; 7: 288–90.
Tanno T , Bhanu NV , Oneal PA , et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–101.
Mast AE , Foster TM , Pinder HL , et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48: 2197–204.
Lee PL , Gelbart T , West C , Halloran C , Felitti V , Beutler E . A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis 2001; 27: 783–802.
Hofmann WK , Tong XJ , Ajioka RS , Kushner JP , Koeffler HP . Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. Blood 2002; 100: 1099–100.
Lee P , Gelbart T , West C , Halloran C , Beutler E . Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002; 29: 471–87.
Kelleher T , Ryan E , Barrett S , O'Keane C , Crowe J . DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis. Blood Cells Mol Dis 2004; 33: 35–9.
Lee PL , Barton JC , Brandhagen D , Beutler E . Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol 2004; 127: 224–9.
Le Gac G , Scotet V , Ka C , et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004; 13: 1913–18.
Mura C , Le Gac G , Scotet V , Raguenes O , Mercier AY , Ferec C . Variation of iron loading expression in C282Y homozygous haemochromatosis probands and sib pairs. J Med Genet 2001; 38: 632–6.
Barton JC , Wiener HW , Acton RT , Go RC . HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol Dis 2005; 34: 38–47.
Olatunbosun D , Corbett WE , Ludwig J , Valberg LS . Alteration of cobalt absorption in portal cirrhosis and idiopathic hemochromatosis. J Lab Clin Med 1970; 75: 754–62.
Akesson A , Stal P , Vahter M . Phlebotomy increases cadmium uptake in hemochromatosis. Environ Health Perspect 2000; 108: 289–91.
Barton JC , Patton MA , Edwards CQ , et al. Blood lead concentrations in hereditary hemochromatosis. J Lab Clin Med 1994; 124: 193–8.
Barton JC . The absorption and metabolism of non-ferrous metals in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 131–44.
Pietrangelo A , Rocchi E , Casalgrandi G , et al. Regulation of transferrin, transferrin receptor, and ferritin genes in human duodenum. Gastroenterology 1992; 102: 802–9.
Feder JN , Penny DM , Irrinki A , et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472.
Altstatt LB , Pollack S , Feldman MH , Reba RC , Crosby WH . Liver manganese in hemochromatosis. Proc Soc Exp Biol Med 1967; 124: 353.
Adams PC , Bradley C , Frei JV . Hepatic zinc in hemochromatosis. Clin Invest Med 1991; 14: 16–20.
Brissot P , Le Treut A , Dien G , Cottencin M , Simon M , Bourel M . Hypovitaminemia A in idiopathic hemochromatosis and hepatic cirrhosis. Role of retinol-binding protein and zinc. Digestion 1978; 17: 4698.
Sargent T, 3rd , Lim TH , Jenson RL . Reduced chromium retention in patients with hemochromatosis, a possible basis of hemochromatotic diabetes. Metabolism 1979; 28: 70–9.
Spencer H , Sontag SJ , Derler J , Osis D . Intestinal absorption of iron in patients with hemochromatosis. In: Weintraub LR , Edwards CQ , Krikker M , eds. Hemochromatosis. Proceedings of the First International Conference. New York, The New York Academy of Sciences. 1988; 336–8.
Barton JC , Bertoli LF . Zinc gluconate lozenges for treating the common cold. Ann Intern Med 1997; 126: 738–9.
Walshe JM , Cox DW . Effect of treatment of Wilson's disease on natural history of haemochromatosis. Lancet 1998; 352: 112–13.
Dib N , Valsesia E , Malinge MC , Mauras Y , Misrahi M , Cales P . Late onset of Wilson's disease in a family with genetic haemochromatosis. Eur J Gastroenterol Hepatol 2006; 18: 43.
Onalaja AO , Claudio L . Genetic susceptibility to lead poisoning. Environ Health Perspect 2000; 108 Suppl 1: 23–8.
Mandelli C , Cesarini L , Piperno A , et al. Saturability of hepatic iron deposits in genetic hemochromatosis. Hepatology 1992; 16: 956–9.
Niederau C , Fischer R , Sonnenberg A , Stremmel W , Trampisch HJ , Strohmeyer G . Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256–62.
Wood MJ , Powell LW , Ramm GA . Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008; 111: 4456–62.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.
Edwards CQ , Griffen LM , Goldgar D , Drummond C , Skolnick MH , Kushner JP . Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–62.
Bulaj ZJ , Ajioka RS , Phillips JD , et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529–35.
McLaren GD , McLaren CE , Adams PC , et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol 2008; 22: 923–30.
Adams PC . Non-expressing homozygotes for C282Y hemochromatosis: minority or majority of cases? Mol Genet Metab 2000; 71: 81–6.
Barton JC , Harmon L , Rivers C , Acton RT . Hemochromatosis: association of severity of iron overload with genetic markers. Blood Cells Mol Dis 1996; 22: 195–204.
Pratiwi R , Fletcher LM , Pyper WR , et al. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. J Hepatol 1999; 31: 39–46.
Piperno A , Arosio C , Fargion S , et al. The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology 1996; 24: 43–6.
Barton JC , Wiener HW , Acton RT , Go RC . HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol Dis 2005; 34: 38–47.
Cartwright GE , Edwards CQ , Kravitz K , et al. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 1979; 301: 175–9.
Pietrangelo A . Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 2004; 350: 2383–97.
Barton JC , Sawada-Hirai R , Rothenberg BE , Acton RT . Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis 1999; 25: 1475.
Beutler E , Gelbart T , West C , et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22: 187–94.
Marshall DS , Linfert DR , Tsongalis GJ . Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. Int J Mol Med 1999; 4: 389–93.
Bradley LA , Johnson DD , Palomaki GE , Haddow JE , Robertson NH , Ferrie RM . Hereditary haemochromatosis mutation frequencies in the general population. J Med Screen 1998; 5: 34–6.
McDonnell SM , Hover A , Gloe D , Ou CY , Cogswell ME , Grummer-Strawn L . Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999; 107: 30.
Garry PJ , Montoya GD , Baumgartner RN , Liang HC , Williams TM , Brodie SG . Impact of HLA-H mutations on iron stores in healthy elderly men and women. Blood Cells Mol Dis 1997; 23: 277–87.
Monaghan KG , Rybicki BA , Shurafa M , Feldman GL . Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African-American(s). Am J Hematol 1998; 58: 213–17.
A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997; 41: 841–4.
Willis G , Jennings BA , Goodman E , Fellows IW , Wimperis JZ . A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England. Blood Cells Mol Dis 1997; 23: 288–91.
Murphy S , Curran MD , McDougall N , Callender ME , O'Brien CJ , Middleton D . High incidence of the Cys282Tyr mutation in the HFE gene in the Irish population—implications for haemochromatosis. Tissue Antigens 1998; 52: 484–8.
Ryan E , O'Keane C , Crowe J . Hemochromatosis in Ireland and HFE . Blood Cells Mol Dis 1998; 24: 428–32.
Miedzybrodzka Z , Loughlin S , Baty D , et al. Haemochromatosis mutations in northeast Scotland. Br J Haematol 1999; 106: 385.
Jazwinska EC , Cullen LM , Busfield F , et al. Haemochromatosis and HLA-H . Nat Genet 1996; 14: 2491.
Rossi E , Henderson S , Chin CY , et al. Genotyping as a diagnostic aid in genetic haemochromatosis. J Gastroenterol Hepatol 1999; 14: 427–30.
Adams PC , Chakrabarti S . Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998; 114: 319–23.
Milman N , Koefoed P , Pedersen P , Nielsen FC , Eiberg H . Frequency of the HFE C282Y and H63D mutations in Danish patients with clinical haemochromatosis initially diagnosed by phenotypic methods. Eur J Haematol 2003; 71: 403.
Erhardt A , Niederau C , Osman Y , Hassan M , Haussinger D . [Demonstration of HFE polymorphism in German patients with hereditary hemochromatosis.] Dtsch Med Wochenschr 1999; 124: 14482.
Gottschalk R , Seidl C , Schilling S , et al. Iron overload and genotypic expression of HFE mutations H63D/C282Y and transferrin receptor Hin6I and BanI polymorphism in German patients with hereditary haemochromatosis. Eur J Immunogenet 2000; 27: 129–34.
Hellerbrand C , Bosserhoff AK , Seegers S , et al. Mutation analysis of the HFE gene in German hemochromatosis patients and controls using automated SSCP-based capillary electrophoresis and a new PCR-ELISA technique. Scand J Gastroenterol 2001; 36: 1211–16.
Nielsen P , Carpinteiro S , Fischer R , Cabeda JM , Porto G , Gabbe EE . Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from northern Germany. Br J Haematol 1998; 103: 842.
Van Vlierberghe H , Messiaen L , Hautekeete M , De Paepe A , Elewaut A . Prevalence of the Cys282Tyr and His63Asp mutation in Flemish patients with hereditary hemochromatosis. Acta Gastroenterol Belg 2000; 63: 250–3.
de Juan D , Reta A , Castiella A , Pozueta J , Prada A , Cuadrado E . HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum Genet 2001; 9: 961–4.
Guix P , Picornell A , Parera M , et al. Prevalence of the C282Y mutation for haemochromatosis on the Island of Majorca. Clin Genet 2000; 58: 123–8.
Sanchez M , Bruguera M , Quintero E , et al. Hereditary hemochromatosis in Spain. Genet Test 2000; 4: 171–6.
Fabrega E , Castro B , Sanchez-Castro L , Benito A , Fernandez-Luna JL , Pons-Romero F. [The prevalence of the Cys282Tyr mutation in the hemochromatosis gene in Cantabria in patients diagnosed with hereditary hemochromatosis.] Med Clin (Barc) 1999; 112: 451–3.
Sanchez M , Bruguera M , Bosch J , Rodes J , Ballesta F , Oliva R . Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 1998; 29: 725–8.
Moreno L , Vallcorba P , Boixeda D , Cabello P , Bermejo F , San Roman C. [The usefulness of the detection of Cys282Tyr and His63Asp mutations in the diagnosis of hereditary hemochromatosis.] Rev Clin Esp 1999; 199: 632–6.
Jorquera F , Dominguez A , Diaz-Golpe V , et al. C282Y and H63D mutations of the haemochromatosis gene in patients with iron overload. Rev Esp Enferm Dig 2001; 93: 293–302.
Jouanolle AM , Fergelot P , Gandon G , Yaouanq J , Le Gall JY , David V . A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet 1997; 100: 544.
Mura C , Raguenes O , Ferec C . HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93: 2502.
Aguilar-Martinez P , Biron C , Blanc F , et al. Compound heterozygotes for hemochromatosis gene mutations: may they help to understand the pathophysiology of the disease? Blood Cells Mol Dis 1997; 23: 2696.
Borot N , Roth M , Malfroy L , et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 1997; 45: 320–4.
Mercier G , Burckel A , Bathelier C , Boillat E , Lucotte G . Mutation analysis of the HLA-H gene in French hemochromatosis patients, and genetic counseling in families. Genet Couns 1998; 9: 181–6.
Cardoso EM , Stal P , Hagen K , et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 1998; 243: 203–8.
Olsson KS , Ritter B , Sandberg L , Raha-Chowdhury R , Gruen J , Worwood M . The ancestral haplotype in patients with genetic hemochromatosis from central and western Sweden. 1997. St. Malo, International Symposium on Iron in Biology and Medicine.
Calandro L , Thorsen T , Barcellos L , Griggs J , Baer D , Sensabaugh GF . Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22: 194A–4B.
Sham RL , Ou CY , Cappuccio J , Braggins C , Dunnigan K , Phatak PD . Correlation between genotype and phenotype in hereditary hemochromatosis: analysis of 61 cases. Blood Cells Mol Dis 1997; 23: 314–20.
Brandhagen DJ , Fairbanks VF , Baldus WP , et al. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am J Gastroenterol 2000; 95: 2910–14.
Asberg A , Hveem K , Thorstensen K , et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001; 36: 1108–15.
Porto G , de Sousa M . Variation of hemochromatosis prevalence and genotype in national groups. In: Barton JC , Edwards CQ , eds. Hewmochromatosis; Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 51–62.
Datz C , Lalloz MR , Vogel W , et al. Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. J Hepatol 1997; 27: 773–9.
Carella M , D'Ambrosio L , Totaro A , et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997; 60: 828–32.
Piperno A , Sampietro M , Pietrangelo A , et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114: 996–1002.
Papanikolaou G , Politou M , Roetto A , et al. Linkage to chromosome 1q in Greek families with juvenile hemochromatosis. Blood Cells Mol Dis 2001; 27: 744–9.

Reference Title: References

Reference Type: reference-list

Lucotte G , Dieterlen F . A European allele map of the C282Y mutation of hemochromatosis: Celtic versus Viking origin of the mutation? Blood Cells Mol Dis 2003; 31: 262.
Distante S , Robson KJ , Graham-Campbell J , Arnaiz-Villena A , Brissot P , Worwood M . The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004; 115: 2699.
Naugler C . Hemochromatosis: a Neolithic adaptation to cereal grain diets. Med Hypotheses 2008; 70: 691–2.
Fairbanks VF . Hemochromatosis: population genetics. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 420.
Feder JN , Gnirke A , Thomas W , et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.
Gruen JR , Weissman SM . Evolving views of the major histocompatibility complex. Blood 1997; 90: 4252–65.
Datz C , Haas T , Rinner H , Sandhofer F , Patsch W , Paulweber B . Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 1998; 44: 2429–32.
Rossi E , Olynyk JK , Cullen DJ , et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000; 46: 162–6.
Chavarro JE , Rich-Edwards JW , Rosner BA , Willett WC . Iron intake and risk of ovulatory infertility. Obstet Gynecol 2006; 108: 11452.
De Braekeleer M . A prevalence and fertility study of haemochromatosis in Saguenay-Lac-Saint-Jean. Ann Hum Biol 1993; 20: 501.
Nelson RL , Persky V , Davis F , Becker E . Is hereditary hemochromatosis a balanced polymorphism: an analysis of family size among hemochromatosis heterozygotes. Hepatogastroenterology 2001; 48: 523–6.
Rochette J , Pointon JJ , Fisher CA , et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999; 64: 1056–62.
Bullen JJ . Bacterial infections in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge, Cambridge University Press. 2000; 381–6.
Bulaj ZJ , Griffen LM , Jorde LB , Edwards CQ , Kushner JP . Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335: 1799–805.
Edwards CQ , Griffen LM , Bulaj ZJ , Ajioka RS , Kushner JP . The iron phenotype of hemochromatosis heterozygotes. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 411–18.
Edwards CQ , Griffen LM , Goldgar D , Drummond C , Skolnick MH , Kushner JP . Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–62.
McLaren CE , Gordeuk VR , Looker AC , et al. Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 1995; 86: 2021.
Hunt JR , Zeng H . Iron absorption by heterozygous carriers of the HFE C282Y mutation associated with hemochromatosis. Am J Clin Nutr 2004; 80: 924–31.
Bassett ML , Halliday JW , Powell LW . HLA typing in idiopathic hemochromatosis: distinction between homozygotes and heterozygotes with biochemical expression. Hepatology 1981; 1: 120–6.
Morrison ED , Brandhagen DJ , Phatak PD , et al. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627–33.
Rossi E , Bulsara MK , Olynyk JK , Cullen DJ , Summerville L , Powell LW . Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 2001; 47: 202–8.
George DK , Goldwurm S , MacDonald GA , et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311–18.
Beutler E , Felitti V , Gelbart T , Ho N . The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329–37.
Barton JC , Bertoli LF , Rothenberg BE . Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med 2000; 135: 96–104.
Beutler E , Felitti V , Gelbart T , Waalen J . Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry. Br J Haematol 2003; 120: 887–93.
McLaren CE , Barton JC , Gordeuk VR , et al. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study. Am J Hematol 2007; 82: 898–905.
Jacobs P , Finch CA . Iron for erythropoiesis [abstract]. Blood 1971; 37: 220.
Cazzola M , Huebers HA , Sayers MH , MacPhail AP , Eng M , Finch CA . Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood 1985; 66: 935–9.
Feeney GP , Carter K , Masters GS , Jackson HA , Cavil I , Worwood M . Changes in erythropoiesis in hereditary hemochromatosis are not mediated by HFE expression in nucleated red cells. Haematologica 2005; 90: 180.
Goodnough LT . Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007; 35: 1672.
Iliadou A , Evans DM , Zhu G , et al. Genome-wide scans of red cell indices suggest linkage on chromosome 6q23. J Med Genet 2007; 44: 24–30.
Lin JP , O'Donnell CJ , Levy D , Cupples LA . Evidence for a gene influencing haematocrit on chromosome 6q23–24: genome-wide scan in the Framingham Heart Study. J Med Genet 2005; 42: 75–9.
Garner C , Mitchell J , Hatzis T , Reittie J , Farrall M , Thein SL . Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am J Hum Genet 1998; 62: 14684.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.
Roe MA , Spinks C , Heath AL , et al. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007; 97: 544–9.
Rivard SR , Mura C , Simard H , et al. Clinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Blood Cells Mol Dis 2000; 26: 10–14.
Merryweather-Clarke AT , Pointon JJ , Jouanolle AM , Rochette J , Robson KJ . Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4: 183–98.
Mortimore M , Merryweather-Clarke AT , Robson KJ , Powell LW . The haemochromatosis gene: a global perspective and implications for the Asia-Pacific region. J Gastroenterol Hepatol 1999; 14: 838–43.
Porto G , de Sousa M . Variation of hemochromatosis prevalence and genotype in national groups. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 51–62.
Acton RT , Barton JC , Snively BM , et al. Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis 2006; 16: 815–21.
Barton JC , Patton MA , Edwards CQ , et al. Blood lead concentrations in hereditary hemochromatosis. J Lab Clin Med 1994; 124: 193–8.
Nelson RL , Davis FG , Persky V , Becker E . Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer 1995; 76: 875–9.
Waalen J , Beutler E . No age-related decrease in frequency of heterozygotes for the HFE C282Y haemochromatosis mutation. J Hepatol 2004; 40: 1044.
Oliva R , Novials A , Sanchez M , et al. The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. Endocrine 2004; 24: 111–14.
Zamboni P , Tognazzo S , Izzo M , et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 2005; 42: 309–14.
Fracanzani AL , Fargion S , Stazi MA , et al. Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis 2005; 35: 27–32.
Pacal L , Husa P , Znojil V , Kankova K . HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population. Hepatol Res 2007; 37: 740.
Nahon P , Sutton A , Rufat P , et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008; 134: 102–10.
Lauret E , Rodriguez M , Gonzalez S , et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 1016–21.
Barton JC , McDonnell SM , Adams PC , et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9.
Bonkovsky HL , Poh-Fitzpatrick M , Pimstone N , et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north America. Hepatology 1998; 27: 1661–9.
Stuart KA , Busfield F , Jazwinska EC , et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28: 404–9.
Martinelli AL , Zago MA , Roselino AM , et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 2000; 95: 3516–21.
Tannapfel A , Stolzel U , Kostler E , et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001; 439: 1.
Egger NG , Goeger DE , Payne DA , Miskovsky EP , Weinman SA , Anderson KE . Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47: 419–26.
Hift RJ , Corrigall AV , Hancock V , Kannemeyer J , Kirsch RE , Meissner PN . Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol (Noisy-le-grand) 2002; 48: 853–9.
Lamoril J , Andant C , Gouya L , et al. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol (Noisy-le-grand) 2002; 48: 33–41.
Chiaverini C , Halimi G , Ouzan D , Halfon P , Ortonne JP , Lacour JP. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology 2003; 206: 212–16.
Nagy Z , Koszo F , Par A , et al. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int 2004; 24: 16–20.
Toll A , Celis R , Ozalla MD , Bruguera M , Herrero C , Ercilla MG . The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J Eur Acad Dermatol Venereol 2006; 20: 1201–6.
Kratka K , Dostalikova-Cimburova M , Michalikova H , Stransky J , Vranova J , Horak J . High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic. Br J Dermatol 2008; 159: 585–90.
Brandenberg JB , Demarmels BF , Lutz HU , Wuillemin WA . Hereditary spherocytosis and hemochromatosis. Ann Hematol 2002; 81: 202–9.
Montes-Cano MA , Rodriguez-Munoz F , Franco-Osorio R , Nunez-Roldan A , Gonzalez-Escribano MF . Hereditary spherocytosis associated with mutations in HFE gene. Ann Hematol 2003; 82: 7692.
Valenti L , Pulixi EA , Arosio P , et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007; 92: 1037–42.
Blanc JF , De Ledinghen V , Bernard PH , et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000; 32: 805–11.
Varkonyi J , Tarkovacs G , Karadi I , et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003; 109: 64.
Nearman ZP , Szpurka H , Serio B , et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82: 1076–9.
Nelson JE , Bhattacharya R , Lindor KD , et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with non-alcoholic steatohepatitis. Hepatology 2007; 46: 723–9.
Kushner JP , Edwards CQ , Dadone MM , Skolnick MH . Heterozygosity for HLA-linked hemochromatosis as a likely cause of the hepatic siderosis associated with sporadic porphyria cutanea tarda. Gastroenterology 1985; 88: 1232–8.
Ivanova A , von Ahsen N , Adjarov D , Krastev Z , Oellerich M , Wieland E . C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology 1999; 30: 1531–2.
Chitturi S , Weltman M , Farrell GC , et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142–9.
Bugianesi E , Manzini P , D'Antico S , et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatology 2004; 39: 179–87.
Kallianpur AR , Hall LD , Yadav M , et al. Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 205–12.
Shaheen NJ , Silverman LM , Keku T , et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst 2003; 95: 154–9.
Dorak MT , Burnett AK , Worwood M . Hemochromatosis gene in leukemia and lymphoma. Leuk Lymphoma 2002; 43: 4677.
Dorak MT , Burnett AK , Worwood M , Sproul AM , Gibson BE . The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia. Blood 1999; 94: 3957.
Guerreiro RJ , Bras JM , Santana I , et al. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease, and mild cognitive impairment in a Portuguese cohort. BMC Neurol 2006; 6: 24.
Kwan T , Leber B , Ahuja S , Carter R , Gerstein HC . Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med 1998; 21: 251.
Moczulski DK , Grzeszczak W , Gawlik B . Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 2001; 24: 1187–91.
Cauza E , Hanusch-Enserer U , Bischof M , et al. Increased C282Y heterozygosity in gestational diabetes. Fetal Diagn Ther 2005; 20: 3494.
Rasmussen ML , Folsom AR , Catellier DJ , Tsai MY , Garg U , Eckfeldt JH . A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2001; 154: 739–46.
Pankow JS , Boerwinkle E , Adams PC , et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 2008; 152: 3–10.

Reference Title: References

Reference Type: reference-list

Elder GH . Molecular genetics of disorders of haem biosynthesis. J Clin Pathol 1993; 46: 977–81.
Phillips JD , Bergonia HA , Reilly CA , Franklin MR , Kushner JP . A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 2007; 104: 5079–84.
Bulaj ZJ , Phillips JD , Ajioka RS , et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95: 15651.
Lambrecht RW , Thapar M , Bonkovsky HL . Genetic aspects of porphyria cutanea tarda. Semin Liver Dis 2007; 27: 99–108.
Lamoril J , Andant C , Gouya L , et al. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol (Noisy-le-grand) 2002; 48: 33–41.
Bonkovsky HL , Poh-Fitzpatrick M , Pimstone N , et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north America. Hepatology 1998; 27: 1661–9.
Stuart KA , Busfield F , Jazwinska EC , et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28: 404–9.
Fargion S , Piperno A , Cappellini MD , et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322–6.
Stolzel U , Kostler E , Schuppan D , et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003; 139: 309–13.
D'Amato M , Macri A , Griso D , Biolcati G , Ameglio F . Are His63Asp or Cys282Tyr HFE mutations associated with porphyria cutanea tarda? Data of patients from central and southern Italy. J Invest Dermatol 1998; 111: 1241–2.
Santos M , Clevers HC , Marx JJ . Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med 1997; 336: 1327–8.
Roberts AG , Whatley SD , Morgan RR , Worwood M , Elder GH . Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321–3.
de Salamanca RE , Morales P , Castro MJ , Rojo R , Gonzalez M , Arnaiz-Villena A. The most frequent HFE allele linked to porphyria cutanea tarda in Mediterraneans is His63Asp. Hepatology 1999; 30: 819–20.
Furuyama K , Kondo M , Hirata K , Fujita H , Sassa S . Extremely rare association of HFE mutations with porphyria cutanea tarda in Japanese patients. Hepatology 1999; 30: 1532–3.
Egger NG , Goeger DE , Payne DA , Miskovsky EP , Weinman SA , Anderson KE . Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47: 419–26.
Mehrany K , Drage LA , Brandhagen DJ , Pittelkow MR . Association of porphyria cutanea tarda with hereditary hemochromatosis. J Am Acad Dermatol 2004; 51: 205–11.
Christiansen L , Bygum A , Thomsen K , Brandrup F , Horder M , Petersen NE . Denaturing gradient gel electrophoresis analysis of the hemochromatosis (HFE) gene: impact of HFE gene mutations on the manifestation of porphyria cutanea tarda. Clin Chem 1999; 45: 2025–6.
Brady JJ , Jackson HA , Roberts AG , et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000; 115: 8684.
Toll A , Celis R , Ozalla MD , Bruguera M , Herrero C , Ercilla MG . The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J Eur Acad Dermatol Venereol 2006; 20: 1201–6.
Gonzalez-Hevilla M , de Salamanca RE , Morales P , et al. Human leukocyte antigen haplotypes and HFE mutations in Spanish hereditary hemochromatosis and sporadic porphyria cutanea tarda. J Gastroenterol Hepatol 2005; 20: 456–62.
Chiaverini C , Halimi G , Ouzan D , Halfon P , Ortonne JP , Lacour JP. Porphyria cutanea tarda, C282Y, H63D, and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology 2003; 206: 212–16.
Skowron F , Berard F , Grezard P , Wolf F , Morel Y , Perrot H. [Role of the hemochromatosis gene in prophyria cutanea tarda. Prospective study of 56 cases.] Ann Dermatol Venereol 2001; 128: 600–4.
Dereure O , Aguilar-Martinez P , Bessis D , et al. HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: a prospective study of 36 cases from southern France. Br J Dermatol 2001; 144: 533–9.
Sampietro M , Piperno A , Lupica L , et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998; 27: 181–4.
Frank J , Poblete-Gutierrez P , Weiskirchen R , Gressner O , Merk HF , Lammert F. Hemochromatosis gene sequence deviations in German patients with porphyria cutanea tarda. Physiol Res 2006; 55 Suppl 2: S75–83.
Tannapfel A , Stolzel U , Kostler E , et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001; 439: 1.
Nagy Z , Koszo F , Par A , et al. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int 2004; 24: 16–20.
Malina L , Zd'arsky E , Dandova S , Michalikova H , Cerna M , Cimburova M. [Significance and prevalence of the C282Y gene mutation of primary hemochromatosis in the pathogenesis of pophyria cutanea tarda.] Cas Lek Cesk 2000; 139: 728–30.
Ivanova A , von Ahsen N , Adjarov D , Krastev Z , Oellerich M , Wieland E . C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology 1999; 30: 1531–2.
Wolff CF , Armas RM , Frank J , Poblete PG. [Mutations of hemochromatosis gene in volunteer blood donors and Chilean porphyria cutanea tarda patients.] Medicina (B Aires) 2006; 66: 421–6.
Mendez M , Rossetti MV , Del C Battle AM , Parera VE . The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol 2005; 52: 417–24.
Martinelli AL , Zago MA , Roselino AM , et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 2000; 95: 3516–21.
Hift RJ , Corrigall AV , Hancock V , Kannemeyer J , Kirsch RE , Meissner PN . Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol (Noisy-le-grand) 2002; 48: 853–9.
Bulaj ZJ , Franklin MR , Phillips JD , et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med 2000; 136: 482–8.
Rossouw JE , Anderson GL , Prentice RL , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.
Bertoli LF , Barton JC . Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. Clin Breast Cancer 2007; 7: 716–18.
Roche M , Daly P , Crowley V , Darby C , Barnes L . A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole. Clin Exp Dermatol 2007; 32: 327–8.
Roberts AG , Whatley SD , Nicklin S , et al. The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology 1997; 25: 159–61.

Reference Title: References

Reference Type: reference-list

Bottomley SS . Iron overload in sideroblastic and other non-thalassemic anemias. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 435–41.
Shaw GC , Cope JJ , Li L , et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006; 440: 96–100.
Gattermann N , Retzlaff S , Wang YL , et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90: 49612.
Britton RS . Mechanisms of iron toxicity. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 229–38.
Lagerstrom-Fermer M , Olsson C , Forsgren L , Syvanen AC . Heteroplasmy of the human mtDNA control region remains constant during life. Am J Hum Genet 2001; 68: 1299–301.
Kim JH , Park KS , Cho YM , et al. The prevalence of the mitochondrial DNA 16189 variant in non-diabetic Korean adults and its association with higher fasting glucose and body mass index. Diabet Med 2002; 19: 681–4.
Lin TK , Chen SD , Wang PW , et al. Increased oxidative damage with altered antioxidative status in type 2 diabetic patients harboring the 16189 T to C variant of mitochondrial DNA. Ann N Y Acad Sci 2005; 1042: 64–9.
Park KS , Chan JC , Chuang LM , et al. A mitochondrial DNA variant at position 16189 is associated with type 2 diabetes mellitus in Asians. Diabetologia 2008; 51: 602–8.
Poulton J , Brown MS , Cooper A , Marchington DR , Phillips DI . A common mitochondrial DNA variant is associated with insulin resistance in adult life. Diabetologia 1998; 41: 54–8.
Poulton J , Marchington DR , Scott-Brown M , Phillips DI , Hagelberg E . Does a common mitochondrial DNA polymorphism underlie susceptibility to diabetes and the thrifty genotype? Trends Genet 1998; 14: 387–9.
Poulton J , Luan J , Macaulay V , Hennings S , Mitchell J , Wareham NJ . Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum Mol Genet 2002; 11: 1581–3.
Livesey KJ , Wimhurst VL , Carter K , et al. The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. J Med Genet 2004; 41: 6–10.
Beutler E , Beutler L , Lee PL , Barton JC . The mitochondrial nt 16189 polymorphism and hereditary hemochromatosis. Blood Cells Mol Dis 2004; 33: 344.
Salvador M , Villegas A , Llorente L , Ropero P , Gonzalez FA , Bustamante L. 16189 Mitochondrial variant and iron overload. Ann Hematol 2007; 86: 463–4.

Reference Title: References

Reference Type: reference-list

Eason RJ , Adams PC , Aston CE , Searle J . Familial iron overload with possible autosomal dominant inheritance. Aust N Z J Med 1990; 20: 226–30.
Pietrangelo A , Montosi G , Totaro A , et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725–32.
Njajou OT , Vaessen N , Joosse M , et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213–14.
Montosi G , Donovan A , Totaro A , et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619–23.
Arden KE , Wallace DF , Dixon JL , et al. A novel mutation in ferroportin 1 is associated with haemochromatosis in a Solomon Islands patient. Gut 2003; 52: 1215–17.
Njajou OT , de Jong G , Berghuis B , et al. Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. Blood Cells Mol Dis 2002; 29: 439–43.
Sham RL , Phatak PD , West C , Lee P , Andrews C , Beutler E . Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005; 34: 157–61.
Cazzola M , Cremonesi L , Papaioannou M , et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002; 119: 539–46.
Devalia V , Carter K , Walker AP , et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100: 695.
Roetto A , Merryweather-Clarke AT , Daraio F , et al. A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood 2002; 100: 733–4.
Wallace DF , Pedersen P , Dixon JL , et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692–4.
Wallace DF , Browett P , Wong P , Kua H , Ameratunga R , Subramaniam VN . Identification of ferroportin disease in the Indian subcontinent. Gut 2005; 54: 567–8.
Zoller H , McFarlane I , Theurl I , et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology 2005; 42: 4662.
Wallace DF , Subramaniam VN . Non-HFE haemochromatosis. World J Gastroenterol 2007; 13: 4690–8.
Subramaniam VN , Wallace DF , Dixon JL , Fletcher LM , Crawford DHG . Ferroportin disease due to the A77D mutation in Australia. Gut 2005; 54: 1048–9.
Agarwal S , Sankar VH , Tewari D , Pradhan M . Ferroportin (SLC40A1) gene in thalassemic patients of Indian descent. Clin Genet 2006; 70: 86.
Barton JC , Acton RT , Rivers CA , et al. Genotypic and phenotypic heterogeneity of African-Americans with primary iron overload. Blood Cells Mol Dis 2003; 31: 310–19.
Beutler E , Barton JC , Felitti VJ , et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305–9.
Gordeuk VR , Caleffi A , Corradini E , et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31: 299–304.
Barton JC , Acton RT , Lee PL , West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells Mol Dis 2007; 39: 206–11.
Rivers CA , Barton JC , Gordeuk VR , et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African-Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis 2007; 38: 2472.
Nemeth E , Tuttle MS , Powelson J , et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090–3.
Donovan A , Brownlie A , Zhou Y , et al. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776–81.
Donovan A , Lima CA , Pinkus JL , et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1: 191–200.
McKie AT , Marciani P , Rolfs A , et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299–309.
De Domenico I , Nemeth E , Nelson JM , et al. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab 2008; 8: 1466.
De Domenico I , Lo E , Ward DM , Kaplan J . Hepcidin-induced internalization of ferroportin requires binding and co-operative interaction with Jak2. Proc Natl Acad Sci USA 2009; 106: 3800.
De Domenico I , Ward DM , Nemeth E , et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA 2005; 102: 8955–60.
Andrews NC . Of mice and iron: ferroportin disease. Blood 2007; 109: 4115.
Zohn IE , De Domenico I , Pollock A , et al. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease. Blood 2007; 109: 4174–80.
De Domenico I , Ward DM , Musci G , Kaplan J . Iron overload due to mutations in ferroportin. Haematologica 2006; 91: 92.
Sham RL , Phatak PD , Nemeth E , Ganz T . Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood 2009; 114: 493–4.
Fernandes A , Preza GC , Phung Y , et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009; 114: 437–43.
Aisen P , Enns C , Wessling-Resnick M . Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001; 33: 9409.
Syed BA , Beaumont NJ , Patel A , et al. Analysis of the human hephaestin gene and protein: comparative modeling of the N-terminus ecto-domain based upon ceruloplasmin. Protein Eng 2002; 15: 205–14.
Pietrangelo A . The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131–8.
Corradini E , Ferrara F , Pollicino T , et al. Disease progression and liver cancer in the ferroportin disease. Gut 2007; 56: 1030–2.
Pietrangelo A , Corradini E , Ferrara F , et al. Magnetic resonance imaging to identify classic and non-classic forms of ferroportin disease. Blood Cells Mol Dis 2006; 37: 192–6.
Drakesmith H , Schimanski LM , Ormerod E , et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106: 1092.
Cunat S , Giansily-Blaizot M , Bismuth M , et al. Global sequencing approach for characterizing the molecular background of hereditary iron disorders. Clin Chem 2007; 53: 2060–9.
Liu W , Shimomura S , Imanishi H , et al. Hemochromatosis with mutation of the ferroportin 1 (IREG1) gene. Intern Med 2005; 44: 285–9.
Koyama C , Wakusawa S , Hayashi H , et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med 2005; 44: 990–3.
Pelucchi S , Mariani R , Salvioni A , et al. Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. Clin Genet 2008; 73: 171–8.
Corradini E , Montosi G , Ferrara F , et al. Lack of enterocyte iron accumulation in the ferroportin disease. Blood Cells Mol Dis 2005;35: 315–18.
De Domenico I , McVey WD , Nemeth E , et al. Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica 2006; 91: 1092.
Cremonesi L , Forni GL , Soriani N , et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 2005; 131: 6630.
Bach V , Remacha A , Altes A , Barcelo MJ , Molina MA , Baiget M . Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol Dis 2006; 36: 41.
Wallace DF , Clark RM , Harley HA , Subramaniam VN . Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol 2004; 40: 710–13.
Girelli D , De Domenico I , Bozzini C , et al. Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations. J Hepatol 2008; 49: 6641.
Hetet G , Devaux I , Soufir N , Grandchamp B , Beaumont C . Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003; 102: 1904–10.
Speletas M , Kioumi A , Loules G , et al. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV. Blood Cells Mol Dis 2008; 40: 353–9.
Morris TJ , Litvinova MM , Ralston D , Mattman A , Holmes D , Lockitch G . A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis. Blood Cells Mol Dis 2005; 35: 309–14.
Zaahl MG , Merryweather-Clarke AT , Kotze MJ , van der Merwe S , Warnich L , Robson KJ . Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet 2004; 115: 409–17.
Robson KJ , Merryweather-Clarke AT , Cadet E , et al. Recent advances in understanding haemochromatosis: a transition state. J Med Genet 2004; 41: 721–30.
Lok CY , Merryweather-Clarke AT , Viprakasit V , et al. Iron overload in the Asian community. Blood 2009; 114: 20.
Wallace DF , Dixon JL , Ramm GA , Anderson GJ , Powell LW , Subramaniam VN . A novel mutation in ferroportin implicated in iron overload. J Hepatol 2007; 46: 921–6.
Lee PL , Gelbart T , West C , Barton JC. SLC40A1 c.1402G→A results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype. Acta Haematol 2007; 118: 237–41.
Griffiths WJ , Mayr R , McFarlane I , et al. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. Hepatology 2009, Oct 19. [Epub ahead of print]
Jouanolle AM , Douabin-Gicquel V , Halimi C , et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol 2003; 39: 286–9.
Letocart E , Le Gac G , Majore S , et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009; 147: 379–85.
Duca L , Delbini P , Nava I , Vaja V , Fiorelli G , Cappellini MD . Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. Am J Hematol 2009; 84: 592–3.

Reference Title: References

Reference Type: reference-list

Bezançon F , de Gennes L , DeLarue J , Oumensky V . Cirrhose pigmentaire avec infantilisme et insuffisance cardiaque et aplasie endocriniennes multiples. Bull Mém Soc Méd Hôp Paris 1932; 48: 9674.
de Gennes L , DeLarue J , de Vericourt R . Sur un nouveau cas de cirrhose pigmentaire avec infantilisme et myocarde. Le syndrome endocrine-hepato-cardiaque. Bull Mém Soc Méd Hôp Paris 1935; 51: 1228.
de Vericourt R . Le syndrome endocrino-hepato-myocardiaque (sur an aspect des cirrhoses pigmentaires). Paris, 1935.
Pietrangelo A , Caleffi A , Henrion J , et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128: 470–9.
Sham RL , Phatak PD , West C , Lee P , Andrews C , Beutler E . Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005; 34: 157–61.
Sheldon JH . Haemochromatosis. London, Oxford University Press, 1935; 381.
Finch SC , Finch CL. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine 1955; 34: 381–430.
Goossens JP. Idiopathic haemochromatosis: Juvenile and familial type—endocrine aspects. Neth J Med 1975; 18: 161–9.
Lamon JM , Marynick SP , Roseblatt R , Donnelly S. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology 1979; 76: 178–83.
Kaltwasser JP . Juvenile hemochromatosis. In: Barton JC , Edward CQ , eds. Hemochromatosis: Genetics, Pathogenesis, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 318–25.
Roetto A , Totaro A , Cazzola M , et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64: 1388–93.
Papanikolaou G , Samuels ME , Ludwig EH , et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77–82.
Vaiopoulos G , Papanikolaou G , Politou M , Jibreel I , Sakellaropoulos N , Loukopoulos D . Arthropathy in juvenile hemochromatosis. Arthritis Rheum 2003; 48: 227–30.
Barton JC , Rao SV , Pereira NM , et al. Juvenile hemochromatosis in the southeastern United States: a report of seven cases in two kinships. Blood Cells Mol Dis 2002; 29: 104–15.
Mendes AI , Ferro A , Martins R , et al. Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes. Ann Hematol 2009; 88: 229–34.
Barton JC , Rivers CA , Niyongere S , Bohannon SB , Acton RT . Allele frequencies of hemojuvelin gene (HJV) I222N and G320V missense mutations in white and African-American subjects from the general Alabama population. BMC Med Genet 2004; 5: 29.
Lee PL , Barton JC , Brandhagen D , Beutler E . Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol 2004; 127: 224–9.
Murugan RC , Lee PL , Kalavar, MR , Barton JC . Early age-of-onset iron overload and homozygosity for the novel hemojuvelin mutation HJV R54X (exon 3; c.160>T) in an African-American male of West Indies descent. Clin Genet 2008; 74: 88–92.
Koyama C , Hayashi H , Wakusawa S , et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol 2005; 43: 740–2.
Lok CY , Merryweather-Clarke AT , Viprakasit V , et al. Iron overload in the Asian community. Blood 2009; 114: 20.
Lin L , Nemeth E , Goodnough JB , Thapa DR , Gabayan V , Ganz T . Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis 2008; 40: 122–31.
Silvestri L , Pagani A , Fazi C , et al. Defective targeting of hemojuvelin to plasma membrane is a common pathogenetic mechanism in juvenile hemochromatosis. Blood 2007; 109: 4503–10.
Truksa J , Peng H , Lee P , Beutler E . Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor-2 (Tfr2), and IL-6. Proc Natl Acad Sci USA 2006; 103: 10289–93.
Zhang AS , Anderson SA , Meyers KR , Hernandez C , Eisenstein RS , Enns CA . Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem 2007; 282: 125476.
Muhlestein JB . Cardiac abnormalities in hemochromatosis. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 297–311.
Rivard SR , Mura C , Simard H , et al. Mutation analysis in the HFE gene in patients with hereditary haemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Br J Haematol 2000; 108: 854–8.
Rivard SR , Mura C , Simard H , et al. Clinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Blood Cells Mol Dis 2000; 26: 10–14.
Le Gac G , Scotet V , Ka C , et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004; 13: 1913–18.
van Dijk BA , Kemna EH , Tjalsma H , et al. Effect of the new HJV-L165X mutation on penetrance of HFE . Blood 2007; 109: 5525–6.
de Gobbi M , Roetto A , Piperno A , et al. Natural history of juvenile haemochromatosis. Br J Haematol 2002; 117: 973–9.
Kelly AL , Rhodes DA , Roland JM , Schofield P , Cox TM . Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91: 607–18.
Fabio G , Minonzio F , Delbini P , Bianchi A , Cappellini MD . Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007; 109: 362–4.
Barton JC . Chelation therapy for iron overload. Curr Gastroenterol Rep 2007; 9: 74–82.
Jensen PD , Bagger JP , Jensen FT , Baandrup U , Christensen T , Ellegaard J . Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies. Eur J Haematol 1993; 51: 199–205.
De Gobbi M , Pasquero P , Brunello F , Paccotti P , Mazza U , Camaschella C . Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. Haematologica 2000; 85: 865.
Kaltwasser JP , Werner E , Schalk K , Hansen C , Gottschalk R , Seidl C . Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998; 43: 69904.
Cazzola M , Ascari E , Barosi G , et al. Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983; 65: 1494.
Kelly TM , Edwards CQ , Meikle AW , Kushner JP . Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101: 629–32.
Farina G , Pedrotti C , Cerani P , et al. Successful pregnancy following gonadotropin therapy in a young female with juvenile idiopathic hemochromatosis and secondary hypogonadotropic hypogonadism. Haematologica 1995; 80: 335.
Lee PL , Beutler E , Rao SV , Barton JC . Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood 2004; 103: 46691.
Huang FW , Rubio-Aliaga I , Kushner JP , Andrews NC , Fleming MD . Identification of a novel mutation (C321X) in HJV . Blood 2004; 104: 2176.
Beutler L , Beutler E . Hematologically important mutations: iron storage diseases. Blood Cells Mol Dis 2004; 33: 40–4.
Wallace DF , Subramaniam VN . Non-HFE haemochromatosis. World J Gastroenterol 2007; 13: 4690–8.
Filali M , Le Jeunne C , Durand E , et al. Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. Blood Cells Mol Dis 2004; 33: 120–4.

Reference Title: References

Reference Type: reference-list

Park CH , Valore EV , Waring AJ , Ganz T . Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–10.
Krause A , Neitz S , Magert HJ , et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 1470.
Gehrke SG , Kulaksiz H , Herrmann T , et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102: 371–6.
Hunter HN , Fulton DB , Ganz T , Vogel HJ . The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem 2002; 277: 37 597–603.
Courselaud B , Pigeon C , Inoue Y , et al. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 2002; 277: 41 1630.
Truksa J , Peng H , Lee P , Beutler E . Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol 2007; 139: 138–47.
Island ML , Jouanolle AM , Mosser A , et al. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE-related hemochromatosis. Haematologica 2009; 94: 720–4.
Lee PL , Beutler E . Regulation of hepcidin and iron overload disease. Annu Rev Pathol 2009; 4: 48915.
Truksa J , Lee P , Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 2009; 113: 688–95.
Nemeth E , Roetto A , Garozzo G , Ganz T , Camaschella C . Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105: 1803–6.
Zoller H , McFarlane I , Theurl I , et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology 2005; 42: 4662.
Ganz T , Nemeth E . Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta 2006; 1763: 690–9.
Origa R , Galanello R , Ganz T , et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92: 583–8.
Piperno A , Girelli D , Nemeth E , et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 2007; 110: 4096–100.
Nicolas G , Chauvet C , Viatte L , et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037–44.
Nicolas G , Bennoun M , Porteu A , et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596–601.
Ganz T . Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–8.
Roetto A , Papanikolaou G , Politou M , et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21–2.
Delatycki MB , Allen KJ , Gow P , et al. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clin Genet 2004; 65: 378–83.
Matthes T , Aguilar-Martinez P , Pizzi-Bosman L , et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene. Blood 2004; 104: 2181–3.
Lok CY , Merryweather-Clarke AT , Viprakasit V , et al. Iron overload in the Asian community. Blood 2009; 114: 20.
Porto G , Roetto A , Daraio F , et al. A Portuguese patient homozygous for the -25G>A mutation of the HAMP promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron. Blood 2005; 106: 2922–3.
Barton JC , LaFreniere S , Leiendecker-Foster C , et al. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. Am J Hematol 2009; 84: 710–14.
Merryweather-Clarke AT , Cadet E , Bomford A , et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241.
Valenti L , Pulixi EA , Arosio P , et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007; 92: 1037–42.
Roetto A , Daraio F , Porporato P , et al. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood 2004; 103: 2407–9.
Jacolot S , Le Gac G , Scotet V , Quere I , Mura C , Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103: 2835–40.
Biasiotto G , Belloli S , Ruggeri G , et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor-2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003; 49: 1981–8.
Barton JC , LaFreniere S , Leiendecker-Foster C , et al. HAMP promoter mutation nc.−153C>T in 785 HEIRS Study participants. Haematologica 2009; 94: 1465.
Lee PL , Gelbart T , West C , Halloran C , Felitti V , Beutler E . A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis 2001; 27: 783–802.
Rideau A , Mangeat B , Matthes T , Trono D , Beris P . Molecular mechanism of hepcidin deficiency in a patient with juvenile hemochromatosis. Haematologica 2007; 92: 127–8.
Casanovas G , Mleczko-Sanecka K , Altamura S , Hentze MW , Muckenthaler MU . Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med 2009; 87: 471–80.
Biasiotto G , Roetto A , Daraio F , et al. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele. Blood Cells Mol Dis 2004; 33: 338–43.
Majore S , Binni F , Pennese A , De Santis A , Crisi A , Grammatico P. HAMP gene mutation c.208T>C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. Hum Mutat 2004; 23: 400.

Reference Title: References

Reference Type: reference-list

Kawabata H , Yang R , Hirama T , et al. Molecular cloning of transferrin receptor-2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826–32.
Chua ACG , Delima RD , Morgan EH , et al. Iron uptake from plasma transferin by a transform receptor-2 mutant mouse model of haemochromatosis. J Hepatiol 2010; 52: 425–31.
Camaschella C , Roetto A , Cali A , et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14–15.
Le Gac G , Mons F , Jacolot S , Scotet V , Ferec C , Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004; 125: 674–8.
Majore S , Milano F , Binni F , et al. Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. Haematologica 2006; 91: ECR33.
Biasiotto G , Camaschella C , Forni GL , Polotti A , Zecchina G , Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica 2008; 93: 309–10.
Piperno A , Roetto A , Mariani R , et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004; 89: 359–60.
Pietrangelo A , Caleffi A , Henrion J , et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128: 470–9.
Roetto A , Totaro A , Piperno A , et al. New mutations inactivating transferrin receptor-2 in hemochromatosis type 3. Blood 2001; 97: 2555–60.
Mattman A , Huntsman D , Lockitch G , et al. Transferrin receptor-2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002; 100: 1075.
Camaschella C , Roetto A. TFR2-related hereditary hemochromatosis [Type 3 hereditary hemochromatosis.] In: Pagon RA , ed. GeneReviews. Seattle, University of Washington. 2006.
Nemeth E , Roetto A , Garozzo G , Ganz T , Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105: 1803–6.
Girelli D , Bozzini C , Roetto A , et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor-2 gene. Gastroenterology 2002; 122: 1295–302.
Hsiao PJ , Tsai KB , Shin SJ , et al. A novel mutation of transferrin receptor-2 in a Taiwanese woman with type 3 hemochromatosis. J Hepatol 2007; 47: 303–6.
Lee PL , Barton JC. Hemochromatosis and severe iron overload associated with compound heterozygosity for TFR2 R455Q and two novel mutations TFR2 R396X and G792R. Acta Haematol 2006; 115: 102.
Barton EH , West PA , Rivers CA , Barton JC , Acton RT. Transferrin receptor-2 (TFR2) mutation Y250X in Alabama Caucasian and African-American subjects with and without primary iron overload. Blood Cells Mol Dis 2001; 27: 279–84.
Dereure O , Esculier C , Aguilar-Martinez P , Dessis D , Guillot B , Guilhou JJ. No evidence of Y250X transferrin receptor type 2 mutation in patients with porphyria cutanea tarda. A study of 38 cases. Dermatology 2002; 204: 158–9.
Lee PL , Halloran C , West C , Beutler E. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol Dis 2001; 27: 285–9.
Biasiotto G , Belloli S , Ruggeri G , et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor-2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003; 49: 1981–8.
De Gobbi M , Daraio F , Oberkanins C , et al. Analysis of HFE and TFR2 mutations in selected blood donors with biochemical parameters of iron overload. Haematologica 2003; 88: 396–401.
Mariani R , Salvioni A , Corengia C , et al. Prevalence of HFE mutations in upper northern Italy: study of 1132 unrelated blood donors. Dig Liver Dis 2003; 35: 479–81.
Hofmann WK , Tong XJ , Ajioka RS , Kushner JP , Koeffler HP. Mutation analysis of transferrin receptor-2 in patients with atypical hemochromatosis. Blood 2002; 100: 1099–100.
Barton JC , Acton RT , Leiendecker-Foster C , et al. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. Am J Hematol 2008; 83: 126–32.
Riva A , Mariani R , Bovo G , et al. Type 3 hemochromatosis and beta-thalassemia trait. Eur J Haematol 2004; 72: 370–4.
Barton JC , Acton RT , Leiendecker-Foster C , et al. HFE C282Y homozygotes aged 25–29 years at HEIRS Study initial screening. Genet Test 2007; 11: 2695.
Witte DL , Crosby WH , Edwards CQ , Fairbanks VF , Mitros F. A Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200.
Barton JC , McDonnell SM , Adams PC , et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9.
Koyama C , Wakusawa S , Hayashi H , et al. Two novel mutations, L490R and V561X, of the transferrin receptor-2 gene in Japanese patients with hemochromatosis. Haematologica 2005; 90: 302.
Hattori A , Wakusawa S , Hayashi H , et al. AVAQ 59497 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003; 26: 154–6.
Jouanolle AM , Mosser A , David V , et al. Early onset iron overload in two patients presenting with new mutations in TFR2 [abstract]. The Second Congress of the International BioIron Society 2007; 72.
Wallace DF , Subramaniam VN. Non-HFE haemochromatosis. World J Gastroenterol 2007; 13: 4690–8.
Beutler L , Beutler E. Hematologically important mutations: iron storage diseases. Blood Cells Mol Dis 2004; 33: 40–4.
Chan V , Wong MS , Ooi C , et al. Can defects in transferrin receptor-2 and hereditary hemochromatosis genes account for iron overload in HbH disease? Blood Cells Mol Dis 2003; 30: 107–11.
Mendes AI , Ferro A , Martins R , et al. Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes. Ann Hematol 2009; 88: 229–34.
Barton JC , Lee PL. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G>A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis 2006; 36: 342–6.
Barton JC , Lee PL , West C , Bottomley SS. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 2006; 81: 760.
Meregalli M , Pellagatti A , Bissolotti E , Fracanzani AL , Fargion S , Sampietro M. Molecular analysis of the TFR2 gene: report of a novel polymorphism (1878C>T). Hum Mutat 2000; 16: 532.

Reference Title: References

Reference Type: reference-list

Harrison PM , Arosio P . The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161–203.
Hentze MW , Rouault TA , Caughman SW , Dancis A , Harford JB , Klausner RD . A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci USA 1987; 84: 6730–4.
McGill JR , Naylor SL , Sakaguchi AY , et al. Human ferritin H and L sequences lie on ten different chromosomes. Hum Genet 1987; 76: 662.
Eisenstein RS . Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000; 20: 627–62.
Hentze MW , Caughman SW , Rouault TA , et al. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science 1987; 238: 1570–3.
Leibold EA , Munro HN . Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy- and light-subunit mRNAs. Proc Natl Acad Sci USA 1988; 85: 2171.
Theil EC . Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 1987; 56: 289–315.
Thomson AM , Rogers JT , Leedman PJ . Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol 1999; 31: 11392.
Kato J , Fujikawa K , Kanda M , et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69: 191.
Caughman SW , Hentze MW , Rouault TA , Harford JB , Klausner RD . The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor. J Biol Chem 1988; 263: 19,0482.
Kawanaka M , Kinoyama S , Niiyama G , et al. [A case of idiopathic hemochromatosis which occurred in three siblings with high level of serum CA 19–9.] Nippon Shokakibyo Gakkai Zasshi 1998; 95: 910–15.
Ferreira C , Bucchini D , Martin ME , et al. Early embryonic lethality of H ferritin gene deletion in mice. J Biol Chem 2000; 275: 3021–4.
Hattori A , Wakusawa S , Hayashi H , et al. AVAQ 59497 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003; 26: 154–6.
Hentze MW , Keim S , Papadopoulos P , et al. Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene. Proc Natl Acad Sci USA 1986; 83: 7226–30.

Reference Title: References

Reference Type: reference-list

Roetto A , Bosio S , Gramaglia E , Barilaro MR , Zecchina G , Camaschella C . Pathogenesis of hyperferritinemia cataract syndrome. Blood Cells Mol Dis 2002; 29: 532.
Girelli D , Olivieri O , De Franceschi L , Corrocher R , Bergamaschi G , Cazzola M . A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol 1995; 90: 931–4.
Girelli D , Corrocher R , Bisceglia L , et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the “Verona mutation”). Blood 1995; 86: 4050–3.
Bonneau D , Winter-Fuseau I , Loiseau MN , et al. Bilateral cataract and high serum ferritin: a new dominant genetic disorder? J Med Genet 1995; 32: 778–9.
Levi S , Girelli D , Perrone F , et al. Analysis of ferritins in lymphoblastoid cell lines and in the lens of subjects with hereditary hyperferritinemia-cataract syndrome. Blood 1998; 91: 4180.
Cazzola M , Bergamaschi G , Tonon L , et al. Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. Blood 1997; 90: 814–21.
Brooks DG , Manova-Todorova K , Farmer J , et al. Ferritin crystal cataracts in hereditary hyperferritinemia cataract syndrome. Invest Ophthalmol Vis Sci 2002; 43: 1121–6.
Chang-Godinich A , Ades S , Schenkein D , Brooks D , Stambolian D , Raizman MB . Lens changes in hereditary hyperferritinemia-cataract syndrome. Am J Ophthalmol 2001; 132: 786–8.
Craig JE , Clark JB , McLeod JL , et al. Hereditary hyperferritinemia-cataract syndrome: prevalence, lens morphology, spectrum of mutations, and clinical presentations. Arch Ophthalmol 2003; 121: 1753–61.
Girelli D , Bozzini C , Zecchina G , et al. Clinical, biochemical, and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. Br J Haematol 2001; 115: 334–40.
Cheng Q , Gonzalez P , Zigler JS, Jr . High level of ferritin light chain mRNA in lens. Biochem Biophys Res Commun 2000; 270: 3495.
Ismail AR , Lachlan KL , Mumford AD , Temple IK , Hodgkins PR . Hereditary hyperferritinemia-cataract syndrome: ocular, genetic, and biochemical findings. Eur J Ophthalmol 2006; 16: 153–60.
Campagnoli MF , Pimazzoni R , Bosio S , et al. Onset of cataract in early infancy associated with a 32G→C transition in the iron responsive element of L-ferritin. Eur J Pediatr 2002; 161: 49902.
Hetet G , Devaux I , Soufir N , Grandchamp B , Beaumont C . Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003; 102: 1904–10.
Cremonesi L , Cozzi A , Girelli D , et al. Case report: a subject with a mutation in the ATG start codon of L-ferritin has no haematological or neurological symptoms. J Med Genet 2004; 41: e81.
Burdon KP , Sharma S , Chen CS , Dimasi DP , Mackey DA , Craig JE . A novel deletion in the FTL gene causes hereditary hyperferritinemia-cataract syndrome (HHCS) by alteration of the transcription start site. Hum Mutat 2007; 28: 742.
Allerson CR , Cazzola M , Rouault TA . Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome. J Biol Chem 1999; 274: 26 439–47.
Lachlan KL , Temple IK , Mumford AD . Clinical features and molecular analysis of seven British kindreds with hereditary hyperferritinaemia-cataract syndrome. Eur J Hum Genet 2004; 12: 790–6.
Barton JC , Beutler E , Gelbart T . Coinheritance of alleles associated with hemochromatosis and hereditary hyperferritinemia-cataract syndrome. Blood 1998; 92: 4480.
Camaschella C , Zecchina G , Lockitch G , et al. A new mutation (G51C) in the iron-responsive element (IRE) of L-ferritin associated with hyperferritinaemia-cataract syndrome decreases the binding affinity of the mutated IRE for iron-regulatory proteins. Br J Haematol 2000; 108: 480–2.
Ferrari F , Foglieni B , Arosio P , et al. Microelectronic DNA chip for hereditary hyperferritinemia-cataract syndrome, a model for large-scale analysis of disorders of iron metabolism. Hum Mutat 2006; 27: 201–8.
Cazzola M , Foglieni B , Bergamaschi G , Levi S , Lazzarino M , Arosio P . A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. Br J Haematol 2002; 116: 6670.
Rosochova J , Kapetanios A , Pournaras C , Vadas L , Samii K , Beris P . Hereditary hyperferritinaemia-cataract syndrome: does it exist in Switzerland? Schweiz Med Wochenschr 2000; 130: 324–8.
Cremonesi L , Fumagalli A , Soriani N , et al. Double-gradient denaturing gradient gel electrophoresis assay for identification of L-ferritin iron-responsive element mutations responsible for hereditary hyperferritinemia-cataract syndrome: identification of the new mutation C14G. Clin Chem 2001; 47: 491.
Bozzini C , Galbiati S , Tinazzi E , Aldigeri R , De Matteis G , Girelli D . Prevalence of hereditary hyperferritinemia-cataract syndrome in blood donors and patients with cataract. Haematologica 2003; 88: 219–20.
Barton JC , Acton RT , Dawkins FW , et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test 2005; 9: 231–41.
Barton JC , Acton RT , Lovato L , et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening Study. Clin Genet 2006; 69: 487.
Harris EL , McLaren CE , Reboussin DM , et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med 2007; 167: 722–6.
Kannengiesser C , Jouanolle AM , Hetet G , et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009; 94: 335–9.
Garcia Erce JA , Cortes T , Cremonesi L , Cazzola M , Perez-Lungmus G , Giralt M. [Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: “Zaragoza”).] Med Clin (Barc) 2006; 127: 55–8.
Cremonesi L , Paroni R , Foglieni B , et al. Scanning mutations of the 5′UTR regulatory sequence of L-ferritin by denaturing high-performance liquid chromatography: identification of new mutations. Br J Haematol 2003; 121: 173–9.
Girelli D , Corrocher R , Bisceglia L , et al. Hereditary hyperferritinemia-cataract syndrome caused by a 29-base pair deletion in the iron responsive element of ferritin L-subunit gene. Blood 1997; 90: 2084–8.
Bosio S , Campanella A , Gramaglia E , et al. C29G in the iron-responsive element of L-ferritin: a new mutation associated with hyperferritinemia-cataract. Blood Cells Mol Dis 2004; 33: 31–4.
Vanita V , Hejtmancik JF , Hennies HC , et al. Sutural cataract associated with a mutation in the ferritin light-chain gene (FTL) in a family of Indian origin. Mol Vis 2006; 12: 93–9.
Wong K , Barbin Y , Chakrabarti S , Adams P . A point mutation in the iron-responsive element of the L-ferritin in a family with hereditary hyperferritinemia-cataract syndrome. Can J Gastroenterol 2005; 19: 253.
Martin ME , Fargion S , Brissot P , Pellat B , Beaumont C . A point mutation in the bulge of the iron-responsive element of the L ferritin gene in two families with the hereditary hyperferritinemia-cataract syndrome. Blood 1998; 91: 319–23.
Ladero JM , Balas A , Garcia-Sanchez F , Vicario JL , Diaz-Rubio M. Hereditary hyperferritinemia-cataract syndrome. Study of a new family in Spain. Rev Esp Enferm Dig 2004; 96: 507–1.
Balas A , Aviles MJ , Garcia-Sanchez F , Vicario JL . Description of a new mutation in the L-ferritin iron-responsive element associated with hereditary hyperferritinemia-cataract syndrome in a Spanish family. Blood 1999; 93: 4020–1.
Mumford AD , Vulliamy T , Lindsay J , Watson A . Hereditary hyperferritinemia-cataract syndrome: two novel mutations in the L-ferritin iron-responsive element. Blood 1998; 91: 367–8.
Garderet L , Hermelin B , Gorin NC , Rosmorduc O . Hereditary hyperferritinemia-cataract syndrome: a novel mutation in the iron-responsive element of the L-ferritin gene in a French family. Am J Med 2004; 117: 138–9.
Papanikolaou G , Chandrinou H , Bouzas E , et al. Hereditary hyperferritinemia-cataract syndrome in three unrelated families of western Greek origin caused by the C39 > G mutation of L-ferritin IRE. Blood Cells Mol Dis 2006; 36: 33–40.
Arosio C , Fossati L , Vigano M , Trombini P , Cazzaniga G , Piperno A . Hereditary hyperferritinemia-cataract syndrome: a de novo mutation in the iron responsive element of the L-ferritin gene. Haematologica 1999; 84: 560–1.
Cicilano M , Zecchina G , Roetto A , et al. Recurrent mutations in the iron regulatory element of L-ferritin in hereditary hyperferritinemia-cataract syndrome. Haematologica 1999; 84: 489–92.
Beaumont C , Leneuve P , Devaux I , et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet 1995; 11: 444–6.
Aguilar-Martinez P , Biron C , Masmejean C , Jeanjean P , Schved JF . A novel mutation in the iron responsive element of ferritin L-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome. Blood 1996; 88: 1895.
Perez dN , Castano L , Martul P , et al. Molecular analysis of hereditary hyperferritinemia-cataract syndrome in a large Basque family. J Pediatr Endocrinol Metab 2001; 14: 295–300.
Del Castillo RA , Fernandez Ruano ML. [Hereditary hyperferritinemia-cataracts syndrome in a Spanish family caused by the A40G mutation (Paris) in the L-ferritin (FTL) gene associated with the mutation H63D in the HFE gene.] Med Clin (Barc) 2007; 129: 414–17.
Feys J , Nodarian M , Aygalenq P , Cattan D , Bouccara AS , Beaumont C. [Hereditary hyperferritinemia syndrome and cataract.] J Fr Ophtalmol 2001; 24: 8470.
Phillips JD , Warby CA , Kushner JP . Identification of a novel mutation in the L-ferritin IRE leading to hereditary hyperferritinemia-cataract syndrome. Am J Med Genet A 2005; 134: 77–9.

Reference Title: References

Reference Type: reference-list

Strachan AS. Haemosiderosis and haemochromatosis in South African natives with a comment on the etiology of haemochromatosis. MD thesis. University of Glasgow, 1929.
Sheldon JH. Haemochromatosis. Oxford, Oxford University Press, 1935.
Walker ARP , Arvidsson UB. Iron “overload” in the South African Bantu. Trans Royal Soc Trop Med Hyg 1964; 47: 1964.
Gordeuk V , Mukiibi J , Hasstedt SJ , et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95–100.
Pippard MJ. Secondary iron overload. In: Brock JH , Halliday JW , Pippard MJ , Powell LW , eds. Iron Metabolism in Health and Disease. London, WB Saunders Company Ltd. 1994; 271–310.
Bothwell TH , Charlton RW , Cook JD , Finch CA. Alcohol, iron and liver disease. In: Bothwell TH , Charlton RW , Cook JD , Finch CA , eds. Iron Metabolism in Man. Oxford, Oxford University Press. 1979; 1564.
Bothwell TH , Isaacson C. Siderosis in the Bantu. A comparison of incidence in males and females. Br Med J 1962; 1: 522–4.
Moyo VM , Makunike R , Gangaidzo IT , et al. African iron overload and hepatocellular carcinoma (HA-7–0–080). Eur J Haematol 1998; 60: 28–34.
Moyo VM , Gangaidzo IT , Gomo ZA , et al. Traditional beer consumption and the iron status of spouse pairs from a rural community in Zimbabwe. Blood 1997; 89: 2159–66.
Moyo VM , Mandishona E , Hasstedt SJ , et al. Evidence of genetic transmission in African iron overload. Blood 1998; 91: 1076–82.
Kasvosve I , Delanghe JR , Gomo ZA , et al. Transferrin polymorphism influences iron status in blacks. Clin Chem 2000; 46: 1535–9.
McNamara L , MacPhail AP , Gordeuk VR , Hasstedt SJ , Rouault T. Is there a link between African iron overload and the described mutations of the hereditary haemochromatosis gene? Br J Haematol 1998; 102: 1176–8.
Roth M , Giraldo P , Hariti G , et al. Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (Mzab), Ethiopia, and Senegal. Immunogenetics 1997; 46: 222.
Gangaidzo IT , Moyo VM , Saungweme T , et al. Iron overload in urban Africans in the 1990s. Gut 1999; 45: 278–83.
Jeffery S , Crosby A , Plange-Rhule J , et al. Evidence from a Ghanaian population of known African descent to support the proposition that hemochromatosis is a Caucasian disorder. Genet Test 1999; 3: 375.
Barton JC , Acton RT , Rivers CA , et al. Genotypic and phenotypic heterogeneity of African-Americans with primary iron overload. Blood Cells Mol Dis 2003; 31: 310–19.
Beutler E , Barton JC , Felitti VJ , et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305–9.
Rivers CA , Barton JC , Gordeuk VR , et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African-Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis 2007; 38: 2472.
Gordeuk VR , Caleffi A , Corradini E , et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31: 299–304.
Barton JC , Acton RT , Lee PL , West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells Mol Dis 2007; 39: 206–11.
Bothwell TH , Seftel H , Jacobs P , Torrance JD , Baumslag N. Iron overload in Bantu subjects; studies on the availability of iron in Bantu beer. Am J Clin Nutr 1964; 14: 471.
Gordeuk VR , Boyd RD , Brittenham GM. Dietary iron overload persists in rural sub-Saharan Africa. Lancet 1986; 1: 1310–13.
Mandishona EM , Moyo VM , Gordeuk VR , et al. A traditional beverage prevents iron deficiency in African women of childbearing age. Eur J Clin Nutr 1999; 53: 722.
MacPhail AP , Mandishona EM , Bloom PD , Paterson AC , Rouault TA , Gordeuk VR. Measurements of iron status and survival in African iron overload. S Afr Med J 1999; 89: 9662.
Bothwell TH , Bradlow BA. Siderosis in the Bantu. A combined histopathological and chemical study. Arch Pathol 1960; 70: 279–92.
Isaacson C , Seftel HC , Keeley KJ , Bothwell TH. Siderosis in the Bantu: the relationship between iron overload and cirrhosis. J Lab Clin Med 1961; 58: 8453.
Seftel HC , Malkin C , Schmaman A , et al. Osteoporosis, scurvy, and siderosis in Johannesburg bantu. Br Med J 1966; 1: 642–6.
Lynch SR , Berelowitz I , Seftel HC , et al. Osteoporosis in Johannesburg Bantu males. Its relationship to siderosis and ascorbic acid deficiency. Am J Clin Nutr 1967; 20: 799–807.
Wapnick AA , Lynch SR , Seftel HC , Charlton RW , Bothwell TH , Jowsey J. The effect of siderosis and ascorbic acid depletion on bone metabolism, with special reference to osteoporosis in the Bantu. Br J Nutr 1971; 25: 3676.
Schnaid E , MacPhail AP , Sweet MB. Fractured neck of femur in black patients: a prospective study. J Bone Joint Surg Br 2000; 82: 872.
Gordeuk VR , McLaren CE , MacPhail AP , Deichsel G , Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996; 87: 3470–6.
MacPhail AP , Simon MO , Torrance JD , Charlton RW , Bothwell TH , Isaacson C. Changing patterns of dietary iron overload in black South Africans. Am J Clin Nutr 1979; 32: 1272–8.
Bloom PD , Burstein GR , Gordeuk VR. Iron overload in African-Americans. In: Barton JC , Edwards CQ , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 475–83.
Friedman BM , Baynes RD , Bothwell TH , et al. Dietary iron overload in southern African rural blacks. S Afr Med J 1990; 78: 301.
Walker AR , Segal I. Iron overload in sub-Saharan Africa: to what extent is it a public health problem? Br J Nutr 1999; 81: 427–34.
Speight AN , Cliff J. Iron storage disease of the liver in Dar es Salaam: a preliminary report on venesection therapy. East Afr Med J 1974; 51: 895–902.
Cliff JL , Speight AN. Venesection therapy in haemosiderosis. East Afr Med J 1976; 53: 287–91.
Krainin P , Kahn BS. Hemochromatosis: report of a case in a Negro; discussion of iron metabolism. Ann Intern Med 1950; 33: 462.
Prasad AS , Tranchida L , Konno ET , et al. Hereditary sideroblastic anemia and glucose-6-phosphate dehydrogenase deficiency in a Negro family. J Clin Invest 1968; 47: 1415–24.
Barton JC , Edwards CQ , Bertoli LF , Shroyer TW , Hudson SL. Iron overload in African-Americans. Am J Med 1995; 99: 616–23.
Wurapa RK , Gordeuk VR , Brittenham GM , Khiyami A , Schechter GP , Edwards CQ. Primary iron overload in African-Americans. Am J Med 1996; 101: 9–18.
Monaghan KG , Rybicki BA , Shurafa M , Feldman GL. Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African-Americans. Am J Hematol 1998; 58: 213–17.
Barton JC , Acton RT. Inheritance of two HFE mutations in African-Americans: cases with hemochromatosis phenotypes and estimates of hemochromatosis phenotype frequency. Genet Med 2001; 3: 294–300.
Rosner IA , Askari AD , McLaren GD , Muir A. Arthropathy, hypouricemia and normal serum iron studies in hereditary hemochromatosis. Am J Med 1981; 70: 870–4.
Conrad ME. Sickle cell disease and hemochromatosis. Am J Hematol 1991; 38: 150–2.
Acton RT , Barton JC , Snively BM , et al. Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis 2006; 16: 815–21.
Adams PC , Reboussin DM , Leiendecker-Foster C , et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101 168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Clin Chem 2005; 51: 10482.
Beutler E , Felitti V , Gelbart T , Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329–37.
Barton JC , Acton RT , Dawkins FW , et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test 2005; 9: 231–41.
Lee PL , Gelbart T , West C , Halloran C , Felitti V , Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis 2001; 27: 783–802.
Murugan RC , Lee PL , Kalavar MR , Barton JC. Early age-of-onset iron overload and homozygosity for the novel hemojuvelin mutation HJV R54X (exon 3; c.160>T) in an African-American male of West Indies descent. Clin Genet 2008; 74: 88–92.
Lee PL , Barton JC , Brandhagen D , Beutler E. Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol 2004; 127: 224–9.
Barton JC , Rivers CA , Niyongere S , Bohannon SB , Acton RT. Allele frequencies of hemojuvelin gene (HJV) I222N and G320V missense mutations in white and African-American subjects from the general Alabama population. BMC Med Genet 2004; 5: 29.
Barton JC , Acton RT , Leiendecker-Foster C , et al. HFE C282Y homozygotes aged 25–29 years at HEIRS Study initial screening. Genet Test 2007; 11: 2695.
Lee PL , Halloran C , West C , Beutler E. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol Dis 2001; 27: 285–9.
Barton EH , West PA , Rivers CA , Barton JC , Acton RT. Transferrin receptor-2 (TFR2) mutation Y250X in Alabama Caucasian and African-American subjects with and without primary iron overload. Blood Cells Mol Dis 2001; 27: 279–84.
Zaahl MG , Merryweather-Clarke AT , Kotze MJ , van der MS , Warnich L , Robson KJ. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet 2004; 115: 409–17.
Barton JC , Rothenberg BE , Bertoli LF , Acton RT. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999; 1: 89–93.
Barton JC , Lee PL , Bertoli LF , Beutler E. Iron overload in an African-American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells Mol Dis 2005; 34: 226–8.
Castro O , Hasan O , Kaur K , Loyevsky M , Gordeuk V. Hemochromatosis in non-transfused African-American patient with sickle cell anemia. Blood 1998; 92 (suppl): 13b.
Collins TS , Arcasoy MO. Iron overload due to X-linked sideroblastic anemia in an African-American man. Am J Med 2004; 116: 501–2.
Gordeuk VR. African iron overload. Semin Hematol 2002; 39: 263–9.
Duane P , Raja KB , Simpson RJ , Peters TJ. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol 1992; 27: 539–44.
Willner IR , Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2005; 21: 323–30.
Fletcher LM , Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 2003; 30: 131–6.
Barton JC , Acton RT , Richardson AK , Brissie RM. Stainable hepatic iron in 341 African-American adults at coroner/medical examiner autopsy. BMC Clin Pathol 2005; 5: 2.
Alter MJ , Kruszon-Moran D , Nainan OV , et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–62.
Howell C , Jeffers L , Hoofnagle JH. Hepatitis C in African-Americans: summary of a workshop. Gastroenterology 2000; 119: 1385–96.
Ioannou GN , Dominitz JA , Weiss NS , Heagerty PJ , Kowdley KV. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003; 37: 795–801.
Falck-Ytter Y , Younossi ZM , Marchesini G , McCullough AJ. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17–26.
Caldwell SH , Harris DM , Patrie JT , Hespenheide EE. Is NASH underdiagnosed among African-Americans? Am J Gastroenterol 2002; 97: 149600.
Mokdad AH , Ford ES , Bowman BA , et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9.
Schafer AI , Cheron RG , Dluhy R , et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319–24.
Brown KE , Khan CM , Zimmerman MB , Brunt EM. Hepatic iron overload in blacks and whites: a comparative autopsy study. Am J Gastroenterol 2003; 98: 1594–8.
Cotler SJ , Bronner MP , Press RD , et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 1998; 29: 257–62.
Ludwig J , Hashimoto E , Porayko MK , Moyer TP , Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997; 112: 882–8.
Strasser SI , Kowdley KV , Sale GE , McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 1998; 22: 1673.
Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we finally there? J Hepatol 2005; 42: 153–4.
Dawkins FW , Gordeuk VR , Snively BM , et al. African-Americans at risk for increased iron stores or liver disease. Am J Med 2007; 120: 734–9.
Barton JC , Alford TJ , Bertoli LF , Barton NH , Edwards CQ. Histochemically demonstrable hepatic iron excess in African-Americans [abstract]. Blood 1995; 86: 128a.
Phatak PD , Sham RL , Raubertas RF , et al. Prevalence of hereditary hemochromatosis in 16,031 primary care patients. Ann Intern Med 1998; 129: 954–61.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.
Yang Q , McDonnell SM , Khoury MJ , Cono J , Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998; 129: 9463.
Barton JC , Acton RT , Anderson LE , Alexander CB. A comparison between whites and blacks with severe multi-organ iron overload identified in 16 152 autopsies. Clin Gastroenterol Hepatol 2009; 7: 781.e2.
Bassett ML. Iron and hepatitis C: beginning to make sense. J Gastroenterol Hepatol 2007; 22: 1703–4.
Desai TK , Jamil LH , Balasubramaniam M , Koff R , Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008; 53: 815–22.
Barton JC , McDonnell SM , Adams PC , et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9.
Gordeuk VR , McLaren CE , Looker AC , Hasselblad V , Brittenham GM. Distribution of transferrin saturations in the African-American population. Blood 1998; 91: 2175–9.
Schnitzler CM , MacPhail AP , Shires R , Schnaid E , Mesquita JM , Robson HJ. Osteoporosis in African hemosiderosis: role of alcohol and iron. J Bone Miner Res 1994; 9: 18653.

Reference Title: References

Reference Type: reference-list

Heilmeyer L , Keller W , Vivell O , Betke K , Woehler F , Keiderling W. [Congenital atransferrinemia.] Schweiz Med Wochenschr 1961; 91: 1203.
Bernstein SE. Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. J Lab Clin Med 1987; 110: 69005.
Trenor CC, III , Campagna DR , Sellers VM , Andrews NC , Fleming MD. The molecular defect in hypotransferrinemic mice. Blood 2000; 96: 1113–18.
Fairbanks VF , Brandhagen DJ . Disorders of iron transport and storage. In: Beutler E , Lichtman MA , Coller BS , Kipps TJ , Seligsohn U , eds. Williams Hematology. New York, McGraw-Hill. 2001; 48902.
Goldwurm S , Casati C , Venturi N , et al. Biochemical and genetic defects underlying human congenital hypotransferrinemia. Hematol J 2000; 1: 390–8.
Sakata T. [A case of congenital atransferrinemia.] Shonika Shinryo 1969.
Goya N , Miyazaki S , Kodate S , Ushio B. A family of congenital atransferrinemia. Blood 1972; 40: 239–45.
Beutler E , Gelbart T , Lee P , Trevino R , Fernandez MA , Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood 2000; 96: 4071–4.
Asada-Senju M , Maeda T , Sakata T , Hayashi A , Suzuki T. Molecular analysis of the transferrin gene in a patient with hereditary hypotransferrinemia. J Hum Genet 2002; 47: 355–9.
Aslan D , Crain K , Beutler E. A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene. Acta Haematol 2007; 118: 244.
Cap J , Lehotska V , Mayerova A. [Congenital atransferrinemia in a 11-month-old child.] Cesk Pediatr 1968; 23: 1020.
Hromec A , Payer J, Jr. , Killinger Z , Rybar I , Rovensky J. [Congenital atransferrinemia.] Dtsch Med Wochenschr 1994; 119: 663–6.
Knisely AS , Gelbart T , Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood 2004; 104: 2607.
Goldwurm S , Biondi A. Case of congenital hypotransferrinemia suggests that tissue hypoxia during fetal development may cause hypospadias. Am J Med Genet 2000; 95: 287–90.
Hamill RL , Woods JC , Cook BA. Congenital atransferrinemia. A case report and review of the literature. Am J Clin Pathol 1991; 96: 215–18.
Loperena L , Dorantes S , Medrano E , et al. [Hereditary atransferrinemia.] Bol Med Hosp Infant Mex 1974; 31: 519–35.
Dorantes-Mesa S , Marquez JL , Valencia-Mayoral P. [Iron overload in hereditary atransferrinemia.] Bol Med Hosp Infant Mex 1986; 43: 99–101.
Walbaum R. [Congenital transferrin deficiency.] Lille Med 1971; 16: 1122–4.
Espinheira R , Geada H , Mendonca J , Reys L. Alpha-1-antitrypsin and transferrin null alleles in the Portuguese population. Hum Hered 1988; 38: 372–4.
Weidinger S , Cleve H , Schwarzfischer F , Postel W , Weser J , Gorg A. Transferrin subtypes and variants in Germany; further evidence for a Tf null allele. Hum Genet 1984; 66: 356–60.
Püshel K , Krüger A , Soder R. Further evidence of a silent Tf allele. Int Congr Soc Forens Haemog (Vienna) 1987.
Lukka M , Enholm C. A silent transferrin allele in a Finnish family. Hum Hered 1985; 35: 157–60.
Lee PL , Ho NJ , Olson R , Beutler E. The effect of transferrin polymorphisms on iron metabolism. Blood Cells Mol Dis 1999; 25: 374–9.
Hayashi A , Wada Y , Suzuki T , Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. Am J Hum Genet 1993; 53: 201–13.
Oliva G , Dominici G , Latini P , Cozzolino G. [Atransferrinemic nephrotic syndrome. Clinical contribution and etiopathogenetic evaluation.] Minerva Med 1968; 59: 1297–309.
Gaston Morata JL , Rodriguez CA , Urbano JF , Gonzalez MF , Ampuero AJ. [Atransferrinemia secondary to hepatic cirrhosis, hemochromatosis, and nephrotic syndrome.] Rev Esp Enferm Apar Dig 1982; 62: 491.
Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001; 38: 1–8.
Warshaw BL , Check IJ , Hymes LC , DiRusso SC. Decreased serum transferrin concentration in children with the nephrotic syndrome: effect on lymphocyte proliferation and correlation with serum immunoglobulin levels. Clin Immunol Immunopathol 1984; 33: 210–19.
Prinsen BH , de Sain-van der Velden MG , Kaysen GA , et al. Transferrin synthesis is increased in nephrotic patients insufficiently to replace urinary losses. J Am Soc Nephrol 2001; 12: 1017–25.
Hitzig WH , Schmid M , Betke K , Rothschild M. [Erythroleukemia with hemoglobin disorders and disorders of iron metabolism.] Helv Paediatr Acta 1960; 15: 203–22.
Westerhausen M , Meuret G. Transferrin-immune complex disease. Acta Haematol 1977; 57: 96–101.
Alyanakian MA , Taes Y , Bensaid M , et al. Monoclonal immunoglobulin with antitransferrin activity: a rare cause of hypersideremia with increased transferrin saturation. Blood 2007; 109: 359–61.
Forni GL , Girelli D , Lamagna M , et al. Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: a case report. Am J Hematol 2008; 83: 932–4.
den Dunnen JT , Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7–12.
Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998; 11: 1–3.

Reference Title: References

Reference Type: reference-list

Gunshin H , Mackenzie B , Berger UV , et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482–8.
Hubert N , Hentze MW . Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci USA 2002; 99: 123450.
Vidal S , Belouchi AM , Cellier M , Beatty B , Gros P . Cloning and characterization of a second human NRAMP gene on chromosome 12q13. Mamm Genome 1995; 6: 224–30.
Shahidi NT , Nathan DG , Diamond LK . Iron deficiency anemia associated with an error of iron metabolism in two siblings. J Clin Invest 1964; 43: 510–21.
Priwitzerova M , Pospisilova D , Prchal JT , et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood 2004; 103: 3991–2.
Priwitzerova M , Nie G , Sheftel AD , Pospisilova D , Divoky V , Ponka P . Functional consequences of the human DMT1 (SLC11A2) mutation on protein expression and iron uptake. Blood 2005; 106: 3985.
Mims MP , Guan Y , Pospisilova D , et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005; 105: 1337–42.
Beaumont C , Delaunay J , Hetet G , Grandchamp B , de Montalembert M , Tchernia G . Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 2006; 107: 41680.
Iolascon A , d'Apolito M , Servedio V , Cimmino F , Piga A , Camaschella C . Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006; 107: 3494.
Lam-Yuk-Tseung S , Mathieu M , Gros P . Functional characterization of the E399D DMT1/NRAMP2/SLC11A2 protein produced by an exon 12 mutation in a patient with microcytic anemia and iron overload. Blood Cells Mol Dis 2005; 35: 212–16.
Lam-Yuk-Tseung S , Camaschella C , Iolascon A , Gros P . A novel R416C mutation in human DMT1 (SLC11A2) displays pleiotropic effects on function and causes microcytic anemia and hepatic iron overload. Blood Cells Mol Dis 2006; 36: 3474.
Fleming MD , Trenor CC, III , Su MA , et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16: 383–6.
Fleming MD , Romano MA , Su MA , Garrick LM , Garrick MD , Andrews NC . Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci USA 1998; 95: 11483.
Mackenzie B , Ujwal ML , Chang MH , Romero MF , Hediger MA . Divalent metal-ion transporter DMT1 mediates both H+ -coupled Fe2+ transport and uncoupled fluxes. Pflugers Arch 2006; 451: 5448.
Shayeghi M , Latunde-Dada GO , Oakhill JS , et al. Identification of an intestinal heme transporter. Cell 2005; 122: 789–801.
Trinder D , Oates PS , Thomas C , Sadleir J , Morgan EH . Localization of divalent metal transporter-1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. Gut 2000; 46: 270–6.
Shindo M , Torimoto Y , Saito H , et al. Functional role of DMT1 in transferrin-independent iron uptake by human hepatocyte and hepatocellular carcinoma cell, HLF. Hepatol Res 2006; 35: 152–62.
Lee P , Gelbart T , West C , Halloran C , Beutler E . Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002; 29: 471–87.
Kelleher T , Ryan E , Barrett S , O'Keane C , Crowe J . DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis. Blood Cells Mol Dis 2004; 33: 35–9.
Xiong L , Dion P , Montplaisir J , et al. Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 911–17.
Ludwiczek S , Theurl I , Muckenthaler MU , et al. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med 2007; 13: 4484.

Reference Title: References

Reference Type: reference-list

Weatherall DJ. The Thalassaemia Syndromes. Oxford, Blackwell Scientific Publications, 2001.
Pippard MJ , Callender ST , Warner GT , Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 1979; 2: 819–21.
Pippard MJ. Secondary iron overload. In: Brock JHH , Powell LW , Halliday JW , Pippard MJ , eds. Iron Metabolism in Health and Disease. London, WB Saunders Co. Ltd. 1994; 271–309.
Tanno T , Bhanu NV , Oneal PA , et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–101.
Vaulont S , Labie D. [Erythroblasts-derived GDF15 supresses hepcidin in thalassemia.] Med Sci (Paris) 2008; 24: 139–41.
Tanno T , Porayette P , Sripichai O , et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181–6.
Camaschella C , Mazza U , Roetto A , et al. Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol 1995; 48: 82.
Bowdler AJ , Huehns ER. Thalassaemia minor complicated by excessive iron storage. Br J Haematol 1963; 9: 13–24.
Barton JC , Lee PL , West C , Bottomley SS. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 2006; 81: 760.
Barton JC , Acton RT , Anderson LE , Alexander CB. A comparison between whites and blacks with severe multi-organ iron overload identified in 16 152 autopsies. Clin Gastroenterol Hepatol 2009; 7: 781.
Zimmermann MB , Fucharoen S , Winichagoon P , et al. Iron metabolism in heterozygotes for hemoglobin E (HbE), alpha-thalassemia 1, or beta-thalassemia and in compound heterozygotes for HbE/beta-thalassemia. Am J Clin Nutr 2008; 88: 1026–31.
Johnson CS , Tegos C , Beutler E. Alpha-Thalassemia: prevalence and hematologic findings in American Blacks. Arch Intern Med 1982; 142: 1280–2.
Beutler E , West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood 2005; 106: 740.
Chim CS , Chan V , Todd D. Hemosiderosis with diabetes mellitus in untransfused Hemoglobin H disease. Am J Hematol 1998; 57: 160–3.
Edwards CQ , Skolnick MH , Kushner JP. Coincidental non-transfusional iron overload and thalassemia minor: association with HLA-linked hemochromatosis. Blood 1981; 58: 844–8.
Piperno A , Mariani R , Arosio C , et al. Haemochromatosis in patients with beta-thalassaemia trait. Br J Haematol 2000; 111: 908–14.
Arruda VR , Agostinho MF , Cancado R , Costa FF , Saad ST. Beta-thalassemia trait might increase the severity of hemochromatosis in subjects with the C282Y mutation in the HFE gene. Am J Hematol 2000; 63: 230.
Longo F , Zecchina G , Sbaiz L , Fischer R , Piga A , Camaschella C. The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica 1999; 84: 799–803.
Karimi M , Yavarian M , Delbini P , et al. Spectrum and haplotypes of the HFE hemochromatosis gene in Iran: H63D in beta-thalassemia major and the first E277K homozygous. Hematol J 2004; 5: 524.
Sharma V , Panigrahi I , Dutta P , Tyagi S , Choudhry VP , Saxena R. HFE mutation H63D predicts risk of iron overload in thalassemia intermedia irrespective of blood transfusions. Indian J Pathol Microbiol 2007; 50: 82.
Melis MA , Cau M , Deidda F , Barella S , Cao A , Galanello R. H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers. Haematologica 2002; 87: 242.
Martins R , Picanç I , Fonseca A , et al. The role of HFE mutations on iron metabolism in beta-thalassemia carriers. J Hum Genet 2004; 49: 651.
Garewal G , Das R , Ahluwalia J , Marwaha RK. Prevalence of the H63D mutation of the HFE in north India: its presence does not cause iron overload in beta-thalassemia trait. Eur J Haematol 2005; 74: 333–6.
Valenti L , Pulixi EA , Arosio P , et al. Relative contribution of iron genes, dysmetabolism, and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007; 92: 1037–42.
Kattamis A , Papassotiriou I , Palaiologou D , et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006; 91: 809–12.
Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 2392.
Borgna-Pignatti C , Rugolotto S , De Stefano P , et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227–31.
Origa R , Fiumana E , Gamberini MR , et al. Osteoporosis in beta-thalassemia: clinical and genetic aspects. Ann NY Acad Sci 2005; 1054: 451–6.
Shalitin S , Carmi D , Weintrob N , et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005; 74: 93–100.
Borgna-Pignatti C , Rugolotto S , De Stefano P , et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187–93.
Vogiatzi MG , Macklin EA , Trachtenberg FL , et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in north America. Br J Haematol 2009; 146: 5466.
Gamberini MR , De Sanctis, V , Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 2008; 6 Suppl 1: 158–69.
Kyriakou A , Savva SC , Savvides I , et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev 2008; 6 Suppl 1: 116–22.
Vogiatzi MG , Macklin EA , Fung EB , et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009; 24: 5437.
Fung EB , Harmatz PR , Lee PD , et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135: 574–82.
Skordis N , Michaelidou M , Savva SC , et al. The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol 2006; 77: 150–6.
De Sanctis, V , Eleftheriou A , Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia